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Summary 
Amyotrophic Lateral Sclerosis is a debilitating, progressive and fatal 
neurodegenerative disorder resulting from the degeneration and death of 
motoneurons in the spinal cord and motor cortex which leads to muscle 
paralysis and death. Neuroinflammation is prominent in ALS pathogenesis, 
and other neurodegenerative disorders, and is believed to contribute to 
disease progression. Mutations in the superoxide dismutase 1 gene (SOD1) 
account for approximately 12 – 20 % of familial ALS cases.  Microglia, the 
resident immune cells of the CNS, are activated concurrent with neuronal 
injury and mediate mutant SOD1 – induced neurotoxicity thus exacerbating 
disease progression. Additionally, mutant SOD1 has been shown to bind to 
the innate immune receptors Toll – like receptors -2 and -4 (TLR2, TLR4), 
which are highly expressed on microglia.  
The transcription factor nuclear factor ҡB (NF- ҡB) elicits the transcription of 
multiple pro-inflammatory genes, and its activation is upregulated in ALS 
pathology. The Bcl-2 family member Bid is demonstrated to promote NF-ҡB 
activation in astrocytes in response to TLR4 activation, and here it is also 
identified that Bid promotes TLR4 - NF- ҡB signalling in microglia, and that 
bid – deficiency attenuates the TLR4 – and mutant SOD1 - induced pro-
inflammatory response. 
Detailed TLR4 - NF- ҡB pathway analysis identified an interaction between 
Bid and tumour necrosis factor α receptor adaptor protein 6 (TRAF6) in 
microglia, with Bid demonstrated to promote TRAF6 polyubiquitination. 
Further experiments demonstrated that Bid does not affect the activation of 
viii 
 
the Interleukin 1 receptor - associated kinase (IRAK) complex upon TLR4 
activation; however reduced Peli1 protein levels are evident in the absence 
of Bid in TLR4 – activated microglia.  
Collectively the results demonstrate that Bid regulates TLR4 signalling by 
promoting TRAF6 ubiquitin ligase activity and therefore promotes 
downstream signalling to NF-ҡB. Depletion of microglial Bid offers a potential 
therapeutic target for the attenuation of the SOD1 – induced microglial 
mediated toxicity evident in ALS pathogenesis. 
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1. Introduction 
1.1 Overview of Amyotrophic Lateral Sclerosis 
1.1.1 Genetics and Aetiology 
Amyotrophic Lateral Sclerosis (ALS) is a fatal, progressive 
neurodegenerative disease, characterised by the selective death of upper 
motor neurons in the cerebral cortex and lower motor neurons in the brain 
stem and anterior horn of the spinal cord (Ferraiuolo et al., 2011, Sargsyan 
et al., 2011, Lomen-Hoerth, 2008, Shaw, 2005).  ALS was first described 
over 150 years ago by the French neurologist Charcot (Goetz, 2000) and is 
the most common form of Motoneuron Disease (MND) (Cruts et al., 2013). 
The clinical manifestations of ALS are muscle atrophy and weakness, which 
lead to eventual paralysis and death within 2-5 years of onset (Ticozzi et al., 
2011, Muyderman et al., 2009). The incidence of this adult – onset disease is 
3.9 per 100,000 in the United States and approximately 1.7 – 2.6 per 
100,000 worldwide (Mehta et al., 2014, Logroscino et al., 2010).   
Genetic studies have recognised a familial link in approximately 10% of ALS 
cases [Familial ALS (fALS)], with the remainder of disease cases 
characterised as Sporadic ALS (sALS) (Ticozzi et al., 2011, Mulder et al., 
1986). Mutations in the Superoxide Dismutase 1 (sod1) gene, linked to 
chromosome 21q22.1, were discovered to account for approximately 12 % of 
the familial cases of ALS (Renton et al., 2014, Rosen et al., 1993). Further 
mutations were discovered in TAR (trans-active response) DNA binding 
protein 43 (tdp-43) (Van Deerlin et al., 2008) and in Fused in Sarcoma (fus) 
genes (Vance et al., 2009) each composing approximately 2 - 5 % of fALS 
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cases (Kwiatkowski et al., 2009, Kabashi et al., 2008). Recent studies have 
identified hexanucleotide repeat expansions of C9orf72 to be associated with 
approximately 40 % of fALS cases (Renton et al., 2014, van Blitterswijk et 
al., 2012).  Less frequent mutations in genes associated with fALS have also 
been reported, such as Angiogenin [Ang, (Greenway et al., 2006)],  Profiling 
1 [Pfn1, (Wu et al., 2012)],  Valosin - containing protein [VCP, (Johnson et 
al., 2010)], Optineurin [Optn, (Chio et al., 2012)], Ubiquilin 2 [Ubqln2, (Deng 
et al., 2011)],  and Sequentosome 1 [Sqstm1, (Fecto et al., 2011)] (Table 
1.1). Additionally, recent exome sequencing data identified TANK binding 
kinase 1 (Tbk1) as an ALS gene (Cirulli et al., 2015).  
 
Table 1.1: Genes with mutations associated with ALS pathogenesis. The 
below table represents an overview of genes carrying known ALS - causing 
mutations, their location, percentage incidence in fALS and sALS, and known 
protein function under non-disease conditions. Adapted from (Renton et al., 
2014). 
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Sod1 mutations are implicated in both familial and apparently sporadic ALS 
cases (Pasinelli and Brown, 2006), further demonstrating that misfolding of 
both wild-type (wt) and mutated SOD1 may cause ALS disease progression 
(Bosco et al., 2010, Forsberg et al., 2010) (Figure 1.1).  
 
 
Figure 1.1: Graphical representation of the percentage of ALS cases 
associated with each ALS - carrying gene mutation. Adapted from (Renton et 
al., 2014). SOD1 mutations are associated with both familial and sporadic 
ALS pathogenesis.  
 
More than 150 disease - associated Sod1 mutations having been described 
to date (Ticozzi et al., 2011), which are inherited in an autosomal dominant 
manner (Rosen et al., 1993).  SOD1 is a ubiquitously expressed cytoplasmic 
antioxidant enzyme that induces the breakdown of free radicals (Ilieva et al., 
2009).   SOD1, which composes between 0.1 and 0.2 % of cellular Central 
Nervous System (CNS) proteins, converts the superoxide anion to hydrogen 
peroxide by the concurrent oxidation and reduction of copper (Cu2+), a 
process known as dismutation (Pasinelli and Brown, 2006). The cytotoxicity 
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of mutant SOD1 is due to a gain - of - function mechanism (Bruijn et al., 
1998, Reaume et al., 1996), and mutations in Sod1 lead to protein misfolding 
and the formation of cytosolic aggregates (Rotunno and Bosco, 2013, Boillee 
et al., 2006a). SOD1G93A, a mutation which occurs at the 93rd amino acid 
where Glycine is replaced with Alanine, has been shown to induce multiple 
mechanisms of ALS disease progression (Grad et al., 2011, Muyderman et 
al., 2009, Shaw and Valentine, 2007, Pasinelli and Brown, 2006). 
Interestingly, it was demonstrated that mutant SOD1G93A aggregates in a self 
- perpetuating manner, and elicits its protein misfolding pathology from cell to 
cell in a prion - like manner (Munch et al., 2011). In addition, mutant 
SOD1G93A is reported to have marked misfolding effects on SOD1wt (Grad et 
al., 2011).   
The SOD1G93A mouse model (B6SJL.SOD1-G93A), which carries 
approximately 20 - 25 copies of the Sod1 human transgene, is the most 
widely used in vivo ALS model as it is the most characterised and well 
understood model of ALS disease progression and therefore is an invaluable 
resource for examining SOD1 – associated ALS pathogenesis and 
therapeutics (McGoldrick et al., 2013, Gurney et al., 1994). Mutant SOD1 
expression in motoneurons is closely associated with the initiation and early 
progression of ALS, with the later stages and exacerbations of disease 
believed to be largely due to toxicity induced by non – neuronal cells  (Ilieva 
et al., 2009, Wang et al., 2009). 
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1.1.2 Current Therapeutics and Care for ALS patients 
At present, there is only one ALS therapeutic drug approved by the U.S. 
Food and Drug Administration (FDA), Riluzole, which has been shown to 
prolong patient survival by approximately 2 - 3 months on administration in 
early disease onset (Zoccolella et al., 2007). Riluzole targets glutamate 
toxicity (Frizzo et al., 2004), however the mechanism is unclear and while 
this drug can attenuate the symptoms of ALS, its modest improvement in 
survival outcome highlights that the need for increased understanding of the 
pathogenesis of this complex disease is vital for the progression of 
therapeutics.  
Current care of ALS patients engages a multidisciplinary approach to tackle 
the loss of muscle function and control in the limbs, respiratory muscles, 
swallowing, and speech in order to reduce disease burden on the patient and 
care giver. A study of ALS patients in Ireland from 1996 – 2000 identified that 
the multidisciplinary therapeutic approach increased the life span of up to 7.5 
months (Traynor et al., 2003). ALS clinics incorporate Riluzole treatment with 
consistent monitoring by a nutrition specialist, a speech and swallow 
specialist, and continuous home visits conducted by an ALS nurse for 
patients unable to visit the clinic, with occupational therapy and psychological 
support. An updated set of guidelines for the treatment, management and 
care of ALS patients was published by the American Academy for Neurology 
in 2009. Some interventions include non-invasive positive pressure 
ventilation (NIPPV) which includes the use of a nasal mask, a facemask or 
nasal plugs in place of a tracheostomy (Miller et al., 2009). An alternative 
form of non-invasive ventilation is diaphragm pacing, which involves the 
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stimulation of the diaphragm with surgically implanted electrodes having the 
advantage over a facemask in reducing claustrophobia and a communication 
barrier, and is currently practiced in the U.S (Jenkins et al., 2014).  
Treatment for symptoms such as hyper-salivation (also referred to as 
sialorrhea) includes low-dose radiation therapy or botulinum toxin B 
administration (Miller et al., 2009). Additionally treatment is available for 
pseudobulbar effects, which involves spontaneous or excessive laughing or 
crying and occur in approximately 25 % of ALS patients. This treatment 
includes a combination of dextromethorphan and quinidine (Miller et al., 
2009). Gastrostomy is deemed to only have a modest improvement in life 
span, due to aiding nutrition in the case of dysphagia (Spataro et al., 2011). 
ALS patients are also treated for symptoms such as muscle cramps, muscle 
spasticity, fatigue, depression and anxiety. 
Studies have shown that palliative care improves the patients quality of life 
and that of the carer (Bede et al., 2011), and joint palliative care between 
ALS nurses and hospice staff is currently practiced in Ireland. 
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1.1.3 Evidence for Non-Cell Autonomous Neuronal Degeneration in ALS  
The precise aetiology of ALS has not yet been fully elucidated, however 
multiple molecular mechanisms have been implicated such as misfolded 
protein aggregation, oxidative stress, glutamate excitotoxicity, impaired 
axonal transport and non-cell autonomous neuronal degeneration (see 
Figure 1.2) (Ferraiuolo et al., 2011, Munch et al., 2011, Sargsyan et al., 
2011, Shaw, 2005).  Accumulating evidence highlights the role of non - cell 
autonomous mechanisms in neuropathology (Garden and La Spada, 2012, 
Glass et al., 2010, Di Giorgio et al., 2007). Dysregulated communication 
between neurons and glial cells is identified to have a central role in many 
neurodegenerative diseases, with interactions between misfolded proteins 
and glial cells believed to further exacerbate neuropathological states 
(Hovden et al., 2013, Liu et al., 2009). Activated microglia and astrocytes 
accumulate in areas of localized neurodegeneration (Kawamata et al., 1992). 
Glial cell involvement has been shown in amyloid-β pathology in Alzheimer’s 
disease (AD) (Lambert et al., 2009, Hickman et al., 2008) and in the 
aggregation of α-synuclein in Parkinson’s disease (PD) (Dauer and 
Przedborski, 2003). In addition, activation of microglia is evident early in 
Huntington’s disease progression (Sapp et al., 2001). With regard to ALS, 
elevated levels of microglial activation along with extensive astrogliosis and 
microgliosis in the motor cortex and spinal cord is observed in ALS disease 
progression (Casula et al., 2011, Zhao et al., 2010, Hensley et al., 2006, Ince 
et al., 1998). Mutant SOD1 has been shown to be secreted by NSC-34 cells, 
a motoneuron cell line, and secreted SOD1G93A mediates microgliosis 
(Urushitani et al., 2006, Turner et al., 2005).  In addition, both primary murine 
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astrocytes and microglia derived from mutant SOD1 mice induce toxicity 
when co - cultured with either embryonic stem cell derived or primary 
motoneurons (Di Giorgio et al., 2007, Nagai et al., 2007). Interestingly cell – 
autonomous expression of mutant SOD1 does not induce motoneuron 
degeneration, but rather the combined concert of mutant SOD1 – expression 
in motoneurons, astrocytes and microglia leads to ALS pathogenesis (Beers 
et al., 2006, Clement et al., 2003, Pramatarova et al., 2001, Gong et al., 
2000).           
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Figure 1.2: Molecular Mechanisms contributing to ALS pathogenesis. The 
above schematic highlights the molecular mechanisms implicated in ALS 
disease progression in motoneurons, astrocytes and microglia. These 
include pro - inflammatory cytokines, extracellular and intracellular protein 
aggregation, proteasomal dysfunction, glutamate excitotoxicity and impaired 
axonal transport. Adapted from (Shaw, 2005). 
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1.2 Inflammation and Neurodegeneration 
1.2.1 Microglia and Inflammation 
The concept of microglia was first introduced by pathologist Pío del Río-
Hortega in 1932 (Kettenmann et al., 2011, Rio-Hortega, 1932). Hortega 
proposed a number of fundamentals regarding microglia which are still held 
at high regard today, including their mesodermal origin, microglial entry into 
the brain during development, homogeneous dispersion of microglia 
throughout the CNS, and the ability of microglia to proliferate and migrate 
(Rio-Hortega, 1932) . Although the CNS was once believed to be immune 
privileged, microglia were discovered to be the resident immune cells of the 
CNS, comprising approximately 10% of total CNS cell population (Aguzzi et 
al., 2013). A variety of functions have been established for microglia, 
including their phagocytic role in development which facilitates synaptic 
pruning and the secretion of cytokines and neurotrophic factors (Boche et al., 
2013, Wake et al., 2009). Microglia in the healthy adult brain and spinal cord 
are ramified and ‘resting’, with a small soma and long fine processes 
(Kettenmann et al., 2011). Resting or non – activated microglia, previously 
presumed to be dormant until activation, are now recognised to have a 
constant role in environmental surveillance, ensuring tissue homeostasis and 
neuronal integrity, with studies demonstrating a dynamic housekeeping 
function evident by the consistent motion of their processes (Nimmerjahn et 
al., 2005). Upon disturbances in CNS homeostasis, such as ischemia, 
infection, neurodegenerative disease or trauma microglia become activated 
and both morphological and functional changes are induced (see figures 1.3 
and 1.4). Pathological insult results in the retraction of microglial processes, 
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and the cell becomes amoeboid in shape, acquiring mobility (Hanisch and 
Kettenmann, 2007, van Rossum and Hanisch, 2004, Kreutzberg, 1996). 
Activated microglia rapidly migrate to the site of injury forming a barrier 
between damaged and healthy tissue and commence the clearance of toxic 
factors, secreting cytokines and mediating phagocytosis (Loane and Byrnes, 
2010).  Microglia sense changes in their microenvironment through a variety 
of cell surface receptors including receptors responding to ATP, complement, 
immunoglobulins and pro- and anti- inflammatory cytokines (van Rossum 
and Hanisch, 2004, Raivich et al., 1999). 
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Figure1.3: Microglial morphological states. (A) Drawings by Rio-Hortega 
representing ramified resting microglia (Rio-Hortega, 1919). (B) Microscopy 
images showing the morphological changes in microglia upon phagocytic 
activation. Panel A. Resting ramified microglia. Panel B. Microglial processes 
begin to contract upon activation. Panel C. Microglia assuming a rounder 
shape with shorter extensions. Panel D & E. Amoeboid activated microglia. 
Panel F - H. Microglia in the process of phagocytosis. Panel I. Microglia 
mitotically proliferating. 
 
Neuroinflammation is marked by microglial migration and activation at the 
site of neuronal injury (Appel et al., 2011), resulting in the release of either 
neuroprotective or neurotoxic molecules (Kettenmann et al., 2011, 
Gehrmann et al., 1995). Classification of microglial activation states is based 
on their phenotypic response to stimuli and includes an ‘M1’ pro-
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inflammatory state and an ‘M2’ anti-inflammatory, regenerative state (Perry 
et al., 2010, Ransohoff and Perry, 2009).  
 
Figure 1.4: Schematic representation of microglial activation and the M1 and 
M2 phenotypes. Upon stimulation microglia assume either an M1 or M2 
activated state. The ramified resting microglia (M0) becomes amoeboid in 
shape and either secretes cytotoxic (M1) or neuroprotective (M2) molecules 
in response to specific stimuli.  Balance between the M1 and M2 response is 
a desired therapeutic goal. Aβ, Amyloid-β; IL-6, Interleukin-6; H2O2, 
hydrogen peroxide.  
 
Within the M2 state there are unique functional subtypes divided further into 
‘M2a’, which is associated with alternative activation and an anti - 
inflammatory response; ‘M2b’, classified as immunoregulatory; and ‘M2c’ 
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which encompasses acquired deactivation (Tang, 2015, Chhor et al., 2013). 
Inducers of these specific phenotypes have been well characterised and are 
summarised below (Table 1.2). 
Table 1.2 Microglial Activation States. Summary of the microglial activation 
states M1, M2a, M2b, M2c, known inducers of each phenotype and the 
specific response. (Tang, 2015, Chhor et al., 2013). LPS, 
Lipopolysaccharide; IFNγ, Interferon γ; TNFα, tumour necrosis factor α; IL-
1β, Interleukin 1β; iNOS, Inducible nitric oxide synthase; IL-4, Interleukin 4; 
IL-13, Interleukin 13; IL-10, Interleukin 10; SOC3, Suppressor of Cytokines 3; 
IL-1R, Interleukin 1 Receptor; TGFβ, Transforming growth factor β. 
 
 
The initial activation of microglia in response to toxic stimuli is thought to be 
beneficial as demonstrated by studies reporting exacerbated neuronal 
damage in ischemia and stroke upon ablation of the microglial response 
(Faustino et al., 2011, Lalancette-Hebert et al., 2007). However, polarization 
towards the M1 activation state leads to a chronic pro-inflammatory 
microglial state and contributes to neuronal death (Murdock et al., 2015, 
Block et al., 2007).  
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1.2.2 Microglia and ALS 
Neuroinflammation is recognised as a pathological hallmark of 
neurodegenerative disease (Murdock et al., 2015, Carson et al., 2006, Shaw, 
2005), and is evident in the brain and spinal cord of both ALS patients and in 
mouse models of ALS, with elevated levels of the pro - inflammatory 
cytokines IL-6 and TNFα identified in the CSF and serum of ALS patients 
(McGeer and McGeer, 2002, Sekizawa et al., 1998). The chronic state of 
neuroinflammation seen in ALS disease progression is believed to be a 
secondary response to a primary neuronal insult, as demonstrated by the 
denervation of peripheral neurons prior to increased immune response (Kano 
et al., 2012, Smith et al., 2012, Appel et al., 2011, Glass et al., 2010). Upon 
disease progression motoneuron degeneration is accompanied by 
simultaneous and  sustained inflammation in the brain and spinal cord which 
contributes to the rapid rate of disease progression (Bowerman et al., 2013). 
Mutant SOD1 expressing microglia respond with a  heightened sensitivity to 
toxic insult and induce a more rapid disease progression, compared with wt 
microglia (Beers et al., 2006). Microglia from ALS mice adopt an activated 
neuroinflammatory state and acquire neurotoxic properties contributing to 
ALS disease progression (Dibaj et al., 2012, Berger et al., 2011, Sargsyan et 
al., 2011). In early ALS pathogenesis microglia  are associated with anti – 
inflammatory M2 activity, however a fateful switch to the M1 microglial 
activation state is evident upon disease onset and is concurrent with 
neuronal death (Liao et al., 2012). Aggregation of misfolded proteins is 
closely associated with microglial activation, and microglia expressing 
SOD1G93A are phenotypically M1 (Tang, 2015). The accumulation of mutant 
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SOD1 aggregates in microglia leads to a self – perpetuating neurotoxicity 
and a polarization towards M1 pro-inflammatory activation (Block et al., 
2007). Importantly, SOD1G93A - expressing microglia can induce neuronal 
death (Zhao et al., 2010). These studies strengthen the argument for an 
orchestrated dialogue between motoneurons and microglia in ALS 
pathogenesis. 
 
1.2.3 Immunity in the CNS – Microglia and the Adaptive Immune Response 
in ALS 
Although microglia are considered to elicit the primary immune response in 
the CNS other glial cells such as astrocytes and oligodendrocytes play a role 
in facilitating neuroinflammation and interact with peripheral immune cells 
such as T cells and B cells (Evans et al., 2013). During healthy conditions a 
small number of T cells carry out homeostatic surveillance in the perivascular 
and ventricular regions of the CNS, however upon infection, trauma or 
neurodegenerative states a large amount of T cells infiltrate the CNS across 
the blood brain barrier (BBB) (Sallusto et al., 2012, von Andrian and Mackay, 
2000). Microglial-astrocyte and microglia-lymphocyte communication is 
closely regulated by changes in the environment and mediates T cell 
infiltration into the CNS (Evans et al., 2013, Beers et al., 2008). Crosstalk 
between immune cells occurs in the CNS which may potentiate the 
inflammatory response. The role of T cells, which are phenotypically varied, 
in facilitating neuronal death and the switch from protective to cytotoxic 
phenotype is a matter of debate (Sallusto et al., 2012). Interestingly, some 
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studies have identified CD4+ T cells to exert protective effects on glial cells in 
ALS (Beers et al., 2008). However, CD4+ T cells have recently been shown 
to induce macrophage activation thus inducing neurotoxicity after CNS injury 
(Walsh et al., 2014). Activated astrocytes, microglia, macrophages and T 
cells are all identified in the CNS and spinal cord in ALS pathogenesis 
(Evans et al., 2013, Henkel et al., 2004, Troost et al., 1989). Microglia are 
activated early in ALS pathogenesis and are evident in the spinal cord prior 
to T cell activation, which is seen at day 120 (post symptom onset) in 
SOD1G93A mice (Alexianu et al., 2001). Interestingly spinal cord microglia 
were found to express high levels of dendritic receptors in SOD1G93A mice 
which is believed to be a key event in initiating the infiltration of peripheral 
immune cells (Chiu et al., 2008). Additionally decreased microglial activation 
was observed in T cell deficient SOD1G93A mice, highlighting an important 
bidirectional interplay between the innate and adaptive immune system in 
ALS pathology (Beers et al., 2008, Chiu et al., 2008).  Importantly, there is 
evidence for the involvement of microglial Toll-like Receptor signalling in 
initiating the adaptive immune response (Olson and Miller, 2004). Figure 1.5 
below illustrates glial – T cell and glial – neuronal cross talk that occurs in 
ALS. 
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Figure 1.5: Schematic representing T cell infiltration in the CNS in SOD1G93A 
– induced ALS mediated by microglia and astrocytes. Adapted from (Evans 
et al., 2013). Interactions between astrocytes, neurons and microglia in ALS 
lead to a robust inflammatory response that elicits the infiltration of large 
number of lymphocytes into the CNS by crossing the blood brain barrier 
(BBB). Astrocyte and microglia communicate through secretions of 
inflammatory molecules such as TGFβ and Il-6. Motoneurons expressing 
SOD1G93A secrete SOD1G93A and factors such as HMGB1 that activate glia 
and activate TLR2 and TLR4 signalling pathways, thus potentiating the pro-
inflammatory response. Additionally, microglia interact with lymphocytes and 
endothelial cells by secreting pro-inflammatory TNFα and IL-1β, inducing 
infiltration through a leaky BBB. T cells potentiate the pro-inflammatory 
response and interact with glial cells and neurons, however they may have a 
role in neuroprotection (Evans et al., 2013, Chiu et al., 2009, Babcock et al., 
2003). GM-CSF, granulocyte macrophage colony stimulating factor; HMGB1, 
high mobility group protein B1; IFNγ, Interferon γ; IL-1β, Interleukin 1β; IL-6, 
interleukin 6; NO, nitric oxide; TNFα, tumour necrosis factor α; TGFβ, 
transforming growth factor β. 
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1.3 Toll-like Receptor (TLR) Signalling to NF-B 
 
1.3.1 Toll-like Receptors  
Toll-like Receptors (TLRs) are the mammalian homologue of the Drosophila 
melanogaster Toll (Gillespie and Wasserman, 1994, Gay and Keith, 1991). 
TLRs are highly conserved innate immune receptors, which are expressed in 
immune and non - immune cells, and are highly expressed in microglia 
(Heiman et al., 2014, Doyle and O'Neill, 2006). TLRs are the master 
regulators of the cellular innate immune response (Scheffel et al., 2012, 
Medzhitov et al., 1997), and are responsible for the initiation and propagation 
of the inflammatory cascade in response to bacterial, viral or microbial 
nucleic acids, known as Pathogen Associated Molecular Patterns (PAMPs) 
or Danger Associated Molecular Pattern (DAMPs) (Hennessy et al., 2010, 
Kielian, 2006, Moynagh, 2005).  Some TLRs are intracellularly expressed on 
endosomes (TLR3, TLR7, TLR8 and TLR9) and others are transmembrane 
receptors (all other TLRs, including TLR2 and TLR4), with 13 murine and 11 
human TLRs identified to date (Wang et al., 2015, Kigerl et al., 2014). 
 
TLR2 and TLR4 signalling 
TLRs signal as dimers, and upon stimulation and recruitment of the 
extracellular co - receptors MD2 (Shimazu et al., 1999) and CD14 (Jiang et 
al., 2000), TLRs either homodimerise (TLR4), or heterodimerise 
(TLR1/TLR2) (Ozinsky et al., 2000). Activation of either TLR2 or TLR4 leads 
to the assembly of a cytoplasmic Toll / Interleukin-1 Receptor (TIR) adaptor 
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domain (Yamamoto et al., 2003a, Horng et al., 2002, Fitzgerald et al., 2001). 
The TIR - adaptor domain is comprised of MyD88 (Myeloid Differentiation 
Primary Response Gene 88), Mal (MyD88 adaptor-like), TRIF (TIR-domain-
containing adapter-inducing interferon-β) and TRAM (O'Neill and Bowie, 
2007, Yamamoto et al., 2003b, Kawai et al., 1999). MyD88 is common to all 
TLRs, with the exception of TLR3 (Takeda and Akira, 2004), and Mal (also 
known as TIRAP) bridges MyD88 to TLR2 and TLR4 (Sasai and Yamamoto, 
2013). TRAM connects TRIF with TLR4 (Oshiumi et al., 2003). All TIR 
adaptors contain a TIR domain in their structure, however the death domain 
(DD) is specific to MyD88 (Watters et al., 2007) (Figure1.6). Downstream 
signalling to NF-ҡB is regulated by ubiquitination, a post – translational 
modification which results in the formation of polyubiquitin chains on target 
proteins at different lysine residues (Conze et al., 2008, Lamothe et al., 2007, 
Schauvliege et al., 2007, Alkalay et al., 1995b). 
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Figure 1.6: TIR adaptor domain proteins structures. Adapted from (Watters et 
al., 2007). Each protein in the TIR adaptor complex contains a TIR domain. 
MyD88 contains a death domain (DD) for interaction with downstream kinase 
complexes. Mal, also known as TIRAP, contains a phosphatidylinositol 4, 5 - 
bisphosphate (PIP2) - binding domain, which facilitates the anchoring of the 
TIR adaptor complex to the plasma membrane (Kagan and Medzhitov, 
2006), and a TRAF6 binding domain. TRIF contains both a TRAF6 binding 
domain and a RIP1 binding domain essential for interactions downstream, 
and for TRIF – dependent signalling (Watters et al., 2007).  
 
MyD88 – dependent TLR signalling to NF-ҡB 
MyD88 – dependent signal propagation results in the polyubiquitination of 
the Interleukin - 1 Receptor Associated Kinase 1 (IRAK1). IRAK1 is a 
member of the IRAK complex, which consists of a group of multi – domain 
protein kinases, including IRAK4 whose DD is essential for interaction with 
the death domain on MyD88 (Sasai and Yamamoto, 2013). Activation of 
IRAK4 leads to downstream phosphorylation of IRAK1 facilitating its 
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dissociation form the membrane bound complex leading to the subsequent 
phosphorylation and activation of the  IҡB (IKK) kinase complex (Cao et al., 
1996a). The association of Pellino proteins with IRAK1, specifically Peli1 – 
induced K63 – linked polyubquitination of IRAK1, is critical for the 
downstream phosphorylation and activation of the IKK complex (Moynagh, 
2009, Schauvliege et al., 2007). Tumour necrosis factor alpha receptor 
associated factor 6 (TRAF6) interacts with IRAK1 in the membrane bound 
receptor complex and in the cytosol, mediating IRAK1 - induced 
phosphorylation of the IKK complex but also the recruitment of another 
kinase complex, TAK1 (transforming growth factor β – activated kinase 1), 
prior to NF-ҡB activation (Jiang et al., 2002). TRAF6 – IRAK1 recruits TAK1 
from the membrane to form the TAK1 – TAB1 (TAK1 – binding protein 1) – 
TAB2 (TAK1 –binding protein 2) complex in the cytosol (Verstrepen et al., 
2008), which also activates the IKK complex (Shembade and Harhaj, 2015), 
resulting in the degradation of the NF-ҡB cytosolic inhibitory subunit IҡBα, 
and the nuclear translocation of NF-ҡB subunits, thus inducing the 
transcription of NF-ҡB – related genes (Wu et al., 2006, Moynagh, 2005). 
Both the kinase activity and adaptor functions of IRAK1 facilitate IRAK4 and 
MyD88 interaction, and are essential for TLR – mediated NF-ҡB activation 
(Gottipati et al., 2008).  
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MyD88 – independent TLR signalling to NF-ҡB 
The presence of a MyD88 – independent signalling pathway in response to 
LPS was first reported using MyD88-/- mice (Kawai et al., 1999). The MyD88 
– independent pathway, also called TRIF - dependent TLR signalling, 
requires the TIR adaptor domain protein TRIF (Yamamoto et al., 2003a). 
TRIF interacts with Receptor interacting Protein 1 (RIP1) and with Tumour 
necrosis factor alpha receptor associated factor 6 (TRAF6), to activate NF-
ҡB upon TLR3 and TLR4 stimulation (Kawai and Akira, 2007, Sato et al., 
2003). RIP1 facilitates the polyubiquitination of NEMO which is essential for 
the activation of the IKK complex by phosphorylation (Shembade and Harhaj, 
2015).  Peli1 – mediated ubiquitination of RIP1 is evident in TLR3 signalling, 
but not in TLR4 TRIF – dependent signalling (Sasai and Yamamoto, 2013).  
Additionally TRIF associates with TANK – binding kinase 1 (TBK1) and the 
IKK subunit IKKε to activate the Interferon Regulatory Factor 3 (IRF3) 
transcription factor (Kawai et al., 2001). Both MyD88 and My88-independent 
activation of NF-Ҡb induced by TLR4 is represented in the schematic in 
Figure 1.7. 
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Figure 1.7: Schematic diagram of TLR4 - NF-ҡB signalling, highlighting 
MyD88 – dependent (left) and MyD88 – independent (right) signalling to NF-
ҡB. Upon extracellular stimulation, CD14 and MD2 (not necessary for TLR2 
dimerization) modulate the homodimerization of TLR4. In MyD88 – 
dependent signalling this causes the recruitment of the TIR - adaptor 
molecules and further allows for the polyubiquitination of the IRAK complex 
by Pellino proteins. IRAK1 is activated following the interaction of the IRAK 
complex with Peli1 and TRAF6, which facilitates the activation of 
NEMO/IKKγ to the IKK complex leading to its phosphorylation and activation. 
The NF-ҡB inhibitor IҡBα is degraded and the NF-ҡB subunits p50 and p65 
are translocated to the nucleus, enabling NF-ҡB – dependent transcription of 
pro-inflammatory cytokines. MyD88 - independent signalling to NF-ҡB is 
facilitated by the interaction of TRIF with RIP1 or TRAF6, which leads to the 
activation of the IKK complex (Shembade and Harhaj, 2015, Sasai and 
Yamamoto, 2013, Moynagh, 2009).  
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 1.3.2 NF-ҡB 
TLR activation initiates a cascade of intracellular pathways, one of which 
results in the activation of Nuclear Factor kappa-light-chain-enhancer of 
activated B cells (NF-ҡB). NF-ҡB was discovered in 1986 by Sen and 
Baltimore who demonstrated the first stimulus of NF-ҡB activation to be the 
TLR4 ligand and endotoxin Lipopolysacccharide (LPS) (Sen and Baltimore, 
1986). Following decades of study it is now understood that the NF-ҡB family 
of proteins encompasses a group of transcription factors that regulate a large 
number of genes involved in inflammation, cell proliferation and apoptosis 
(Verstrepen et al., 2008, Doyle and O'Neill, 2006). The NF-ҡB family is 
divided into two subgroups; the Rel subfamily consisting of c-Rel, RelB, and 
p65 (RelA); and the NF-ҡB  subfamily consisting of p100 and p105 (Ghosh et 
al., 1998). Both subfamilies contain a highly conserved DNA - binding 
domain termed the Rel homology domain (RHD) (Camandola and Mattson, 
2007, Gilmore, 1990). NF-ҡB members p100 and p105 are transformed to 
the shorter, DNA – binding proteins p52 and p50, respectively, by partial 
proteolysis (Verstrepen et al., 2008). NF-ҡB signalling is a self-regulatory 
pathway as its inhibitor IҡBα is a target gene of NF-ҡB transcription, thus 
providing a negative feedback loop (Hoffmann et al., 2002).   
Classical or canonical NF-ҡB activation is induced by the activation of Toll-
like Receptors (TLRs), Interleukin-1 Receptor (IL-1R), and the Tumour 
Necrosis Factor Receptor (TNF-R) (Verstrepen et al., 2008, Doyle and 
O'Neill, 2006). NF-ҡB activation is regulated by a number of inhibitory 
proteins named IҡB (IҡBα, IҡBβ, IҡBγ and IҡBε), which retain NF-ҡB subunits 
in the cytosol by an interaction with IҡB proteins, usually IҡBα, and 
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stimulation - induced degradation of IҡBα allows the nuclear translocation of 
NF-ҡB subunits (Gilmore, 2006, Chen et al., 1996). The classical pathway to 
the activation of NF-ҡB phosphorylation of the IҡB kinase β (IKKβ) subunit is 
essential for the degradation of IҡBα (van Delft et al., 2015).  
The non - canonical NF-ҡB pathway plays a role in development and 
adaptive immunity and requires the phosphorylation of the IKK subunit IKKα, 
resulting in p100 phosphorylation instead of IҡBα (Hoffmann et al., 2006). 
Typically the canonical NF-ҡB pathway response is rapid, responding to 
multiple stimuli, whereas the non - canonical pathway is slow with a more 
specific activation by upstream stimuli (Sun, 2011). 
Non- canonical and canonical activation of NF-ҡB is illustrated in Figure 1.8 
below.  
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Figure 1.8: Schematic representing the Canonical and Non-canonical 
pathway to NF-ҡB activation. Adapted from (Sun, 2011). Canonical NF-ҡB 
signalling is induced by the activation of receptors such as TLRs, TNF-R and 
IL-1R, which through the phosphorylation of the IKKβ subunit of the IKK 
complex leads to the proteasomal degradation of IҡBα and nuclear 
translocation of p50 and p65 subunits. Non - canonical NF-ҡB signalling is 
induced by the activation of receptors such as CD40 (Cluster of 
Differentiation 40) and RANK (Receptor Activator of NF-ҡB), which leads to 
the phosphorylation of the IKKα subunit of the IKK complex, leading to p100 
processing and partial degradation via the proteasome and the nuclear 
translocation of the p52 and RelB subunits (van Delft et al., 2015, Sun, 
2011). 
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1.3.3 NF-ҡB in Neurodegenerative Disease 
NF-ҡB activation is associated with pathogenesis in chronic inflammation 
and autoimmunity (Lanzillotta et al., 2015, Lawrence, 2009, Gilmore, 2006, 
Pizzi and Spano, 2006). Classical NF-ҡB dimers, as represented by the p65 
and p50 subunits, are expressed in all cells of the CNS, including astrocytes 
(Sparacio et al., 1992),  neurons (Kaltschmidt et al., 1994b), and microglia 
(Nakajima et al., 1998). NF-ҡB has been implicated in neurodegeneration, 
however inhibition of NF-ҡB as a therapeutic target has proven difficult due 
to the loss of NF-ҡB – mediated anti - apoptotic effects which are 
neuroprotective (Srinivasan and Lahiri, 2015, Lawrence, 2009). In AD, it has 
been demonstrated that amyloid-β (Aβ) increased the immunoreactivity of 
p65 (O'Neill and Kaltschmidt, 1997) and activates NF-ҡB (Barger et al., 
1995). Although this activation is believed to be initially neuroprotective, the 
chronic activation of NF-ҡB contributes to the dysregulated inflammation 
typical of neurodegenerative pathology (Srinivasan and Lahiri, 2015, Frakes 
et al., 2014). 
 
1.3.4 TLRs in mutant SOD1 - induced Neurodegeneration 
There is an emerging emphasis on the role of the innate immune response in 
neurodegenerative disease (Hovden et al., 2013, Okun et al., 2011, Nguyen 
et al., 2004). Both TLR2 and CD14 were found to be upregulated in human 
post mortem brain samples of patients with AD, PD and ALS (Letiembre et 
al., 2009).  Amyloid-β – induced microglial activation requires CD14, TLR2 
and TLR4 (Reed-Geaghan et al., 2009), with aggregates of Prions and 
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Amyloid-β activating TLR2 (Trudler et al., 2010). Additionally, pro – 
inflammatory cytokine expression is upregulated in a TLR4 – dependent 
manner in AD transgenic mice (Jin et al., 2008), with tlr4 deficiency in AD 
mice resulting in reduced levels of pro-inflammatory cytokines (Walter et al., 
2007). Additionally, there is mounting evidence for TLR involvement in ALS 
pathology. Extracellular mutant SOD1 is reported to induce microglial 
activation via the MyD88 pathway, with an elevated pro-inflammatory 
response in wt mice post exposure to mutant SOD1, compared with    
MyD88 -/- mice (Kang and Rivest, 2007).  Additionally, both TLR2 and TLR4 
protein levels were found to be elevated in the spinal cord of SOD1G93A 
transgenic mouse spinal cord (Casula et al., 2011) .  A recent study showed 
that SOD1G93A mice lacking TLR4 had an extended survival and improved 
motor function skills compared with SOD1G93A expressing TLR4 (Lee et al., 
2015). Zhao and co – workers have demonstrated, using CD14-/- mice, that 
mutant SOD1G93A binds to CD14 (see Figure 1.9), an essential extracellular 
modulator of TLR2 and TLR4 signalling (Zhao et al., 2010). This study 
demonstrates that mutant SOD1G93A is a ligand for TLR2 and TLR4 and by 
this mechanism perpetuates microglial – mediated inflammation in SOD1 - 
induced ALS pathogenesis. 
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Figure 1.9: Schematic of TLR2 and TLR4 - mediated extracellular SOD1G93A 
toxicity. Extracellular SOD1G93A aggregates directly activate microglia by 
binding with CD14 which facilitates the dimerization and subsequent 
intracellular signalling of TLR2 and TLR4. Cytosolic protein complexes are 
assembled upon TLR2 and TLR4 stimulation and allow signal propagation to 
NF-ҡB which results in the transcription of pro-inflammatory cytokines (Zhao 
et al., 2010). 
 
 
 
 
 
 
                                                                                                            Chapter I: Introduction 
 
 
32 
 
1.4 BH3 - interacting domain death agonist (Bid) 
1.4.1 Apoptotic function of Bid 
Bid (BH3 - interacting domain death agonist), first identified in 1996, is a pro-
apoptotic BH3 – domain - only Bcl2 (B cell lymphoma 2) family member 
(Wang et al., 1996). Bid is pro - apoptotic in function and is a key executioner 
of the intrinsic apoptotic pathway (Adams and Cory, 1998). Full length Bid is 
structurally similar to Bax and Bak, both pro - apoptotic Bcl-2 family 
members, each containing a BH3 – only domain which is essential for the 
death agonist activity of Bid (Chou et al., 1999, Wang et al., 1996). Bid 
converges death receptor signals on the outer mitochondrial membrane, 
which subsequently leads to its permeabilization (Li et al., 1998). Proteolytic 
cleavage of full length Bid by caspase 8 leads to the translocation of the 
resulting C - terminal fragment, truncated Bid (tBid), to the mitochondria thus 
driving mitochondrial permeabilization, cytochrome c release and apoptosis 
(Crompton, 2000, Wei et al., 2000, Gross et al., 1999). The release of 
cytochrome c from the mitochondria initiates the caspase cascade (Chipuk 
and Green, 2008). Translocation of tBid to the mitochondria induces the 
further translocation or either Bax or Bak, which form a pore resulting in the 
permeabilisation of the mitochondria (Billen et al., 2008). Bid can also be 
cleaved by calpains (Mandic et al., 2002), Caspase 2 (Bonzon et al., 2006), 
and granzyme B (Sutton et al., 2000).  Additionally, Bid has been shown to 
sequester anti - apoptotic Bcl-2 family members and induce the 
oligomerization of both Bak and Bax (Scatizzi et al., 2007, Certo et al., 2006). 
However, Bid is dispensable for apoptosis in some cell types as 
demonstrated by studies using bid – deficient mice, whereby apoptosis was 
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not induced in hepatocytes upon stimulation of the death receptor Fas 
(Kaufmann et al., 2007, Yin et al., 1999).  Moreover, full length Bid has also 
been shown to preserve the genomic integrity of cells, by stimulating the 
DNA damage response (Zinkel et al., 2005). 
 
1.4.2 Bid and Inflammation 
Recent studies have suggested a non - apoptotic role of Bid in cell death via 
inflammatory mechanisms (Konig et al., 2014, Mayo et al., 2011, Yeretssian 
et al., 2011). NF-ҡB induction of Cyclooxygenase – II (COX-II), an NF-ҡB 
target gene, is mediated by Bid in MEFs (mouse embryonic fibroblasts) (Luo 
et al., 2010). Yeretssian and colleagues have demonstrated an interaction 
between Bid and the innate immune receptors Nucleotide - binding and 
Oligomerization Domain (NOD) proteins, and also implicated Bid to associate 
with the IKK complex, specifically NEMO (Yeretssian et al., 2011). 
Interestingly, bid - deficient hepatocytes report reduced expression pro - 
inflammatory cytokines and reduced inflammatory signalling (Wree et al., 
2015). Further studies carried out by Mayo and co - workers strengthened 
the hypothesis of the non - apoptotic inflammatory role of Bid (Mayo et al., 
2011). bid - deficient macrophages displayed reduced phagocytic function. In 
addition the study by Mayo and co - workers suggests that Bid plays a role in 
regulating the immunological profile of both microglia and macrophages by 
attenuating pro-inflammatory cytokine mRNA expression in response to LPS 
stimulation (Mayo et al., 2011). Our laboratory has shown that astrocytic Bid 
protein levels are induced in response to stimulation with LPS or the pro-
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inflammatory cytokines IL-1β and IFNγ. Additionally, this study from our 
laboratory demonstrated lower levels of COX-II in bid – deficient astrocytes 
compared with wt following IL-1β and IFNγ stimulation. Further examination 
of astrocytic Bid indicated an association between the IKKγ/NEMO subunit of 
the IKK complex with Bid following LPS stimulation (Konig et al., 2014). 
Importantly, Bid was not shown to be cleaved in response to pro-
inflammatory stimuli in astrocytes (Konig et al., 2014), indicating the role of 
inflammatory function lies with full length Bid.  
 
1.4.3. Bid and ALS pathogenesis 
Although recent studies have implicated Bid to play a role in inflammation, 
much is yet to be elucidated about the non - apoptotic function of Bid in 
neurodegenerative diseases. However, full length Bid has been found to be 
highly expressed in SOD1G93A transgenic mice (Guegan et al., 2002). In 
addition, increased levels of Bid was identified in the spinal cords of 
SOD1G93A transgenic mice compared with wt at post natal day (PND) 120 
(Konig et al., 2007).  The high levels of Bid reported in SOD1G93A mice may 
contribute to the chronic inflammation which contributes to disease 
progression. 
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 1.5   Aims of study 
As microglia are the primary neurological responders to inflammatory stimuli, 
such as aggregated misfolded proteins, neurotherapeutics with specific 
microglial immunomodulatory potential targeting innate immune signalling 
may prove to be successful. The desired therapeutic goal is the prevention of 
the M1 polarization of microglia which rapidly speeds up disease progression 
(Murdock et al., 2015, Henkel et al., 2009). Microglial activation state greatly 
affects ALS disease progression and obtaining a balance between the M2 
and M1 states may prove beneficial in ALS therapy (Tang, 2015). Enhanced 
understanding of the immune response throughout ALS pathogenesis and 
the balance between protective and pathogenic response will greatly affect 
the efficacy and development of therapeutics.  
The elucidation of the role of Bid in promoting the TLR4 - NF-ҡB pro-
inflammatory response in microglia offers a potential therapeutic target for 
the attenuation of chronic inflammation which contributes to the progression 
of ALS pathogenesis, and also other neurodegenerative diseases. The aim 
of this study was to examine the role of Bid as a positive regulator of TLR – 
NF-ҡB signalling in microglia; 
 Firstly, it is demonstrated that both autocrine and paracrine SOD1G93A 
– mediated toxicity leads to increased TLR2 and TLR4 levels and 
increased NF-ҡB activation in microglia.  
 Secondly, microglial Bid is established to have a positive role in 
promoting TLR4 signalling and subsequent NF-ҡB activation. 
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 Thirdly, the mechanism of action of Bid in this pathway is investigated, 
and the interactions of Bid with TLR4 - NF-ҡB pathway components 
are analysed. 
 Finally, Bid – dependent TRAF6 polyubiquitination is examined, with a 
specific focus on Peli1 – mediated activation of IRAK1 in the TLR4 – 
NF-ҡB pathway.  
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2. Materials and Methods 
2.1 Materials 
2.1.1 Equipment  
Table 2.1 List of Equipment used. 
 
  Equipment 
 
 Manufacturer 
  
Catalogue Number / Model 
 Plate Reader   Tecan  Genios 
 Semi – dry transfer cell   BioRad  TransBlot SD 
 PVDF Immunoblot Membrane   BioRad  162-0177 
 Electrophoresis Chamber   BioRad  Mini –Protean Tetra 
 Magnetic Rack for DYNAbeads  Millipore  MagnaGrIP
TM  
Rack, 
3004854 
 Lightcycler  Roche  2.0 
 Lightcycler Capillaries Roche  04 929 292 001 
 Cell culture well plates (6, 24, 
48, 96)  
 Sarstedt  83.3920, 83.3922, 83.1835 
 Dissection Forceps  Fine Science Tools  Dumont Forceps #5 
 Dissection Scissors  World Precision 
Instruments  
 Vannas Scissors 
 Dissection Scalpel   Swann - Morton  0563 
 Sonicater   Bandelux Electronic  004.00001744.179 
 Fluorescent Microscope   Nikon Eclipse  TE300 
 Chemiluminescent Imager   LAS 3000  FujiFilm 
 Nanodrop   Thermo Scientific  2000c 
 Cell Scrapers   Sarstedt  83.1830.03 
 Cell Culture flasks (T25, T75, 
T175)  
 Sarstedt  83.3910.002, 83.3911.002, 
83.3912.002 
 Dissection Microscope   SZ51  Olympus 
 Homogenizer  IKA  T25 Ultra - Turrax 
Fluorescent Microscope  Nikon  TE 300 
 Thermal Cycler  MJ Research  PTC - 200 
 Cell Strainer  BD Falcon  352340  
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2.1.2 Reagents 
Table 2.2: List of Reagents used. 
 
Reagent 
 
 
Manufacturer 
 
  
Catalogue Number 
 
ECL HRP Substrate 
 
 
Millipore 
 
MDR-100-030Q 
 
Sterile H2O 
 
 
 
Gibco, Life Technologies 
 
15230 - 147 
 
Milk Powder 
 
 
Marvel 
 
3023036 
 
10 X PBS 
 
 
Lonza 
 
BE15 – 517Q 
Tetramethyl – 
ethylenediamine (TEMED) 
 
Sigma Aldrich 
 
T9281 
 
APS (Ammonium 
Persulphate) 
 
 
Sigma Aldrich 
 
A3078 
 
TRIS - HCl 
 
 
Sigma Aldrich 
 
T3253 
 
Protease Inhibitor 
 
Sigma Aldrich 
 
 
P8340 
 
Phosphatase Inhibitor (1 & 2) 
 
 
 
Sigma Aldrich 
 
P5726, P0044 
 
Laminin 
 
 
Sigma Aldrich 
 
L -2020 
 
Poly - ornithine 
 
 
Sigma Aldrich 
 
P4957 
 
DNase – 1 
 
 
Sigma Aldrich 
 
DN-25 
 
Trypsin – EDTA 
 
 
Sigma Aldrich 
 
T4049 
 
Dimethyl sulfoxide (DMSO) 
 
 
Sigma Aldrich 
 
D8418 
 
Granulocyte - macrophage 
colony - stimulating factor    
(GM – CSF) 
 
  
R & D Systems 
 
415-ML-010 
 
Macrophage colony - 
stimulating factor (M – CSF) 
 
 
R & D Systems 
 
416-ML-010 
Lipopolysaccharide (LPS, 
from Escherichia coli 
0111:B4) 
 
 
Sigma Aldrich 
 
L4391 
 
Sodium dodecyl sulphate 
(SDS) 
 
 
Sigma Aldrich 
 
L3771 
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Reagent 
 
 
Manufacturer 
 
  
Catalogue Number 
 
40 % Acrylamide 
 
 
Sigma Aldrich 
 
A7168 
 
Fungizone 
 
 
Invitrogen 
 
15290026 
 
Glial cell - derived 
neurotrophic factor (GDNF) 
 
 
Promega 
 
G2781 
 
Ciliary neurotrophic factor 
(CNTF) 
 
 
R&D Systems 
 
557-NT 
 
L - glutamine 
 
 
Sigma Aldrich 
G7513 
 
Penicillin / Streptomycin 
 
 
Sigma Aldrich 
P0781 
 
Isopropanol 
 
 
Sigma Aldrich 
I9516 
 
Methanol 
 
 
Sigma Aldrich 
322415 
 
Suphuric Acid (H2SO4) 
 
 
Sigma Aldrich 
 
38308 
 
Cycloheximide 
 
 
Sigma Aldrich 
 
C7698 
 
Bortezomib 
 
 
Millennium 
Pharmaceuticals 
(Cambridge, MA, USA) 
 
na 
 
Lipofectamine 
 
 
Invitrogen 
 
11668 - 019 
 
HP Xtreme Gene Reagent 
 
 
Roche 
 
06 366 236 001 
 
OptiMEM 
 
 
Gibco, Life Technologies 
 
31985 - 047 
 
LB agar 
 
 
Sigma Aldrich 
 
L2897 
 
LB broth 
 
 
Sigma Aldrich 
 
L3022 
 
Bovine Serum Albumin 
(BSA) 
 
 
Fisher Scientific Ireland 
 
BPE9700 
 
PAGE Ruler protein ladder 
 
Fermentas 
 
 
26620 
 
RPMI 1640 
 
Sigma Aldrich 
 
 
R0883 
 
 
DMEM 
 
 
Lonza 
 
BE12 604F 
 
DMEM-F12 
 
 
Gibco 
 
31330 038 
 
Paraformaldehyde 
 
Sigma Aldrich 
 
158127 
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2.1.3 Kits 
Table 2.3: List of Kits used. 
 
Kit 
 
 
Manufacturer 
 
Catalogue Number 
 
Pierce TM BCA (Bicinchoninic 
acid ) assay kit 
 
 
Thermo Scientific 
 
23225 
 
EndoFree ® Maxi Prep Kit 
 
 
Qiagen 
 
 
12362 
 
Quantitech SYBR Green 
PCR Master mix 
 
 
Qiagen 
 
 
204143 
 
Qiagen RNA easy kit 
 
Qiagen 
 
 
74104 
 
QiaShredder 
 
Qiagen 
 
 
79654 
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2.1.3 Antibodies 
Table 2.4: Primary Antibodies used for Western Blotting, Flow Cytometry, 
Immunocytochemistry and Immunoprecipitation Experiments.  All of the 
below antibodies were used at the following dilutions for 
immunocytochemistry and Western Blot experiments unless otherwise stated 
in subsequent sections. For immunoprecipitation antibodies were used at a 
concentration of 5 μg / sample (100 - 400μg protein). 
 
Primary Abs 
 
Manufacturer 
 
Species 
 
Catalogue 
Number 
 
Dilution 
 
anti - Bid 
 
Enzo 
Laboratories 
 
Rabbit 
 
AR-52 
 
1:1000 
 
anti - Bid 
 
Abcam 
 
Rabbit 
 
ab62469 
 
1:1000 
 
anti - CD11b 
 
Abcam 
 
Rat 
 
ab8878 
 
1:200 
 
Anti - CD45 
 
Abcam 
 
Rabbit 
 
ab10558 
 
1:500 
 
anti - COX-II 
 
BD Biosciences 
 
Mouse 
 
610203 
 
1:500 
 
anti - FLAG 
(OctA-Probe D-
8) 
 
Santa Cruz 
 
Rabbit 
 
sc-807 
 
1:1000 
 
anti - GAPDH 
 
Abcam 
 
Mouse 
 
ab8245-100 
 
1:5000 
 
anti - GFAP 
 
Sigma Aldrich 
 
Mouse 
 
G3893 
 
1:200 
 
anti - GFP 
 
Calbiochem 
 
Rabbit 
 
PC408 
 
1:1000 
 
anti - Iba1 
 
Abcam 
 
Goat 
 
ab5076 
 
1:500 
 
anti - IL-1β 
 
Abcam 
 
Rabbit 
 
ab9722 
 
1:2000 
 
anti - IκBα 
 
Cell Signaling 
 
Rabbit 
 
9242 
 
1:500 
 
anti - K63 – 
Ubiquitin 
 
Enzo 
Laboratories 
 
Mouse 
 
HWA4C4 
 
1:1000 
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Primary Abs 
 
Manufacturer 
 
Species 
 
Catalogue 
Number 
 
Dilution 
 
anti - LUB9 
(Linear Poly-
ubiquitin 
Specific )  
 
Life Sensors 
 
Mouse 
 
AB130 
 
1:2000 
 
anti - MyD88 
 
Abcam 
 
Rabbit 
 
ab2064 
 
1:1000 
 
anti - NEMO / 
IKKγ 
 
Santa Cruz 
 
Rabbit 
 
sc8330 
 
1:200 
 
anti - Peli1 
 
Abcam 
 
Rabbit 
 
ab13812 
 
1:1000 
 
anti - pIKKα/β 
(Serine 
176/180) 
 
Cell Signaling 
 
Rabbit 
 
92465 
 
1:500 
 
anti - pp65 
(Serine 536) 
 
Cell Signaling 
 
Rabbit 
 
30315 
 
1:500 
 
anti - SMI32 
 
Covance 
 
Mouse 
 
LN E10167EF 
 
1:500 
 
anti - S100b 
 
Sigma Aldrich 
 
Mouse 
 
S 2532 
 
1:500 
 
anti - TLR2 
 
Abcam 
 
Rabbit 
 
ab108998 
 
1:200 
 
anti - TLR4 
 
Santa Cruz 
 
Rabbit 
 
sc-10741 
 
1:100 
 
anti - TRIF 
 
Abcam 
 
Rabbit 
 
ab13810 
 
1:1000 
 
anti - Ubiquitin 
(PD4i) 
 
Santa Cruz 
 
Mouse 
 
sc-8017 
 
1:1000 
 
anti - α-Tubulin 
 
Sigma Aldrich 
 
Mouse 
 
T6199 
 
1:5000 
 
anti - β-Actin 
 
Sigma Aldrich 
 
Mouse 
 
A3853 
 
1:5000 
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Table 2.5: Secondary Antibodies used for Western Blot, Flow Cytometry and 
immunocytochemistry experiments. 
 
 
Secondary Ab 
 
Manufacturer 
 
Species 
 
Catalogue 
Number  
 
Dilution 
 
anti-mouse HRP 
conjugate 
 
Millipore 
 
mouse 
 
AP124P 
 
1:5000 
 
anti-rabbit HRP 
conjugate 
 
Millipore 
 
rabbit 
 
AP132P 
 
1:5000 
 
anti- mouse 
Alexa 488 
 
Invitrogen 
 
mouse 
 
A21441 
 
1:500 
 
anti- mouse 
Alexa 568 
 
Invitrogen 
 
mouse 
 
A10037 
 
1:500 
 
anti-rabbit 
Alexa 568 
 
Invitrogen 
 
rabbit 
 
A11011 
 
1:500 
 
anti-rabbit 
Alexa 488 
 
Invitrogen 
 
rabbit 
 
A21441 
 
1:500 
 
anti-rat 
Alexa 488 
 
Invitrogen 
 
rat 
 
A11006 
 
1:500 
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2.1.4 Plasmids 
Table 2.6: Plasmid information. 
 
Plasmid name 
 
Promoter 
 
Bacterial 
Selection 
 
Origin 
 
pCFP 
 
CMV 
 
Kanamycin 
 
Clontech 
 
pSOD1G93A - CFP 
(CFP fusion protein) 
 
CMV 
 
Kanamycin 
 
Cloned by Dr. Mathew 
King 
 
pDs-Red - Bid 
 
------- 
 
Kanamycin 
 
Lab stock, Origin unknown 
 
pBid – mCherry - N1 
 
CMV 
 
Kanamycin 
 
Cloned by Dr. Caoimhín 
Concannon 
 
pTRAF6 wt FLAG 
(FLAG tag) 
 
 
CMV5 
 
Ampicillin 
 
Addgene (Zhong and 
Kyriakis, 2004) 
 
pSEAP – NF- ҡB 
reporter 
 
ҡB promoter 
sequence 
 
Ampicillin 
 
Clontech 
 
pUbiquitin – HA 
 
CMV 
 
Ampicillin 
 
Donated from James 
Burrows (Centre for 
Cancer Research, Belfast, 
Ireland) 
 
pK63 – linked 
Ubiquitin 
 
CMV 
 
Ampicillin 
 
Donated from James 
Burrows (Centre for 
Cancer Research, Belfast, 
Ireland) 
 
pK48 – linked 
Ubiquitin 
 
CMV 
 
Ampicillin 
 
Donated from James 
Burrows (Centre for 
Cancer Research, Belfast, 
Ireland) 
 
phRL-TK-luc reporter 
(Renilla-luciferase) 
 
 
Thymidine Kinase 
response element 
 
Ampicillin 
 
Promega (Cat#E6241) 
pGL4.32[luc2P/NF-κB-
RE/Hygro] (NF-ҡB – 
luciferase reporter) 
 
NF-ҡB response 
element 
 
Ampicillin 
 
Promega 
                           
pIRES2 – DsRed2 
 
CMV 
 
Ampicillin 
 
Clontech 
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2. Methods 
2.2.1 Cell Culture 
2.2.1.1 Culturing of Microglial BV-2 cells (murine microglial cell line): 
BV-2 cells are an immortalised cell line that displays the functional and 
morphological features of microglia (Blasi et al., 1990, Bocchini et al., 1992). 
The BV-2 cells were cultured in T75 flasks at 37° C and 5 % CO2 in the 
following culture media: RPMI (Lonza), 10 % heat – inactivated Fetal Bovine 
Serum (FBS) (F7524, Sigma-Aldrich, Arklow, Co. Wicklow), Penicillin (100 
μg / ml) – Streptomycin (100 μg / ml) (Pen/Strep) (P0781, Sigma-Aldrich), 2 
mM L-glutamine (G7513, Sigma-Aldrich). The cells were passaged at a ratio 
of 1:5 every 3 days, or as needed for experiments. 
 
2.2.1.2 Culturing of Motoneuron NSC-34 cells (murine motoneuron 
cell line): 
NSC-34 cells are a hybrid cell line generated by fusing aminopterin-sensitive 
neuroblastoma N18TG2 with motor neuron-enriched embryonic day 12 - 14 
spinal cord cells (Cashman et al., 1992). Our NSC-34 cells were kindly 
donated by Dr. Adrian Higginbottom (Pamela Shaw lab, University of 
Sheffield). NSC-34 cells were cultured in DMEM with high glucose (Lonza, 
4.5 g / L glucose, 500 mls), 10 % heat – inactivated FBS, 2 mM L-glutamine, 
and 1 % Pen/Strep. The cells were passaged at a ratio of 1:2 every 3 days or 
as needed for experiments. Seeding densities for cell lines are listed in table 
2.7. 
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Table 2.7: Seeding densities for cell lines and primary cells. 
 
Dish 
  
Area 
(mm2) 
 
Density 
(seeding) 
 
Medium (ml) 
 
Multi-well 
Plates 
 
6 well plate 
 
962 
 
0.35 X 106 
 
2 
  
24 well plate 
 
200 
 
0.1 X 106 
 
0.5 
 
  
48 well plate  
 
100 
 
0.05 X 106 
 
0.25 
 
  
96 well plate 
  
0.02 X 106 
 
 
0.1 
 
Flasks 
 
T-25 
 
2500 
 
1.2 X 106 
 
 
5 
  
T-75 
 
7500 
 
3.5 X 106 
 
 
10 
 
Chamber Slide 
 
8 well 
 
63 
 
0.5 X 106 
 
 
0.25 
 
Willco Dish 
  
70 
 
0.1 X 106 
 
 
0.2  
 
2.2.1.3 Ethics and Animal Licence Information 
All procedures involving animals were conducted under a licence from the 
Department of Health and Children as well as the Health Products 
Regulatory authority in Ireland. Procedures were reviewed by the Ethics 
Committee of the Royal College of Surgeons in Ireland. The ethics licence 
covering the decapitation of mouse pups and the culturing of cortices is 
project authorisation number AE19127-P005 and included approximately 282 
wt pups and 170 bid-/- pups. The euthanizing SOD1G93A mice, using sodium 
pentobarbitone, for harvesting of cortices was covered under the licence 
                                                                                       Chapter II: Materials and Methods 
 
 
48 
 
B100/4414 (REC625b), and included euthanizing 3 SOD1G93A mothers at 
day 50 and 3 mothers at Day 90. The license AE19127-P004 covered 
euthanasia of wt and bid-/- mothers, using sodium pentobarbitone, for the 
removal of embryos and subsequent culturing of spinal cord motoneurons, 
and here 2 mothers of each genotype were euthanized in order to obtain 
embryos. 
 
2.2.1.4 Preparation of Primary Mixed Glial Cultures 
Mixed glial cultures were prepared from the cortices of P0/P1 bid-/- and wt 
mice pups. The cortices were dissected and the meninges were removed. 
The cortices were then incubated in 0.25 % EDTA Trypsin (Sigma) at 37° C 
for 5 minutes. DMEM-F12 (Gibco, Life Technologies) containing Pen/Strep (1 
%, Sigma-Aldrich) and heat – inactivated FBS (10 %, Sigma-Aldrich) was 
then added to the cortices containing trypsin and briefly centrifuged (300 x g 
for 1 minute). The Trypsin / DMEM-F12 (+ P/S + FBS) solution was removed 
and replaced with fresh DMEM-F12 (+ P/S + FBS). The cortices were 
triturated thoroughly, with the supernatant was passed through a nylon filter 
(40 μm) and transferred to a new falcon tube before centrifugation at 800 x g 
for 6 minutes. The pelleted cells were then resuspended in DMEM-12 and 
plated at a density of approximately 3 cortices / T75 flask.   
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2.2.1.5 Isolation of Primary Microglia 
One day post mixed glial plating the cell media was replaced with fresh 
DMEM-F12 (+ P/S + FBS) containing cytokines promoting microglia growth; 
M-CSF (10 ng / ml, R&D Systems, 416-ML-010), and GM-CSF (20 ng / ml, 
R&D Systems, 415-ML-010) (Suzumura et al., 1990). When the microglial 
numbers were satisfactory for the pending experiment the flasks were 
shaken on a plate shaker at 900 rpm for 20 minutes and tapped on the side 
of the flask in order to enable the detachment for the microglia form the 
underlying astrocytic layer. The media containing the detached and floating 
microglia was collected and centrifuged at 800 x g for 6 minutes. The 
pelleted microglia were resuspended in 1 ml DMEM-F12 (+ FBS + P/S), 
counted using a haemocytometer, and plated at an appropriate seeding 
density for the dish (listed in table 2.2.1). The remaining cells in the T75 flask 
can be treated again with cytokines M-CSF and GM-CSF in order to culture 
more microglia or alternatively be trypsinised, re-plated and cultured in the 
absence of GM-CSF and M-CSF in order to obtain astrocyte cultures. 
An alternative method of microglial isolation, isolation by trypsinization 
(Saura et al., 2003) was investigated. Although the trypsinization method 
proved beneficial with regard to a high yield of microglia, the purity is not 
sufficient (approximately 70 % compared with 90 % + purity from shaking 
method) and therefore the shaking method described above was adopted for 
all experiments involving primary microglia. 
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2.2.1.6 Preparation of Spinal Cord mixed Motoneurons 
 
 Spinal Cord Dissection from E12 embryos  
C57 black 6 mice pregnant with E12 pups were anaesthetised with 100 μl of 
20 % sodium pentobarbitone and dissected only when paw withdrawal 
reflexes ceased. The abdomen was sprayed with ethanol and rubbed with 
iodine before an incision was made along the ventral midline. The embryonic 
sacs were removed and placed in sterile PBS on ice. The embryos were 
removed from the sac one at a time and placed in sterile petri dishes 
containing PBS under the dissection microscope. The spinal cord dissection 
procedure was carried out by first separating the spinal cord form the body of 
the embryo. The embryo was decapitated using a sterile scalpel and the skin 
was removed along the dorsal surface covering the length of the spinal cord 
using a sterile forceps allowing the spinal cord and embryo to become 
separated. The meninges were removed and the dorsal horns of the spinal 
cord were removed using a sterile scalpel. The ventral horn of each spinal 
cord was placed into PBS in a falcon tube and incubated on ice.   
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 Purification of mixed Motoneurons form Spinal Cord 
Table 2.8: Reagent volumes for Complete Neurobasal Media recipe (50 
ml total volume). 
 
Reagent 
 
Final Volume (ml) 
 
Company 
 
Neurobasal Media 
 
47.5 
 
 
Gibco (Dublin, Ireland) 
 
Horse Serum 
 
1 
 
Biosciences (Dublin, Ireland) 
 
Glutamine 
 
0.012 
 
Sigma – Aldrich (Co. Wicklow, Ireland) 
 
Penicillin / 
Streptomycin 
 
0.05 
 
Sigma – Aldrich (Co. Wicklow, Ireland) 
 
B27 
 
1 
 
Biosciences (Dublin, Ireland) 
 
GDNF 
 
0.01 
 
Promega (Southhampton, UK) 
 
CNTF 
 
0.01 
 
R&D Systems (Abington, UK) 
 
Fungizone 
 
0.05 
 
Invitrogen (Dublin, Ireland) 
 
 
 
The spinal cords were allowed to settle at the bottom of the falcon tube, the 
PBS was removed and replaced with 1 ml of fresh PBS containing 10 μl 
0.025 % trypsin for 10 minutes at 37° C. The ventral horns were removed 
and placed in a fresh falcon tube containing 900 μl Complete Neurobasal 
media with 25 μl 1 mg / ml DNase 1 and gently dissociated by trituration. 
After 2 minutes, when the cellular debris was allowed the settle, the 
supernatant was transferred to a fresh falcon containing 800 μl Complete 
Neurobasal media with 25 μl DNase 1 (1 mg / ml) and further dissociated by 
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trituration. The cell suspension was centrifuged at 300 x g for 3 minutes. The 
pellet was resuspended in Complete Neurobasal media and counted using a 
haemocytometer (see table 2.8 for complete Neurobasal media 
composition). Cells were plated at a density of 0.25 x106 cells / well in a 24 
well plate pre-coated with polyornithine and laminin. 24 well multiwell plates 
were coated with 1.5 mg / ml polyornithine in sterile H2O and incubated at 
room temperature overnight. The polyornithine was aspirated and the wells 
were washed with H2O and incubated with 1 mg / ml laminin in DMEM 
culture media for 2 h at 37° C.  The Complete Neurobasal media was fully 
replaced on the cells on DIV2 and DIV5 and the cells were harvested for 
Western Blot analysis on DIV7 (day in vitro 7). See figure 2.1 for SMI32 
positive motoneurons in mixed motoneuron cultures. 
 
 
Figure 2.1: SMI-32 – positive and GFAP - positive cells in mixed motoneuron 
cultures DIV7. Mixed cultures were immunostained with anti - SMI-32 to 
identify motoneurons. Co - staining was carried out using anti - GFAP to 
stain astrocytes, and Hoechst to stain nuclei. 
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2.2.1.7 Tissue homogenization 
Mouse Cortices from post – natal day mice (PND 50 and PND 90) were 
harvested by Dr. Karen Coughlan. Cortical tissues were homogenised in 500 
µl RIPA buffer / cortex, plus 1:100 protease and phosphatase inhibitors, and 
the cortices were dissociated using a homogenizer to mechanically break the 
tissue. The cortices were incubated on ice for 20 minutes prior to 
centrifugation at 4° C at 300 x g for 15 minutes. The supernatant was stored 
at -80° C and subsequently prepared for immunoprecipitation analysis. 
2.2.2 Preparation of Plasmids and Transfections 
2.2.2.1 Generation of competent cells 
Competent bacteria were generated from Escherichia Coli DH5α glycerol 
stocks, which were streaked on Luria Betani (LB) agar plates (40 g / l LB-
Agar).  After an overnight incubation at 37° C, a single colony was incubated 
with 5 ml LB broth (20 g / l) 37° C overnight, rotating at 200 rpm. The 
bacterial pre - culture was further incubated with 200 ml LB broth overnight at 
37° C rotating at 200 rpm, and then centrifuged at 1600 x g for 10 minutes at 
4 ° C. The resulting pellet was resuspended in 50 mM CaCl2  (100 ml) and 
incubated on ice for 2 h before being centrifuged for 10 minutes at 1600 x g 
at 4° C, and resuspended in 5 ml of 50 mM CaCl2 and 15 % glycerol. The 
competent bacterial cells were snap frozen using liquid nitrogen and stored 
at -80° C. 
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2.2.2.2 Plasmid Transformation 
100 ng of plasmid DNA was added to 50 μl competent cells and incubated on 
ice for 10 minutes, after which time heat shock at 42° C for 1 - 2 minutes was 
used as a method for plasmid uptake. The plasmid cell solution was placed 
back on ice for 2 minutes. 1 ml of LB broth was added and the solution was 
incubated at 37° C for 1 h on a heating block. The solution was centrifuged at 
5000 rpm for 5 minutes at room temperature and the resulting pellet was 
resuspended in 20 μl  LB media and spread on an agar plate containing the 
appropriate antibiotic resistance (Kanamycin (50 μg / ml or Ampicillin (100 μg 
/ ml)). The plates were incubated overnight at 37° C and a single colony was 
picked and grown up in a pre-culture of LB media containing the appropriate 
resistance (1:1000 dilution) for 8 h before 200 – 250 μl  was added to 250 ml 
LB media (containing appropriate resistance bacteria) and incubated 
overnight at 37° C. The culture was centrifuged at 6000 x g for 20 minutes at 
4° C and the DNA – containing pellet was ready to be purified using the 
Qiagen EndoFreeTM MaxiPrep kit. All plasmids were kept sterile and plasmid 
containing eppendorfs were only opened inside the sterile air flow hood. 
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2.2.2.3 Transfection of cells with CFP, SOD1wt* and SOD1G93A* 
plasmids by Electroporation (Amaxa Nucleofector, Lonza)                                                                                                                          
* Both SOD1wt and SOD1G93A – CFP fusion encoding plasmids were 
generated by Dr. Mathew King, Department of Physiology, Royal College of 
Surgeons in Ireland. See figure 2.2 below for plasmid map.   
 
                                      
 
       SOD1wt  /  SOD1G93A  insertion 
Figure 2.2: pECFP – C1 Vector information (Clontech). Human SOD1wt or 
SOD1G93A was inserted into the pECFP-C1 Vector by Xho I and BamH I (as 
highlighted above). 
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 BV-2 cells were harvested by trypsinization and counted. A density of 5 X 
106 cells per 5 μg of plasmid was used for each Amaxa cuvette. The required 
cell number was washed in RPMI at 90 x g for 10 minutes, and the 
supernatant was removed completely. The pellet was resuspended carefully 
in 100 μl RPMI (in place of nucleofector solution) per Amaxa cuvette. 5 μg 
DNA was combined with each 100 µl cell suspension in RPMI in an 
eppendorf and pipetted carefully into a Nucleofector cuvette. The cuvette 
was placed in Nucleofector cuvette holder and the programme A-023 was 
selected (programme carefully optimized for BV-2 cells based on cell viability 
and cell transfection efficiency). After electroporation had taken place the 
cuvette was removed from the Nucleofector and 1 ml RPMI was added to the 
cuvette and the cells were completely resuspended. Each cuvette was 
incubated at 37° C in the incubator for 5 minutes to let the cells recover. The 
contents of each cuvette were then plated into 2 wells of a 6 well plate (500 
µl into each). Full BV-2 media was added to each well (2 mls total volume for 
6 well plate), and the plate was incubated at 37° C. Transfection efficiency 
was calculated by fluorescence microscopy using the CFP channel (using 
standard filter settings), at the desired timepoint. The homology of GFP and 
CFP protein sequences is 97% and therefore it is likely that CFP levels can 
be detected using an anti - GFP antibody in Western Blot analysis.  
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2.2.2.4 Transfection of NSC-34 cells with SOD1 plasmids using 
Lipofectamine to generate SOD1 conditioned – Media 
 
Table 2.9: Transfection parameters for CFP, SOD1wt-CFP and SOD1G93A –
CFP plasmids using Lipofectamine. Calculations based on one well per 
specified dish. 
 
Well Plate 
 
Total Volume of 
Transfection Mix (μl) 
 
Plasmid amount 
(μg) 
 
Lipofectamine 
Volume (μl) 
 
6 well plate 
 
300 
 
1.5 
 
3 
 
24 well plate 
 
100 
 
0.5 
 
1 
 
48 well plate 
 
50 
 
0.25 
 
0.5 
 
96 well plate 
 
20 
 
0.1 
 
0.2 
  
 
NSC-34 cells were transfected by Reverse Transfection using Lipofectamine 
2000 Reagent (Invitrogen, 11668-030). The cells were plated at a density of 
0.3 x 106 cells / well of a 6 well plat. CFP, SOD1wt – CFP and SOD1G93A – 
CFP plasmids were transfected at a concentration of 5 µg plasmid / well 
using Lipofectamine (6 µl / well). The Lipofectamine was combined with 
OptiMEM (6 µl Lipofectamine: 100 µl OptiMEM) in an eppendorf. The 
plasmid DNA (5 µg) was added to OptiMEM (100 µl / well). Table 2.9 shows 
the transfection conditions and concentrations of plasmids used. The two 
solutions were combined and incubated at room temperature for 20 minutes. 
The transfection solution was then added to the cells and incubated at 37° C 
for 5 hours. After 5 hours the transfection solution was removed and the cells 
were washed carefully with 1 x PBS and full NSC-34 media (DMEM-F12 + 10 
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% FBS, 1% Pen/Strep + 1 % L-glutamine) was added to the wells overnight.  
Serum free NSC-34 media was added to the wells 24 hours post transfection 
and the media was collected after 3 days. SOD1-CFP content in conditioned 
– Media was determined by Western Blot analysis. 1 ml of CFP- cMedia, 
SOD1wt – CFP cMedia, or SOD1G93A - cMedia were transferred to Amicon 
Ultra 10 K filter tubes (Millipore) and centrifuged at 14,000 rpm for 45 
minutes 4° C. 6 X loading buffer was added to the flow - through and the 
sample was boiled for 5 minutes prior to being loaded on an acrylamide gel 
and probed using an anti - GFP antibody. 
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2.2.2.5 Transfection of Luciferase Plasmids and Luciferase Assay to 
quantify NF-ҡB Activation 
 
 
Figure 2.3: The pGL4.32[luc2P/NF-ҠB-RE/Hygro] Vector map (Promega). 
The pGL4.32[luc2P/NF-ҠB-RE/Hygro] Vector contains five copies of an NF-
κB response element (NF-κB-RE). The NF-κB-RE drives the transcription of 
the luciferase reporter gene luc2P (Photinus pyralis).  
 
BV-2 cells were co-transfected with Renilla and Firefly Luciferase Reporter 
Gene Vectors; NF-κB-RE, firefly reporter vector (Promega, Southampton, 
UK, Cat#E8491, GenBank:EU581860.1, see figure 2.3 above for plasmid 
map), and the Renilla - luciferase expressing construct under constitutive 
thymidine - kinase promoter control (phRL-TK-luc, Promega, Cat#E6241). 
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The ratio of luciferase plasmids used was 12:1  Renilla  - luciferase :  Firefly - 
luciferase (0.2 µg / well total plasmid concentration). The plasmids were 
mixed well by pipetting in an eppendorf before OptiMEM (Sigma, 1 µg 
plasmid per well / 100 μl) was added. HP Xtreme Reagent was used as a 
transfection reagent in for NF-ҡB luciferase experiments as it appeared less 
toxic than lipofectamine. 2 µl HP Xtreme Reagent / µg plasmid was added 
drop wise to the solution of plasmid + OptiMEM and the transfection mix was 
incubated at room temperature for 20 minutes. BV-2 cells were transfected 
with the Luciferase plasmids by Reverse Transfection (adding the 
transfection mix to cells in suspension as they are passaged, which 
appeared to increase transfection efficiency). 5 hours after cells were plated 
in the transfection mix the solution was removed and replaced with 250 µl / 
well in 48 well plate of fresh BV-2 media (RPMI + 10 % FBS, 1 % L-
glutamine and 1 % Pen/Strep). The Luciferase assay was carried out 24 – 48 
h post transfection using the Dual Luciferase Assay Kit (Promega). 
Luciferase mixes were made up as follows; solutions were thawed and 10 
mls Firefly Luciferase Assay Buffer was added to D - luciferase to a final 
volume of 0.2 mg / ml. Renilla Luciferase Assay Solution was added to 100 X 
Coelenterazine (50:1, previously made – up in kit) as described by the 
manufacturer. Both solutions were stored until further use at -20° C.  The 
Berthold Luminometer software was formatted so that injectors dispense 
38.5 µl of each luciferase mix per well. Injectors were washed with ethanol 
and dH2O, and then primed with luciferase mixes prior to each experiment. 
15 µl of each sample cell lysate was added to the wells of the 48 well plate. 
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Luminescence generated by firefly- or renilla luciferase substrates was read 
for 10 seconds of integration time, following 2 seconds of lag-time.  
2.2.2.6 SEAP assay protocol 
The SEAP assay was carried out using the Phospha-LightTM System kit 
(T1015, Applied Biosystems, Life Technologies, Dún Laoighaire, Co. Dublin, 
Ireland). This assay detects secreted alkaline phosphatase (SEAP) in cell 
culture supernatant using the enzymatic properties of the secreted reporter 
product. Transfection of BV-2 cells or primary microglia was carried out using 
the SEAP-NF-ҡB vector and EGFP as a transfection control (SEAP- NF-ҡB: 
EGFP, 3:1), with lipofectamine as a transfection reagent in OptiMEM. See 
table 2.10 below for concentration and ratios used.  
Table 2.10: Transfection parameters for SEAP- NF-ҡB transfection of BV-2 
cells and primary microglia. 
 
Multiwell 
Plate 
 
Cell Seeding 
Density 
 
Plasmid 
amount (μg) 
 
Lipofectamine 
Volume (μl) 
 
OptiMEM 
Volume (μl) 
 
48 well 
plate 
 
0.05 x 106 
 
0.15 μg/well 
SEAP-NF-ҡB : 
EGFP 
3 : 1 
0.1μg : 0.05 μg 
 
Lipofectamine : 
DNA 
2 : 1 
0.3 μl / well 
 
40 μl 
20 μl + DNA 
combined with 
20 μl + 
Lipofectamine 
 
 
24 h post transfection the cells were treated with serum free DMEM-F12 (+ 
P/S + L-glutamine) for 2 h prior to treatment with LPS or Vehicle (1 X PBS). 
The cell culture media was collected 1 h post LPS stimulation and 50 μl was 
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combined with 50 μl 1 X Dilution Buffer and incubated for 30 minutes at     
65° C on a thermocycler block. The samples were cooled on ice and 50 μl of 
each sample were pipetted into a black 96 - well multiwell plate with 50 μl of 
Assay Buffer added to each well containing sample, and incubated at room 
temperature for 5 minutes. A standard curve of alkaline phosphatase was 
obtained by diluting purified human placental alkaline phosphatase 1 : 50  
with assay buffer and pipetting a range of volumes from 1 μl to10 μl into a 
multiwell plate and 50 μl of Assay Buffer was added to each well.  50 μl of 
Reaction Buffer containing CSPD® chemiluminescent substrate (1 : 20 
CSPD : Reaction Buffer Diluent) was added to each well and incubated for 
20 minutes before being luminescence was read on a luminometer (Berthold) 
with readings measured at 1 minute / well. 
 
2.2.3 Cell culture treatments 
2.2.3.1 LPS treatment 
Lipopolysachharide (LPS) was sonicated for 5 minutes prior to use. Primary 
microglia and astrocytes were stimulated with 100 ng / ml LPS in serum – 
free culture media for the desired timepoints.  BV-2 cells were treated with 1 
µg / ml LPS in serum – free culture media for the desired timepoints. As LPS 
was resuspended in 1 X PBS, the vehicle control treatment for cells was 1 x 
PBS. 
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2.2.3.2 Bid Inhibitor treatment 
BV-2 cells were treated with 10 µM or 100 µM Bid Inhibitor (Sigma, BI-6C9). 
Bid Inhibitor was resuspended in DMSO to a concentration of 50 mM, and 
further diluted in DMSO for each treatment. DMSO was used as the control 
vehicle in BV-2 cells not treated with Bid Inhibitor. The Bid Inhibitor was 
added to each well one hour prior to LPS treatment.  
2.2.3.3 Addition of DUB inhibitor (PR-619) 
In order to prevent the degradation of polyubiquitin chains by de-
ubiquitinating enzymes upon cell lysis, a DUB inhibitor (PR-619, SI9619, Life 
Sensors, Tebu-Bio, Peterborough, UK) was added to the RIPA buffer at a 
concentration of 50 μΜ.  
2.2.3.4 Treatment with Cycloheximide or Bortezomib 
BV-2 cells or primary microglia were plated one – day prior to treatment with 
Cycloheximide (CHX, 1µg / ml) or Bortezomib (100 µM) in cell culture media. 
 
       2.2.4 Genetic analysis techniques  
2.2.4.1 RNA Extraction (Qiagen RNAeasy kit) 
Cells to be analysed by qPCR are first washed gently with 1 x PBS and lysed 
at the appropriate timepoint with 200µl / well of a 6 well plate in RLT buffer 
(from the Qiagen RNAeasy kit) containing 1:100 β - Mercaptoethanol. The 
lysed pellet was vortexed gently to ensure full lysis of cells. Each lysate was 
then centrifuged at 12,000 x g for 2 minutes at 4° C in a QiaShredder column 
(Qiagen) to ensure homogenisation of the samples. 1 volume (200 µl) of 70 
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% ethanol was added to each sample, and mixed well by pipetting, to 
homogenize the lysate. Each sample containing ethanol was transferred to 
an RNAeasy spin column and centrifuged at room temperature (centrifuge 
adjusted to 20° C) at 8000 x g for 15 seconds. 700 µl of RW1 buffer (from the 
Qiagen RNAeasy kit) was added to each RNAeasy spin column and 
centrifuged at room temperature (centrifuge cooled to 20° C) at 8,000 x g for 
15 seconds. 500 µl of RPE buffer (from the Qiagen RNAeasy kit) was added 
to each sample and centrifuged at room temperature for 15 seconds. A 
further 500  µl of RPE buffer was added to each RNAeasy spin column and 
centrifuged at room temperature for 2 minutes at 8000 X g. Each RNAeasy 
column was then placed in a new 2 ml collection tube and centrifuged at full 
speed (approximately 12,000 x g) for 15 seconds. RNA was eluted from the 
membrane by pipetting and 30 - 50 µl RNase-free water directly onto the 
membrane and spinning at 8000 x g for 1 minute. The RNA concentration for 
each sample was measured using a Spectrophotometer (Nanodrop). 
Samples were stored at -80° C. 
 
2.2.4.2 Reverse Transcription of RNA 
1 μg of RNA was used to generate each sample of cDNA. To each tube 1 μl 
DNase and 1 μl 10 X DNase buffer were added to 1 µg RNA from each 
sample plus the appropriate volume of RNase + Nuclease - free H2O (1 µg 
RNA + RNase-free H20 = 8 µl), and allowed to incubate at room temperature 
for 15 minutes. 1 μl EDTA was added to each tube prior to an 8 minute 
incubation at 65° C. 1 μl of Random Primer was added to each tube and the 
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samples were incubated for 2 minutes at 65° C. The tubes were transferred 
immediately to ice and each tube received 2 μl DNase - free and RNase - 
free H20, 4 μl 5 X Reverse Transcription Buffer, 1 μl 0.1 M DTT, and 1 μl 10 
mM dNTPs before a 2 minute incubation at 42° C. 1 μl Superscript II RT 
enzyme was added to each tube and the samples were incubated at 42° C 
for 50 minutes followed by a 10 minute cycle at 75° C. The samples are then 
stored at -20° C. All heating stages were carried out on a thermocycler block 
using a heated lid. 
 
2.2.4.3 qPCR Analysis 
qPCR analysis was carried out on the Lightcycler using SYBRgreen 
(Quantitect SYBRgreen kit, Qiagen, Cat No. 204143/63). 2 µl of each cDNA 
sample was added to each Lightcycler capillary tube and 18 µl of the 
appropriate Mastermix was added to give a total volume of 20 µl per capillary 
tube. qPCR samples were prepared on a cold block (4° C), to eliminate 
cDNA degradation during the time of preparation. The capillary tubes were 
carefully capped and spun at 2000 rpm for 10 seconds, and inserted into the 
rotor of the Lightcycler. gapdh was used as an internal control for each 
sample analysed. The Mastermix for each sample contained; 1 µl 10 µM 
primer (forward and reverse) 10 µl SYBRgreen, 7 µl RNase-free H20.  The 
cycle parameters for each primer were as follows: 95° C for 15 minutes, 94° 
C for 15 seconds, 57° C for 25 seconds, 72° C for 30 seconds. The 
annealing temperature for each primer used was 57° C. Primers were 
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designed using Primer3, and are between 150 - 250 base pairs which is 
optimal for SYBR detection. See table 2.11 below for primer sequences. 
Table 2.11: qPCR primer sequences. 
 
 
gapdh (mouse) 
 
forward 5’ AACTTTGGCATTGTGGAAGG 3’ 
 
reverse 5’ ACACATTGGGGGTAGGAACA 3’ 
 
 
tlr2 (mouse) 
 
forward 5’ GCGGACTGTTTCCTTCTGAC 3’ 
 
reverse 5’  CCAAAGAGCTCGTAGCATCC 3’  
 
tlr4 (mouse) 
 
forward 5’ GCATGGCTTACACCACCTCT 3’ 
 
reverse 5’ GTCTCCACAGCCACCAGATT 3’ 
 
 
MyD88 (mouse) 
 
forward  5’ GCCCAACTAGGCCCTTTTTA 3’ 
 
reverse 5’ TCCTGAGTTCAAATCCCACA  3’ 
 
 
trif (mouse) 
 
forward 5’ CTCCTCTCTCTGCTGCTATCCT 3’ 
 
reverse 5’ ATACATGAGGCCCTGCATTC 3’ 
 
Mal (mouse) 
 
forward 5' ATGTCCATGGGAATGGCATCATCGACC 3' 
 
reverse 5' AGACGAGGATCCCTAAAGTAGATCAGA 3'  
 
 
tram (mouse) 
 
forward 5’ AATACAGGAAAGGGACGTGAGA 3’ 
 
reverse 5’ GAATAATGTCCTATGTGGCTCCTAC 3’ 
 
bid (mouse) 
 
forward 5’ TCCCCAGAGACATGGAGAAC 3’ 
 
reverse 5’ GTCGTGTGGAAGACATCACG 3’ 
 
Peli1 (mouse) 
 
forward 5’ TGCCGAAATCAATCAATCAA 3’ 
 
reverse 5’ CAATGGAGTGTCACTGGGTG 3’ 
 
 
SOD1 (human) 
 
forward 5’ TCATCAATTTCGAGCAGAA 3’ 
 
reverse 5’ CAGGCCTTCAGTCAGTCCT 3’ 
 
 
tnfα (mouse) 
 
forward 5’ CTCTTCAAGGGACAAGGCTG 3’ 
 
reverse 5’ CGGACTCCGCAAAGTCTAAG 3’ 
 
 
il-6  (mouse) 
 
forward 5’ GGACCAAGACCATCCAATTG 3’ 
 
reverse 5’ ACCACAGTGAGGAATGTCCA 3’ 
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2.2.4.4 siRNA transfection 
BV-2 cells were transfected with siRNAs targeting Bid or Peli1. 100 µM 
siRNA / 3 x 105 cells were transfected, using lipofectamine, following the 
same parameters as described for plasmid transfection in section 2.2.5. 
Optimal silencing of bid and Peli1 were determined by qPCR analysis to be 
48 h, and 24 h respectively (Figures 3.12 and 5.8). Additionally, reduced 
protein levels were confirmed for these timepoints. Two different siRNA 
sequences were exploited for optimization, and the most effective mRNA 
knockdown was used for the following experiments. An siRNA consisting of a 
scrambled nucleotide sequence was used as the Control in siRNA 
experiments. siRNA sequences were generated using an algorithm 
optimized for siRNA selection (Reynolds et al., 2004). siRNA sequences are 
listed in Table 2.12 below. 
Table 2.12: siRNA sequences targeting Bid and Peil1.  
 
siRNA 
 
Targeted 
Gene 
 
Sequence 
 
Obtained from 
 
siBid ‘A’ 
 
bid 
 
CCAUGCUGUUGGCCAAAAAR 
 
 
Sigma - Aldrich 
 
siBid ‘B’ 
 
bid 
 
ACACGACUGUCAACUUUAU 
 
 
Sigma - Aldrich 
 
siPeli1 ‘A’ 
 
Peli1 
 
TATCCAGGGTCTTTAATTA 
 
 
Sigma – Aldrich 
 
siPeli1 ‘B’ 
 
Peli1 
 
TCCAGGGTCTTTAATTATA 
 
 
Sigma - Aldrich 
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2.2.5 Immunological Methods 
2.2.5.1 Western Blotting 
Media was aspirated from the cells and the wells were washed gently with 1 
X PBS and lysed on ice with 80 µl / well of 6 well plate RIPA buffer (Tris 50 
mM, NaCl 150 mM, SDS 0.1 %, NaDeoxycholate 0.5 %, Triton X 100 or 
NP40 1 %, 1:100 Protease Inhibitor and 1:00 phosphatase inhibitor) for 
Western Blot Analysis. The cell lysates were homogenized by trituration    
and / or gentle vortexing and incubated on ice for 15 minutes. The lysates 
were centrifuged at 4° C at 300 X g and the supernatant was transferred to 
new pre-chilled eppendorfs and the protein concentration was determined 
using the BCA assay (Micro BCA protein determination kit, Thermo 
Scientific). A standard curve of BSA (0 – 10 µl of 1 mg / ml BSA) in triplicate 
was set up. 150 µl of 0.9 % NaCl was added to each well. The BCA solution 
was made up (25: 25: 1 for reagents A : B : C) and 150 µl was added to each 
well. 2 µl of each sample was added in triplicate to wells of a 96 well plate 
and incubated at 37° C for 30 minutes. Absorbance was read at 562 nm 
using the Tecan plate reader. Values for Western Blot calculated from BSA 
standard curve best fit line graph. Once the protein concentration was 
determined Lamaeli Buffer was added to each sample to a final 
concentration of 1 X, and the samples were boiled for 10 minutes. 
Appropriate volumes per desired µg protein of samples and marker (5 µl) 
were loaded into wells on an Agarose gel and run at 140 V for approximately 
90 minutes. See table 2.14 below for acrylamide gel recipe. 
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Table 2.13: Acrylamide gel recipes for 1.5 mm gel (10 ml volume). 
 
% Acrylamide 
Gel 
 
6% 
 
10% 
 
12% 
 
15% 
 
Acrylamide (mls) 
 
1.5 
 
2.5 
 
3.0 
 
3.75 
 
1.5 M Tris pH8.8 
(mls) 
 
3.75 
 
3.75 
 
3.75 
 
3.75 
 
H2O (mls) 
 
4.75 
 
3.75 
 
3.25 
 
2.38 
 
10% SDS (mls) 
 
0.100 
 
0.100 
 
0.100 
 
0.100 
 
10% APS (mls) 
 
0.100 
 
0.100 
 
0.100 
 
0.100 
 
TEMED (mls) 
 
0.005 
 
0.005 
 
0.005 
 
0.005 
 
The gel was placed between Whatman paper (pre-soaked in 1 X Transfer 
buffer) with the PVDF membrane (activated by soaking in Methanol for 3 
minutes) placed on top of the gel for transfer. Dry transfer was carried out at 
18 V for 1.5 hours. The membrane was removed, exposed to Ponceau S, 
and placed in 3 % Blocking Solution for 1 hour before being incubated 
overnight at 4° C in 3 % Blocking Buffer containing the appropriate primary 
antibody. The membrane was washed 3 times for 5 minutes in 1 X TBST 
(TRIS - buffered Saline – Tween 20), and placed in 3 % blocking solution 
containing the appropriate secondary antibody (Peroxidase - conjugated anti-
mouse IgG, anti-rabbit IgG, or anti-goat IgG, Sigma, 1:5000) for 2 hours at 
room temperature. The membrane was washed 3 times for 5 minutes in 1 X 
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TBST, and covered in 1 ml ECL Chemilluminescent Reagent (Millipore,  
P90720) for 5 minutes before being imaged on the LAS-3000 Image reader.  
 
2.2.5.2 Immunohistochemistry 
Cells were fixed with 3 % paraformaldehyde 9PFA) for 12 minutes at 37° C, 
and washed 3 times for 5 minutes in 1 x PBS. Briefly, 3 % PFA was prepared 
from 3 g PFA powder in 100 ml PBS (pH 7.2 - 7.4), filtered and stored at -20° 
C. For experiments examining TLR2/4 or CD45 expression the cells were not 
permeabilised as cell membrane expression was of interest. For all other 
experiments cells were permeabilised with 0.1 % Triton-X in PBS solution on 
ice for 3 minutes prior to blocking. The fixed cells were blocked for 30 
minutes at room temperature in 5 % Horse Serum, 0.3 % Triton X-100 
(Sigma) in 1 x PBS. The cells were washed twice with 1 x PBS and the 
primary antibody was added to 1 % Horse Serum, 0.3 % Triton X-100 in 1 x 
PBS and added to the wells (150 µl / well of 24 well plate), and incubated at 
room temperature for 2 hours (or overnight at 4° C). The primary antibody 
solution was removed and the wells were washed 3 times with 1 x PBS 
before the Alexa Fluor secondary antibody solution was added. Alexa Fluor 
secondary antibodies were used at a dilution of 1:500 in 1 % Horse Serum, 
0.3 % Triton X-100 in 1 x PBS (anti-mouse Alexa Fluor, anti-rabbit Alexa 
Fluor 488, anti-rat Alexa Fluor488,anti- mouse Alex Fluor 568, anti-rabbit 
Alexa Fluor 568). The cells were incubated in the dark for 1 hour at room 
temperature and washed 3 times with 1 x PBS before being analysed. 
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Hoechst was used as a nuclear stain (1:1000 in PBS, Hoechst 33342, 
Invitrogen, Cat No. H21492).  Image analysis was carried out using ImageJ. 
 
2.2.5.3 Flow Cytometry for determination of immunofluorescence intensities 
BV-2 cells were transfected by electroporation (5 µg plasmid / 5 x 106 cells) 
and trypsinised 24 hours post transfection. The cells were pelleted and 
resuspended in 1 ml of FACS buffer (1 x PBS + 1 % FBS), and centrifuged at 
300 x g for 5 minutes at room temperature. The supernatant was carefully 
decanted and the pellet was resuspended in primary antibody in FACS buffer 
(anti - TLR2 and anti - TLR4 both used at a dilution of 1:500). The cells plus 
primary antibody solution were incubated on ice for 20 minutes. 500 µl of 
FACS buffer was added to each tube and the samples were centrifuged at 
300 x g for 5 minutes at room temperature. The supernatant was carefully 
decanted and the pellets were resuspended in the AlexaFluor secondary 
antibody in FACS buffer solution and incubated on ice in the dark for 20 
minutes. The secondary antibodies used were anti-mouse AlexaFluor 488 
(1:500) and anti-rabbit AlexaFluor 488 (1:500). 500 µl of FACS buffer was 
again added to each tube and the samples were centrifuged at 300 x g for 5 
minutes at room temperature. The supernatant was carefully decanted and 
the pellets were resuspended in FACS buffer and analysed with the Partec 
CyFlow, using FlowMax software.  Cyflogic v.1.2.1 was used to determine 
the mean fluorescence per sample and to generate histograms based on the 
gated area of interest. 
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 2.2.5.4 Co-Immunoprecipitation  
Immunoprecipitation experiments were carried out using DynaBeads Protein 
G (Life Technologies, 10007D), and a Magnetic Rack (Life Technologies).  
The Dynabeads were completely resuspended by vortexing for 1 minute and 
subsequent pipetting to ensure homogeneity. 35 μl of beads were added to 
each tube and placed on the magnet rack. The supernatant was removed 
and the beads were washed in 750 μl RIPA buffer 3 times for 5 minutes at 
room temperature rotating. The beads were washed briefly in PBS before 5 
μg of antibody and 200 μl of PBS were added to each tube containing 
Dynabeads. The antibody was allowed to bind to the beads for 40 minutes 
rotating at room temperature. The beads were washed 3 times for 5 minutes 
in RIPA buffer. An equal amount of protein (100 - 400 μg) lysed in RIPA 
buffer was added to each tube with PBS added to make a total volume of 
700 μl, followed by a 2.5 h incubation of the protein with the beads at room 
temperature or overnight at 4° C rotating. The beads were washed with RIPA 
buffer for 10 minutes and with PBS for two 10 minute washes. The 
resuspended beads were then transferred to a clean tube and placed on the 
magnetic rack where the supernatant was removed. The beads were gently 
resuspended in 24 μl RIPA Buffer plus 6 μl 6 X loading buffer. Elution of the 
protein from the beads was carried out on a thermocycler block at 70° C for 
10 minutes. The tubes were placed on the magnetic rack and the 
supernatant was collected and placed in a clean tube for analysis on an 
acrylamide gel. 
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2.2.5.5 mTNFα ELISA 
mTNFα ELISA was carried out using R&D Systems DuoSet ELISA kit 
(DY410-05). Conditioned media collected for ELISA analysis was centrifuged 
at 6,000 rpm for 5 minutes at time of collection to remove any cellular debris 
before freezing at -20°C.  mTNFα Capture Antibody was diluted to a working 
concentration of 0.8 μg / ml in PBS, with 100 μl pipetted into each well of a 
96 well ELISA plate. The plate was sealed and incubated overnight at room 
temperature. Each well was aspirated and washed with Wash Buffer (0.05 % 
Tween 20 in PBS, pH 7.2 - 7.4) 3 times, with the plate blotted on a clean 
paper towel after the final wash to ensure complete removal of solution from 
the wells. The wells were blocked with 300 μl Reagent Diluent (1 % BSA in 
PBS) for 1 hour at room temperature, before being washed with wash buffer 
3 times. 100 μl of each standard (in Reagent Diluent) / sample was added to 
each well and the plate was sealed with adhesive strip and incubated at 
room temperature for 2 hours. After 3 washes 100 μl of the mouse TNFα 
Detection Antibody was added to each well and the plate was sealed and 
incubated for 2 hours at room temperature. The wells were washed a further 
3 times before 100 μl of Streptavidin-HRP (working dilution 1: 40 in Reagent 
Diluent) was added and incubated for 20 minutes, covered in aluminium foil 
to avoid contact with light. The wells were washed 3 times. 100 μl of 
Substrate Solution (1 : 1 mixture of Color Reagent A (H2O2) and Color 
Reagent B (Tetramethylbenzidine) (R&D Systems, DY999) was added to 
each well and the plate was incubated at room temperature for 20 minutes 
covered in aluminium foil. 50 μl of Stop Solution (2N H2SO4) was added to 
each well and the plate was gently tapped to ensure thorough mixing of 
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solutions. The optical density of each well was read at using a microplate 
reader at a wavelength of 450 nm. 
 
2.2.5.6 Proximity Ligation Assay (PLA) 
The Proximity Ligation Assay (PLA) was carried out using the Duolink® 
system (DUO92101-1KT, Sigma-Aldrich). This technique allows the 
identification of an  interaction between proteins in a complex in vitro and in 
situ by using ‘proximity probes’ which are plus and minus oligonucleotides 
bound to antibodies against two specific proteins (Soderberg et al., 2006). In 
this case anti - TRAF6 and anti - Bid were used in order to determine an 
interaction. BV-2 cells were plated in a 96 well plate and transfected with 
either pEntry-FLAG or FLAG-TRAF6-wt (Plasmid #21624, Addgene, 
Cambridge, MA 02139, U.S.A.) at a concentration of 0.075 μg / well. 24 h 
post transfection the cells were exposed to serum free media, 2 h prior to 
treatment with either Vehicle (1 X PBS) or LPS (1 μg / ml). The cells were 
fixed in 3 % paraformaldehyde (12 minutes at 37° C) 1 h post LPS treatment.  
The fixed cells were permeabilised on ice with 0.1 % Triton x-100in PBS for 3 
minutes and washed 3 times with PBS. The cells were blocked in PBS 
containing 1 % horse serum and 0.3 % Triton x-100 at room temperature for 
30 minutes.  After 3 washes with PBS the cells were incubated for 2 h in 
primary antibody solution (see table 2.14 below for antibody combinations). 
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Table 2.14: PLA experimental design. Primary Antibody combinations for 
incubation with BV-2 cells. 
  
Condition 
  
TRAF6 (1:100, 
anti-mouse) + Bid 
(1:500, anti-rabbit) 
  
TRAF6 (1:100, anti-
mouse) + HA-probe 
(1:500, anti-rabbit) 
  
Bid (1:500, anti-rabbit) 
+ IRF2 (1:500, anti-
mouse) 
  
1 
FLAG minus 
LPS 
  
Low endogenous 
TRAF6 + Bid 
interaction expected 
  
Negative control for 
TRAF6 specific 
binding to Bid 
  
Negative control for Bid 
specific binding to 
TRAF6 
  
2 
FLAG-
TRAF6-wt 
minus LPS 
  
Endogenous and 
overexpressed 
TRAF6 + Bid 
interaction expected 
  
Negative control for 
TRAF6 specific 
binding to Bid 
  
Negative control for Bid 
specific binding to 
TRAF6 
  
3 
FLAG plus 
LPS 
  
Increased (from 
condition 1) 
endogenous TRAF6 
+ Bid interaction 
expected  
  
Negative control for 
TRAF6 specific 
binding to Bid 
  
Negative control for Bid 
specific binding to 
TRAF6 
  
4 
FLAG-
TRAF6-wt 
plus LPS 
  
Increased (from 
condition 2) 
Endogenous and 
overexpressed 
TRAF6 + Bid 
interaction expected 
  
Negative control for 
TRAF6 specific 
binding to Bid 
  
Negative control for Bid 
specific binding to 
TRAF6 
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After primary antibody incubation the cells were washed 3 times in PBS 
before the addition of the PLA probes. PLA probes were diluted in primary 
antibody diluent (1 % horse serum and 0.3 % Triton x-100 in PBS) at a ratio 
of 1 : 10 i.e. 42 μl MINUS probe stock and 42 μl PLUS probe stock made up 
to 420 μl in primary antibody diluent. The cells were incubated with the PLA 
probe solution for 1 h at 37° C.  The Ligation stock was diluted (1 : 5) with 
high purity H2O and the ligase was added at a ratio of 1 : 40 just before 
addition of the Ligation Solution to the wells. The cells were washed with 
PBS twice for 5 minutes and the Ligation - Ligase solution was added to the 
wells (20 μl / well), and incubated at 37° C for 30 minutes. The Amplification 
solution (photo sensitive) was diluted (1 : 5) with high purity H2O and the 
polymerase enzyme was added a ratio of 1 : 40 just before the addition of 
the Amplification Solution to the wells. The cells were washed with PBS twice 
for 5 minutes and incubated with the Amplification – Polymerase solution 
covered with aluminium foil for 100 minutes at 37° C. The cells were washed 
a further 3 times with PBS and exposed to Hoechst, which was used as a 
nuclear stain (1:1000 in PBS, Hoechst 33342, Invitrogen, Cat No. H21492). 
The wells were imaged using the 568 channel in order to detect the amplified 
PLA probe signal per condition and analysis was carried out using Image J 
software. 
 
 
 
 
                                                                                       Chapter II: Materials and Methods 
 
 
77 
 
2.2.6 Statistical Analysis 
Statistical Analysis was carried out using Graph Pad Prism software 
(GraphPad Software Inc., La Jolla, CA, USA) or Matlab software (version 
2014b, Mathworks). Results are represented as Mean ± SEM, and 
significance was determined using appropriate tests as detailed in the 
respective figure legends (* denotes p ≤ 0.05). 
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Chapter III 
SOD1G93A exerts its toxicity through TLR2 and 
TLR4 signalling in microglia, and bid – deficiency 
attenuates the microglial TLR4 pro - inflammatory 
response 
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3.1 Introduction 
Reactive gliosis, a term used to describe the activation of glial cells in 
response to pathogens (Burda and Sofroniew, 2014), is apparent in 
neurodegenerative disorders and is concurrent with neuronal death and 
disease progression (Prokop et al., 2013, Maragakis and Rothstein, 2006, 
Sasaki et al., 1997). Microglia elicit the primary response to pathogenic insult 
in the CNS (Falsig et al., 2008, Streit et al., 2004), and chronic microglial – 
mediated neuroinflammation is shown to drive pathogenesis in 
neurodegenerative disorders (Lee et al., 2012b, Gao and Hong, 2008, Kim et 
al., 2000). 
TLR involvement, and specifically increased levels of TLR2 and TLR4 are 
reported in ALS pathology (Casula et al., 2011, Letiembre et al., 2009), 
mediating the chronic inflammation that is believed to drive ALS 
pathogenesis  (Zhao et al., 2010, Liu et al., 2009). Moreover, attenuation of 
the TLR4 – mediated inflammatory response, using tlr4-/- SOD1G93A 
transgenic mice, resulted in the increased survival of ALS mice accompanied 
by modest improvements of motor neuron function (Lee et al., 2015).  
Additionally, extracellular SOD1G93A is reported to bind to CD14, the essential 
co - receptor for TL2 and TLR4 dimerization, and to mediate neuronal toxicity 
via microglia (Zhao et al., 2010). These studies highlight the importance of 
microglial – mediated TLR signalling in the chronic neuroinflammatory 
cascade seen in ALS disease progression. 
Increased NF-ҡB activation is evident in neurodegeneration (Frakes et al., 
2014, Khoshnan et al., 2004, Hunot et al., 1997, Migheli et al., 1997, Terai et 
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al., 1996). Additionally, constitutive activation of NF-ҡB in wt microglia 
induces gliosis (Frakes et al., 2014). Activation of NF-ҡB by the canonical 
pathway occurs simultaneous to ALS disease progression, and specifically 
microglial – induced NF-ҡB activation, and not astrocytic NF-ҡB activation, 
induces motoneuron death (Frakes et al., 2014), emphasising the critical 
involvement of microglial – mediated NF-ҡB activation in ALS pathology. 
Modulation of the immunological profile of both macrophages and microglia 
by the Bcl-2 family protein Bid has been reported (Yeretssian et al., 2011), 
and our laboratory has shown reduced NF-ҡB activation in LPS – stimulated 
bid - deficient astrocytes, also represented by reduced IKK phosphorylation 
upstream of NF-ҡB activation (Konig et al., 2014).   
Here levels of TLR2 and TLR4 were examined in response to SOD1G93A 
overexpression in the microglial cell line BV-2.  TIR adaptor protein levels 
and NF-ҡB activation in response to SOD1G93A microglial overexpression 
were also analysed. Secondly, the effects of the absence of Bid on 
SOD1G93A - induced microglial toxicity were investigated, with analysis of NF-
ҡB activation in bid – depleted microglia in response to SOD1G93A paracrine 
stimulation. Finally, examination of the role of Bid in the TLR4 – induced pro - 
inflammatory response were carried out using lipopolysaccharide (LPS), 
which is a well – defined agonist of TLR4 (Chow et al., 1999, Hoshino et al., 
1999) and induces NF-ҡB activation (Zhang et al., 1999).  
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3.2 Results 
3.2.1 Overexpression of SOD1G93A and SOD1G93A paracrine 
stimulation results in increased TLR2 / TLR4 – NF-ҡB signalling in   
BV-2 cells 
Firstly, TLR2 and TLR4 levels in SOD1G93A overexpressing microglia were 
examined. Mutant SOD1 is secreted in vitro from neurons, astrocytes and 
microglia (Basso et al., 2013, Turner et al., 2005, Lafon-Cazal et al., 2003, 
Mondola et al., 1998). BV-2 cells were transiently transfected with CFP or 
SOD1G93A – CFP fusion proteins (vectors described in section 2.2.2.3) using 
electroporation. Both mRNA levels and TLR2 and TLR4 membrane protein 
levels were assessed. 
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Figure 3.1: tlr2 and tlr4 mRNA and protein levels in response to SOD1G93A 
overexpression in BV-2 cells. BV-2 cells were transiently transfected with CFP or 
SOD1G93A – CFP and harvested at 8 h and 24 h post transfection. (A) tlr2 mRNA 
expression in transfected BV-2 cells was measured by qPCR analysis, relative to 
internal control gene gapdh (n  = 3 – 8 cultures pooled from 2 separate platings, p = 
0.005, one - way AVOVA, Tukey post hoc test). (B) CFP - and SOD1G93A – CFP - 
transfected BV-2 cells were lysed 24 h post transfection. Non-permeabilised BV-2 
cells were stained with anti - TLR2 in order to measure membrane TLR2 expression 
only. (n = 5 wells, p = 0.055, two – tailed t – test).  (C) tlr4 mRNA was measured by 
qPCR analysis of BV-2 lysates at 8 h and 24 h post transfection with CFP and 
SOD1G93A – CFP. (n = 3 - 6 cultures pooled from 2 separate platings). Samples 
were normalised to internal control gene gapdh. (D) Flow Cytometry analysis shows 
TLR4 membrane protein levels 24 h post CFP or SOD1G93A transfection (n = 4 wells, 
p = 0.48). (E) qPCR analysis of CFP and SOD1G93A overexpressing BV2 cells 
shows hSOD1 mRNA expression 8 h and 24 h post transfection (n = 4 cultures from 
2 separate platings).  
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Figure 3.1 reveals TLR2 and TLR4 mRNA and protein levels in BV-2 cells 
overexpressing SOD1G93A. Primers detecting hSOD1 were designed and identify 
both human SOD1wt and human SOD1G93A, therefore quantification of expression of 
hSOD1 vectors were assessed without the interference of mouse SOD1wt mRNA 
levels. Analysis of images taken by fluorescent microscopy capturing CFP+ 
cells represents the transfection efficiency of both CFP and SOD1G93A – CFP 
at the time of lysis. The transfection efficiency of both fusion proteins was 
similar at 8 h with a slightly lower SOD1G93A transfection efficiency observed 
at 24 h post transfection, as shown in figure 3.2 below. 
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Figure 3.2: Transfection Efficiency of CFP and SOD1G93A - CFP in BV-2   
cells. Representative images (A) and quantification (B & C) of the 
transfection efficiency of CFP or SOD1G93A - CFP vectors were imaged and 
assessed at the 8 h and 24 h post transfection and immediately prior to cell 
lysis (n = 4 wells). CFP - positive cells were counted and expressed as a 
percentage of total cell population (B) or fold change (C, same data as in B) 
respective to CFP - transfected BV-2 cells at 8 h post transfection. Scale bar 
= 10 μm. 
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Subsequent to the analysis of TLR2 and TLR4 expression levels in 
SOD1G93A – overexpressing BV-2 cells the TIR adaptor proteins were 
analysed. The TIR adaptor complex consists of MyD88 with its adaptor 
protein Mal, and TRIF with its adaptor protein TRAM (Yamamoto and Akira, 
2005). qPCR analysis was carried out to determine the effects of SOD1G93A 
overexpression on the TIR adaptor protein levels and whether the effects of 
increased TLR2 and TLR4 proteins at the membrane led to intracellular 
signalling via increased TIR adaptor mRNA levels.   
 
Figure 3.3: TIR adaptor mRNA expression following SOD1G93A 
overexpression in BV-2 cells. qPCR analysis of MyD88 (A), trif (B), Mal (C), 
and tram (D) post transfection with CFP or SOD1G93A – CFP (A & B, n = 3 
cultures from 2 separate platings, C & D n = 3 cultures from 1 plating). BV-2 
cells were harvested in RLT buffer for gene expression analysis at 8 h and 
24 h for MyD88 and trif, and at 24 h for  assessment of  Mal and tram mRNA 
expression. 
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Elevated levels of MyD88 (1.95 ± 1.14 fold increase) and trif (2.09 ± 1.11 fold 
increase) were observed 24 h post SOD1G93A transfection (Figure 3.3), 
indicating the induced transcription of these genes which occurs in response 
to the positive feedback loop upon TLR4 signalling.  
In order to examine the effects of the paracrine toxicity of SOD1G93A on 
microglia and TLR activation CFP and SOD1G93A – conditioned Media 
(cMedia) using NSC-34 cells was generated. The motoneuron cell line, NSC-
34, was transfected with the CFP or SOD1G93A – CFP followed by a 3 – day 
conditioning period in serum – free BV-2 culture media. The NSC-34 cells 
were lysed for analysis of hSOD1 mRNA expression by qPCR and TNFα 
levels by ELISA at the time of cMedia collection. cMedia was concentrated 
using size exclusion columns and the hSOD1 levels were assessed by 
Western Blot. As the SOD1 vectors are fusion proteins expressing CFP, 
hSOD1 was detected using anti – GFP.  
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Figure 3.4: SOD1G93A conditioned media generated from NSC-34 cells. (A) 
Representative images of transfection efficiency of CFP and SOD1G93A – 
CFP in NSC-34 transfected cells 3 days post transfection. (B) hSOD1 levels 
in cMedia 3 days post transfection as determined from protein concentration 
using size exclusion filter columns and centrifugation (repeated twice with 
similar results). (C) qPCR analysis of hSOD1 mRNA expression in NSC-34 
cell lysates 3 days transfection with CFP or SOD1G93A (n =  5 wells from 2 
separate experiments). (D & E) IL-1β levels in CFP and SOD1G93A – 
transfected NSC-34 cells 3 days post transfection (n = 3 wells, from 3 
separate experiments).  (F) Representative blot of IL-1β levels in cMedia 
concentrated by centrifugation in size exclusion columns 3 days post NSC-
34 transfection (repeated once with similar results). Scale bar = 10 μm. 
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Figure 3.4 represents the transfection efficiency and quantification of SOD1 
and IL-1β levels in SOD1G93A conditioned media. Of note, the levels of 
hSOD1 detected in the SOD1wt – cMedia are greater than that of hSOD1 
levels in SOD1G93A cMedia.  Previous studies have reported a decreased half 
– life of SOD1 from SOD1 mutations compared with that of wt SOD1 
(Borchelt et al. 1994). It was also reported that TNFα levels were increased 
in SOD1G93A but not SOD1wt stimulated microglia treated with the more 
controlled administration of recombinant SOD1wt or SOD1G93A proteins 
(Zhao et al. 2010), and SOD1G93A – induced toxicity is focused on in this 
study. 
NSC-34 derived SOD1G93A cMedia was used to investigate the paracrine 
response and whether the SOD1G93A toxicity seen in microglia is indeed due 
to the direct binding of SOD1G93A to TLR2 and / or TLR4. For this the use of 
a small molecule inhibitor of TLR2 and TLR4 named OxPAPC was employed 
(1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine). OxPAPC is an 
oxidized phospholipid demonstrated to selectively inhibit TLR2 and TLR4 
dimerization by sequestering the essential extracellular components of TLR2 
and TLR4 signalling and rendering them unable to interact with TLR2 and 
TLR4 and thus blocking TLR – induced activation (Erridge et al., 2008). 
OxPAPC interacts with MD2, the essential co - receptor of TLR4 
dimerization, LPS – binding protein which is crucial for LPS – TLR4 binding 
(Wright et al., 1990), and CD14, an extracellular receptor which is 
indispensable for both TLR2 and TLR4 dimerization (Erridge et al., 2008, 
Fitzgerald et al., 2004). These actions result in the inability of ligand – 
receptor binding with TLR4 and TLR2 agonists, such as LPS and Pam3CSK4 
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respectively, leading to the failure to induce TLR2 or TL4 dimerization and 
subsequent intracellular signalling. BV-2 cells were treated with OxPAPC 
and subsequently stimulated with LPS or simultaneously with CFP or 
SOD1G93A cMedia. Firstly, the effects of TLR2 and TLR4 inhibition on BV-2 
cell morphology post stimulus exposure were examined. Figure 3.5 shows a 
schematic demonstrating the mechanism of action of OxPAPC and 
representative images of the effects of OxPAPC on BV-2 morphology. 
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Figure 3.5: Effect of TLR2 and TLR4 inhibitor OxPAPC on BV-2 cell 
activation and morphology. (A) Schematic of the mechanism of action of 
OxPAPC on inhibiting TLR2 and TLR4 dimerization. (B) Representative 
images of BV-2 cell morphology with or without OxPAPC and stimulated with 
LPS (1 µg / ml) for 24 h.  (C) Representative images of BV-2 cell morphology 
with or without OxPAPC and stimulated with CFP or SOD1G93A cMedia for 24 
h.  The morphological state of BV-2 cells was examined using 20 X 
magnification. Activated microglia present as condensed, circular and 
amoeboid in shape, whereas resting / non- activated microglia are ramified 
(as indicated in B & C). Scale bar = 10 μm. 
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Microglia are subject to morphological changes in response to toxic stimuli, 
and upon activation microglia assume an amoeboid shape with retracted 
processes (Kettenmann et al., 2011). Induction of TLR2 and TLR4 signalling 
mediates microglial activation (Hayward and Lee, 2014, Ebert et al., 2005).  
In figure 3.5 an attenuation of morphological changes were observed in LPS 
– treated and SOD1G93A - treated microglia upon OxPAPC - mediated 
inhibition of TLR2 and TLR4. 
Cyclooxygenase – II (COX-II) is an enzyme that is induced in response to 
inflammatory stimuli (Nadjar et al., 2005, Laflamme et al., 1999). NF-ҡB was 
shown to bind to the COX-II promoter inducing COX-II levels (Sorli et al., 
1998), and COX-II is recognised as a target gene of NF-ҡB activation (Nadjar 
et al., 2005, Nakao et al., 2000). The effects of TLR2 and TLR4 inhibition on 
SOD1G93A – induced NF-ҡB activation were assessed by quantifying COX-II 
levels. Firstly, COX-II levels in BV-2 cells overexpressing SOD1G93A were 
examined. Additionally, paracrine SOD1G93A - induced COX-II levels were 
analysed in TLR2 and TLR4 – inhibited BV-2 cells.  
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Figure 3.6: COX-II levels are increased in SOD1G93A – overexpressing BV-2 
cells and reduced when TLR2 and TLR4 are inhibited. (A & B) COX-II levels 
were assessed in SOD1G93A overexpressing BV-2 cells (n = 3 cultures from 2 
separate platings, p = 0.016, two-tailed paired t-test). BV-2 cells were 
transfected with CFP or SOD1G93A – CFP fusion proteins (5 µg DNA / 5 X 106 
cells) via electroporation, lysed in RIPA buffer 24 h post transfection and 
prepared for Western Blot analysis.  (C & D) COX-II levels in TLR2 and TLR4 
inhibited BV-2 cells which were stimulated with CFP or SOD1G93A cMedia 
measured by Western blot. BV-2 cells were treated with OxPAPC (30 µg / 
ml) simultaneous to cMedia treatment. Cells were lysed 24 h post cMedia 
stimulation and prepared for Western Blot analysis (n = 3 wells, p = 0.002, 
one-way ANOVA, Tukey post-hoc test).  
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In Figure 3.6, a lack of a significant induction of COX-II levels in response to 
SOD1G93A was observed in TLR2 - and TLR4 - inhibited BV-2 cells, 
strengthening the evidence for paracrine SOD1G93A – mediated pathogenesis 
via TLR2 or TLR4  – NF-ҡB signalling in microglia. 
 
3.2.2 Absence of Bid attenuates SOD1G93A toxicity in Microglia 
While the BV-2 cell line is widely used as a valid and credible microglial 
platform for experiments (Bocchini et al., 1992), primary murine microglia 
were also exploited in this study. Of note, BV-2 cells and primary microglia 
display similar responses to LPS stimulation in vitro, however the response is 
less pronounced in BV-2 cells suggesting that primary microglia are more 
sensitive in detecting pathogenic insults in vitro (Henn et al., 2009). Firstly, 
the microglial isolation technique was established and optimized. Complete 
separation of microglia from astrocytes and consistent purity of isolated 
cultures is essential for a true microglial response to be examined. 
Optimization of isolation was carried out using two techniques; the more 
common shaking method and isolation by trypsinization. The percentage 
purity of isolation and yield were analysed and is represented in Figure 3.7. 
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Figure 3.7: Isolation and purity of Primary Microglia.  (A) Representative 
images of CD11b+, S100b+ and GFAP+ cells showing microglial purity post 
isolation by either the shaking method or trypsinization method. (B) 
Quantification of % microglial purity (n = 4 – 9 cultures from 2 separate 
platings, p = 0.019, two-tailed t-test, Mann Whitney post hoc test). (C) 
Quantification of microglial yield by both methods of isolation (counts for one 
isolation). (D) Scatterplot showing individual % purity for each image 
analysed (91.4 + / - 8.81, n = 5 wells, 4 fields of view / well) and (E) 
Representative image of CD11b+, S100b+ and GFAP+ cells showing 
microglial purity in the refined isolation procedure. The isolation by shaking 
protocol was adopted for the remainder of experiments in this study. Scale 
bar = 100 μm. 
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The isolation by the shaking method proved to yield high purity cultures of 
microglia (91.4 % ± 8.81), and this method was undertaken for all future 
experiments.  
Full length Bid has been implicated to have a role in mediating inflammation 
(Wree et al., 2015). To investigate the role of microglial Bid further the levels 
of Bid were assessed in unstimulated mixed motoneuron cultures, astrocytes 
and microglia. 
 
 
Figure 3.8: Bid levels in mixed motoneuron cultures, astrocytes and microglia 
at rest. (A) Representative Western Blot showing Bid levels in motoneurons, 
astrocytes and microglia. (B) Quantification of OD analysis of Bid levels in 
primary motoneurons and microglia (n = 4, p = 0.028, two – tailed t – test, 
Mann Whitney post hoc). Primary mixed motoneurons were harvested at 
DIV7, and purified astrocytes and isolated microglia were lysed 2 days post 
plating to allow time for the cells to become quiescent. Bid protein levels 
were examined, by Western Blot, in purified astrocytes and microglia 
compared with mixed motoneurons cultures (Astrocytes 5.9 ± 2.7 fold 
increase, Microglia 6.2 ± 2.1 fold increase). 
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Upon confirmation that Bid levels in unstimulated microglia were higher than 
that of mixed motoneuron cultures, as demonstrated in Figure 3.8, 
examination of whether glial cell Bid levels are affected by inhibition of TLR2 
and TLR4 was undertaken. Previously our laboratory has shown that Bid is 
highly expressed in astrocytes (Konig et al., 2014). Both astrocytes and 
microglia have a prominent role in innate immune signalling in the CNS and 
TLRs are constitutively expressed in both cell types (Carpentier et al., 2005, 
Olson and Miller, 2004). Here BV-2 cells, primary microglia and astrocytes 
were treated with the TLR2 and TLR4 inhibitor OxPAPC and subsequently 
stimulated with LPS for 24 h. Bid levels were analysed by Western Blotting. 
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Figure 3.9: Bid levels are lower in LPS – stimulated Astrocytes when TLR2 
and TLR4 are inhibited compared with uninhibited astrocytes, but Bid levels 
are unchanged in BV-2 cells and Microglia. (A & B) Bid levels in BV-2 cells 
with or without OxPAPC treatment and stimulated with LPS for 24 h (n = 4 – 
5 wells form 2 separate platings). (C & D) Bid levels in primary microglia with 
or without OxPAPC treatment and stimulated with LPS for 24 h (n = 3 wells, 
0.89 ± 0.08 fold decreased in OxPAPC – treated cells). The microglial 
activation marker anti - CD45 and anti - COX-II levels were also assessed as 
a control for TLR – inhibition. (E & F) Bid levels in primary astrocytes with or 
without OxPAPC treatment and stimulated with LPS for 24 h (n = 3 wells). 
Anti – GFAP identifies astrocytes apart from other glial cells. For all cells 
OxPAPC was administered at a concentration of 30 µg / ml 30 minutes prior 
to treatment with LPS. Cells were lysed in RIPA buffer 24 h post LPS 
treatment and prepared for Western Blot analysis. 
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The TLR – inhibitor data demonstrates that Bid levels are reduced in 
OxPAPC – treated astrocytes (0.53 ± 0.27 fold decrease), as shown in figure 
3.9. However a similar decrease in Bid protein was not observed in either 
BV-2 cells or primary microglia. It is proposed that levels of Bid in microglia 
are constitutively highly expressed and may not be induced in response to 
LPS, and therefore may not be affected by TLR2 or TLR4 inhibition.  To 
investigate the effects of SOD1G93A – induced microglial toxicity on Bid, TLR2 
and TLR4 - inhibited and non - inhibited BV-2 cells were exposed to the 
paracrine stimulus of SOD1G93A cMedia and Bid levels were assessed by 
Western Blotting.  
 
 
 
Figure 3.10: Bid protein levels are unaffected by paracrine SOD1G93A 
stimulation. (A & B) Bid levels in BV-2 cells when treated with OxPAPC and 
stimulated with CFP, SOD1wt or SOD1G93A cMedia for 24 h before being 
lysed for Western Blot analysis (n = 4 wells from 2 separate platings, p = 
0.68). 
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Figure 3.10 demonstrates that Bid protein levels were not induced by 
SOD1G93A simulation (minus OxPAPC SOD1G93A – treated cells 1.05 ± 1.07 
fold change), similar to what was observed upon LPS stimulation (figure 3.9), 
and remain unaffected by TLR – inhibition upon SOD1G93A stimulation (plus 
OxPAPC CFP – treated cells 0.82 ± 1.17 vs.  plus OxPAPC SOD1G93A – 
treated cells 0.82 ± 1.23). To further investigate the involvement of Bid in the 
SOD1G93A induced pro-inflammatory microglial response the use of bid-/- 
murine primary microglial cultures was employed. Of note bid – deficient 
mice do not display an apparent phenotype and are resistant to TNFα – 
induced apoptosis (Yin et al., 1999). Wild – type (wt) and bid-/- microglia were 
stimulated with CFP and SOD1G93A cMedia and the levels of Cluster of 
Differentiation 45 (CD45) were analysed by immunocytochemistry. CD45 is a 
transmembrane tyrosine - specific phosphatase (Troiano et al., 1995) 
expressed on microglia, T cells and other cells of hematopoietic origin 
(Cosenza-Nashat et al., 2006), and is shown to modulate microglial 
activation, with experiments using CD45-/- mice reporting an over activated 
phenotype (Tan et al., 2000). CD45 levels are upregulated in microglia in 
response to inflammatory stimuli (Sedgwick et al., 1991). Both CD45 
fluorescence intensity present on the stimulated microglia and the number of 
CD45+ CD11b+ cells were quantified. 
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Figure 3.11: Number of CD45+ cells are reduced in bid-/- microglial cultures 
following paracrine stimulation with SOD1G93A. (A & B) CD45 fluorescence 
intensity measured on CD11b+ cells. Primary wt and bid-/- microglia were 
stimulated with CFP or SOD1G93A cMedia for 24 h, fixed in 3 % 
paraformaldehyde, and stained with anti – CD45 and anti – CD11b. 
Immunohistochemistry analysis measured the mean anti - CD45 
fluorescence intensity in CD11b positive cells (n = 5 cultures from 3 separate 
platings, SOD1G93A – stimulated wt microglia 1.2 ± 0.12 fold increase vs. 
SOD1G93A – stimulated bid – deficient microglia 0.99 ± 0.29 fold decrease). 
(C & D) Number of CD45 – CD11b + cells post stimulation with CFP or 
SOD1G93A cMedia for 24 h.  Quantification of the number of CD45 – CD11b - 
positive cells in each condition was also determined by 
immunohistochemistry analysis (n = 3 cultures from 2 separate platings, p < 
0.001, one-way ANOVA, Tukey Multiple Comparison post hoc test). A 
threshold was set for CD11b+ immunofluorescence and higher fluorescence 
signals were analysed. Scale bar = 10μm. 
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Reduced numbers of CD45 - positive cells in bid – deficient SOD1G93A - 
stimulated microglial cultures compared with wt, suggests lower microglial 
activation in the absence of Bid, as shown in Figure 3.11 above. However 
anti – CD45 mean fluorescence intensity was not significantly reduced when 
Bid was absent and it is proposed that while less bid – deficient microglia 
were activated in response to SOD1G93A, microglial CD45 expression is not 
Bid – dependent and activated bid-/- microglia express similar levels of CD45 
as wt microglia. 
Although CD45 is involved in the regulation of NF-ҡB (Ponnappan, 2002, 
Baur et al., 1994), an alternative method was employed to evaluate the Bid – 
dependent SOD1G93A – induced NF-ҡB activation. Here the levels of COX-II, 
a target gene of NF-ҡB activation (Inoue et al., 2000, Poligone and Baldwin, 
2001), were analysed by Western Blotting.  Additionally, COX-II is regulated 
by TLR4 signalling (Fukata et al., 2006). BV-2 cells were transfected with an 
siRNA targeting Bid and subsequently stimulated with paracrine SOD1G93A in 
cMedia. Figure 3.12 shows the changes in COX-II levels when Bid is 
reduced in BV-2 cells compared with BV-2 cells transfected with a scrambled 
control siRNA and exposed to the same SOD1G93A stimulus, as determined 
by Western Blot analysis. 
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Figure 3.12: Lower levels of COX-II are observed in SOD1G93A – stimulated 
BV-2 cells transfected with an siRNA targeting Bid.  (A & B) COX-II levels in 
Bid – depleted BV-2 cells stimulated with CFP, SOD1wt or SOD1G93A 
cMedia. BV-2 cells were transfected with an siRNA targeting Bid (‘siBid’) or a 
scrambled control siRNA (‘siControl’). BV-2 cells were stimulated with 
cMedia 48 h post siRNA transfection, when Bid mRNA and protein levels 
were optimally reduced. The cells were lysed for Western Blot analysis 24 h 
post cMedia treatment and COX-II levels were measured (repeated once 
with similar results). (C) qPCR and (D) Western Blot analysis revealing 
mRNA (n = 4 cultures, from 2 separate platings, siBid ‘A’ 0.76 ± 0.44 fold 
decrease, siBid ‘B’ 0.24 ± 0.44 fold decrease) and protein levels (repeated 
once with similar results) of Bid following treatment with two different siRNAs 
targeting Bid. siBid ‘B’ was chosen for these experiments at 48 h timepoint 
for optimal Bid silencing.  
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3.2.3 Absence or reduction of Bid results in a reduced pro-
inflammatoryTLR4 – induced activation upon LPS stimulation in 
microglia 
In order to investigate the involvement of Bid in TLR4 - induced microglial 
activation the TLR4 agonist LPS was exploited (Poltorak et al., 1998, 
Takeuchi et al., 1999). LPS primarily elicits its response via TLR4 signalling 
and is a potent agonist of TLR4 – mediated NF-ҡB activation (Bottcher et al., 
2003, Hoshino et al., 1999), however TLR2 has been shown to respond to 
LPS stimulation (Yang et al., 1999). LPS – induced neurotoxicity is mediated 
via microglia, as LPS has no effect on neuronal survival when neurons are 
treated with LPS in the absence of microglia (Lehnardt et al., 2003, Chao et 
al., 1992).  Primary wt and bid-/- microglia were stimulated with LPS or a dual 
treatment of LPS plus IFNγ. IFNγ primarily signals through the Jak / Stat 
pathway (Horvath, 2004), however priming with IFNγ and dual treatment with 
TLR agonists has been shown to increase TLR responsiveness (Schroder et 
al., 2006). Protein levels of TLR4 and pro - inflammatory cytokine IL-1β were 
assessed in wt and bid – deficient microglia by Western Blotting 4 h post 
stimulation.  Interestingly, IL-1β has been demonstrated as critical for NF-ҡB 
activation and the NF-ҡB induction of enzymes that facilitate prostaglandin 
synthesis, such as COX-II, in the CNS (Laflamme et al., 1999).  
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Figure 3.13: TLR4 and IL-1β levels are lower in LPS – stimulated bid-/- 
microglia compared with LPS- stimulated wt microglia. (A & B) TLR4 levels in 
wt and bid-/- microglia 4 h post treatment with LPS or LPS plus IFNγ (n = 3 
cultures from 3 separate platings). (C & D) IL-1β levels in wt and bid-/- 
microglia 4 h post treatment with LPS or LPS plus IFNγ (n = 3 cultures from 3 
separate platings).  Primary wt and bid-/- microglia were stimulated with LPS 
or LPS plus IFNγ in serum free media for 4 h before being harvested with 
RIPA lysis buffer and prepared for Western Blot analysis. 
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Lower levels of TLR4 (wt 1.6 ± 0.83 fold increase, bid-/- 0.79 ± 0.43 fold 
decrease) and IL-1β (wt 1.43 ± 1.25 fold increase, bid-/- 1.0 ± 1.03 fold 
change) were observed in LPS – stimulated bid – deficient microglia, as 
shown in Figure 3.13. Assessment of Bid - dependent modulation of TLR4 
signalling was further evaluated using an siRNA targeting Bid and 
subsequent stimulations with LPS or LPS plus IFNγ. The approach of using 
an siRNA is to complement the data observed in bid – deficient microglia, 
and to identify a more therapeutically relevant inflammatory attenuation 
exhibited by Bid depletion. TLR4 levels were analysed by Western Blotting 
post stimulation. In addition, TNFα levels in the media were evaluated by 
ELISA, and gene expression of pro - inflammatory tnfα and il-6 was 
determined by qPCR. 
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Figure 3.14:TLR4 and pro-inflammatory cytokines TNFα levels are lower in 
LPS – stimulated wt microglia transfected with an siRNA targeting Bid. (A & 
B) TLR4 levels in wt microglia transfected with siBid or a scrambled Control 
siRNA (‘siControl’) and subsequently stimulated with LPS or LPS plus IFNγ 
for 4 h (n = 3 cultures from 3 separate platings). (C) tnfα mRNA expression in 
wt microglia transfected with siBid or siControl stimulated with LPS for 1 h 
and 24 h (n = 6 cultures from 2 separate platings, p > 0.001, Kruskal – 
Wallis, Dunns Multiple Comparison post hoc test). (D) il-6 mRNA expression 
in wt microglia transfected with siBid or siControl and stimulated with LPS for 
1 h or 24 h (n = 5 cultures from 2 separate platings).  Cells were lysed at 1 h 
or 24 and prepared for qPCR analysis. (E & F) TNFα levels in supernatant of 
wt microglia transfected with either siBid or siControl and stimulated with 
LPS or LPS plus IFNγ for 24 h (E, n = 3 – 6 cultures from 2 separate 
platings, p > 0.001, one- way ANOVA, Tukey Multiple comparison post hoc 
test) or LPS for 4 h (F, n = 3 cultures from 2 separate experiments). The 
supernatant was collected at the desired timepoint and centrifuged at 500 x g 
for 5 minutes in order to remove cellular debris before the ELISA was carried 
out.   
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In Figure 3.14, TLR4 protein levels were observed to be similar in LPS – 
stimulated Bid – depleted microglia compared with control siRNA – 
transfected cells, which may be due to the insufficient silencing of Bid for the 
reduction of TLR4 levels in response to pro-inflammatory stimuli. Both TNFα 
and IL-1β are rapidly secreted in response to LPS (Dinarello, 1997). TNFα 
levels in the supernatant were not significantly induced by 24 h LPS 
stimulation in the absence of Bid, however this attenuation of TNFα secretion 
was not seen following 4 h post LPS stimulation. The delayed reduction in 
TNFα levels can be accounted for by the time allowed for secretion to the 
media as bid – deficient microglia did not display a significant increase in tnfα 
mRNA expression following 1 h of LPS treatment compared with wt 
microglia. 
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3.3 Discussion  
In this chapter experiments consolidate previous studies showing SOD1G93A 
microglial toxicity to be mediated through TLR2 and TLR4, with signal 
induction leading to NF-ҡB activation facilitating a pro - inflammatory 
response.  Additionally Bid was identified to promote TLR4 – NF-ҡB 
signalling in microglia in response to stimulation with LPS and SOD1G93A.  
 
3.3.1 SOD1G93A toxicity is mediated through TLR2 and TLR4 
It has been long established that microglia are activated in the inflamed CNS 
(Gonzalez-Scarano and Baltuch, 1999). Microglial TLR signalling is 
responsible for the initiation of the inflammatory response (Olson and Miller, 
2004, Lehnardt et al., 2003), and several TLRs have been implicated in 
neurodegenerative disease, including in mutant SOD1G93A – mediated ALS 
pathogenesis (Lee et al., 2015, Zhao et al., 2010, Letiembre et al., 2009, Liu 
et al., 2009). Another in vivo model of ALS, in mice with the SOD1G37R 
mutation, demonstrated that chronic stimulation of TLRs with LPS 
exacerbated disease progression (Nguyen et al., 2004). Here SOD1G93A – 
induced elevation of TLR2 and TLR4 in BV-2 cells was demonstrated, with 
observations of morphological state indicating a decreased SOD1G93A – 
mediated BV-2 cell activation following inhibition of TLR2 and TLR4. 
Additionally, it was shown that SOD1G93A elicits its toxic effects through NF-
ҡB activation. COX-II expression, which is regulated by NF-ҡB transcription 
(Tsatsanis et al., 2006), is reported to be increased in the spinal cord of 
SOD1 transgenic mice (Almer et al., 2001) and in post mortem ALS patients 
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(Yasojima et al., 2001). Taken together our results demonstrate that 
activation of TLR2 / TLR4 - NF-ҡB signalling is facilitating the toxicity of 
SOD1G93A in BV-2 cells.  
3.3.2 Absence of Bid attenuates the SOD1G93A – induced TLR4 – 
mediated inflammatory response 
Our data shows that Bid, which is identified to be significantly more highly 
expressed in microglia than motoneurons, contributes to microglial activation 
via TLR2 or TLR4 stimulation. Although there is no observed induction of Bid 
in microglia upon stimulation with either LPS or paracrine SOD1G93A it is 
proposed that constitutively high levels of Bid are sufficient to respond to the 
inflammatory response. Reduced microglial activation and reduced NF-ҡB 
activation, as assessed by COX-II levels, is seen when Bid is depleted in BV-
2 cells in response to SOD1G93A paracrine stimulation, respectively. LPS - 
induced COX-II expression in microglia is prevented by the inhibition of NF-
ҡB, suggesting the critical role of NF-ҡB activation in TLR4 – mediated COX-
II expression (Bauer et al., 1997). Previous studies have demonstrated 
reduced COX-II levels in bid-/- mouse embryonic fibroblasts (MEFs) 
compared with wt (Luo et al., 2010). In addition, CD45 activates NF-ҡB (Baur 
et al., 1994), and microglial CD45 expression increases with disease 
progression in the SOD1G93A model (Chiu et al., 2008). Here, a significant 
reduction in the number of CD45 expressing microglia were observed when 
Bid is absent post SOD1G93A stimulation. 
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3.3.3 Bid attenuates TLR4 pro-inflammatory signalling specifically 
While absence of Bid attenuates Nucleotide - binding and oligomerization 
domain (NOD) receptor signalling by associating with the complex containing 
the receptors NOD1, NOD2 and IKK components (Yeretssian et al., 2011), 
our laboratory has previously reported a role in astrocytic TLR4 signalling, 
also through the IKK complex (Konig et al., 2014). However, the involvement 
of Bid in TLR4 signalling and indeed microglial TLR4 - induced NF-Ҡb 
activation had not been previously identified.  In this study an attenuation of 
inflammation in bid-/- microglia, as represented by TLR4 and IL-1β levels, is 
demonstrated in LPS – induced conditions and not in the dual stimulation of 
LPS plus IFNγ.  
Microglia respond to pathogenic stimuli more rapidly than astrocytes, 
activating NF-ҡB and mitogen - activated protein kinase (MAPK) pathways 
and precede the astrocytic  release of TNFα and IL-1β (Brites, 2012), with a 
study suggesting that astrocytes may depend on microglia for an LPS - 
induced response (Holm et al., 2012). Here lower levels of TNFα are 
reported in bid - depleted microglia upon LPS stimulation. Increased levels of 
TNFα are associated with disease progression in SOD1G93A mice (Elliott, 
2001), however TNFα may be dispensable in ALS pathogenesis as ablation 
of TNFα did not alter the lifespan and had no effect on gliosis in SOD1G93A 
tnfα-/- mice, but interestingly a compensatory upregulation of IL-1β and TLR2 
levels were noted (Gowing et al., 2006). The lower levels of pro-inflammatory 
cytokines observed in bid - depleted and bid – deficient microglia highlight 
Bid as a promising target in the attenuation of pro-inflammatory signalling. 
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3.3.4 Conclusions 
SOD1G93A toxicity is facilitated via TLR2 and TLR4 in microglia, and the 
absence of Bid attenuates SOD1G93A activation of NF-ҡB and the LPS – 
induced microglial pro-inflammatory response. 
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Chapter IV 
TLR4 – NF-ҡB pathway analysis: effect of bid – 
deficiency on TLR4 – induced NF-ҡB activation in 
microglia 
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4.1 Introduction 
The transcription factor NF-ҡB is regarded as the master regulator of the 
innate immune response and dysregulation of NF-ҡB signalling is a key 
event in the aetiology of inflammatory disease (Yamamoto and Gaynor, 
2001, Ho and Bray, 1999, Barnes and Karin, 1997), with chronic NF-ҡB 
activation contributing to pathogenesis in neurodegeneration (Frakes et al., 
2014, Ghosh et al., 2007, Schneider et al., 1999, Kaltschmidt et al., 1997). 
Elevated TLR - dependent signalling is implicated in neuroinflammation and  
drives pathogenesis (Jin et al., 2008, Hoffmann et al., 2007, Nguyen et al., 
2004), while microglial TLR signalling mediates and sustains CNS 
inflammation (Gambuzza et al., 2011, Carpentier et al., 2008, Olson and 
Miller, 2004).  
TLR signalling propagates to the IKK complex, culminating in the nuclear 
translocation and activation of NF-ҡB, is regulated by a multifaceted network 
of adaptor proteins, kinases and E3 ubiquitin ligases (Verstrepen et al., 
2008).  TLR4 – induced signalling to NF-ҡB exploits both the MyD88 – 
dependent and TRIF – dependent pathways (Yamamoto et al., 2003a). 
Disruption in pro - inflammatory gene transcription is reported in MyD88 – 
deficient macrophages (Kawai et al., 2001), with microglial trif – deficiency 
resulting in reduced microglial activation and pro - inflammatory gene 
expression (Lin et al., 2012).     
Pellino proteins, originally identified in Drosophila and believed to be scaffold 
proteins, are now identified as a family of E3 Ubiquitin ligases that are highly 
conserved during evolution, and play an important role in catalysing the K63 
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- linked polyubiquitination of the IRAK complex (Griffin et al., 2011, Moynagh, 
2009, Grosshans et al., 1999). Of the Pellino family members, Peli1 is the 
most highly expressed in microglia (Xiao et al., 2013). The Peli1 RING 
domain regulates TLR - NF-ҡB signalling (Schauvliege et al., 2007), and 
Peli1 mediated polyubiquitination of IRAK1 results in the recruitment of 
NEMO / IKKγ to the IKK complex (Wu et al., 2006) . Bi – directional 
communication between IRAK and Peli1 leads to a regulatory loop, whereby 
Peli1 is activated by IRAK – induced phosphorylation, and IRAK1 is 
subsequently polyubiquitinated and activated by Peli1 which is degraded 
preventing further activation of IRAK [reviewed in (Moynagh, 2014)]. 
Interestingly, Peli1 also interacts with Receptor Interacting Protein 1 (RIP1) 
and facilitates TRIF - dependent TLR3 signalling (Chang et al., 2009). Peli1 – 
mediated polyubiquitination of RIP1 results in the recruitment of both the IKK 
and TAK1 complexes, both of which contribute to pro - inflammatory 
signalling through NF-ҡB and MAPK activation (Moynagh, 2014). 
Furthermore, Peli1 expression in the CNS is essential for pro - inflammatory 
induction and the recruitment of T cells into the CNS (Xiao et al., 2013). 
Additionally, Peli1 interacts with tumour necrosis factor (TNF) receptor 
associated factor 6 (TRAF6) facilitating its association with the IRAK complex 
(Jiang et al., 2003a). 
The E3 ubiquitin ligase TRAF6 is a member of the TRAF family which 
consists of a group of intracellular signalling adaptor proteins, all of which 
contain a RING domain (Wu and Arron, 2003). There are seven mammalian 
TRAFs identified, all which functionally overlap (Zotti et al., 2012, 
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Bouwmeester et al., 2004).  TRAF2, 3, 6 ,and 7 promote ubiquitination 
(Alvarez et al., 2010, Ha et al., 2009), however TRAF6 is unique form other 
TRAF family members as it contains a distinct interaction motif, by which it 
interacts with upstream signalling components (Ye et al., 2002). TRAF6 
mediates NF-ҡB activation by associating  with the protein kinases IRAK1 
(Cao et al., 1996b) or TAK1 (Wang et al., 2001), which precedes the 
activation of IKKα/β (Deng et al., 2000). A recent study has demonstrated 
that the reduction in TRAF6 levels attenuated microglial NF-ҡB – induced 
inflammation (Qiu et al., 2015). TRAF6 has been shown to interact with and 
induce the K63 – linked polyubiquitination of proteins upstream of IKK, 
including Peli1 (Moynagh, 2009, Jiang et al., 2003a) and NEMO (Zotti et al., 
2014, Sebban-Benin et al., 2007).  
The activation of NEMO, the regulatory subunit of the IKK complex (Perkins, 
2007, Ghosh and Karin, 2002, Karin and Ben-Neriah, 2000), is critical for 
TLR – NF-ҡB signal propagation (Hacker and Karin, 2006). Recently, our 
laboratory has demonstrated an interaction between NEMO and the Bcl-2 
family protein Bid in astrocytes (Konig et al., 2014). 
The role of full length Bid in innate immune signalling and inflammation has 
previously been reported (Scatizzi et al., 2007), with a  study demonstrating 
a reduced pro - inflammatory cytokine expression in bid-/- macrophages in 
response to NOD receptor stimulation (Yeretssian et al., 2011). Additionally, 
an attenuation of the LPS – induced pro - inflammatory response is evident 
in bid – deficient macrophages and microglia (Mayo et al., 2011), highlighting 
a positive role of Bid in facilitating neuroinflammatory pathogenesis. 
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Interestingly Mayo and co - workers also demonstrated that Bid is involved in 
modulating the effects of systemic inflammation on microglial activation in 
response to LPS (Mayo et al., 2011). Furthermore, the phagocytic function of 
microglia and macrophages was impaired when bid is absent, resulting in a 
diminished ability to phagocytose amyloid -β peptides (Mayo et al., 2011), 
contributing to the pathogenesis of Alzheimer’s disease (Napoli and 
Neumann, 2009).   
In this chapter, the effects of bid - deficiency on TLR4 – induced NF-ҡB 
activation in microglia are critically assessed. Additionally, a specific role for 
Bid in the regulation of the microglial pro - inflammatory NF-ҡB response by 
associating with the upstream mediator of NF-ҡB activation TRAF6 is 
identified.  
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4.2 Results 
4.2.1 Effect of the absence of Bid on Microglial TLR4 - induced NF-ҡB    
signalling 
Following the analysis of the Bid – dependent effects on the regulation of the 
LPS - induced microglial pro - inflammatory response, the possibility of an 
interaction between Bid and modulators of TLR4 signalling was investigated. 
TIR adaptors MyD88 and TRIF mediate TLR4 – induced NF-ҡB activation 
(Yamamoto et al., 2003a). MyD88 is critical for microglial TLR – mediated 
responses to PAMPs (excluding TLR3 stimulation) (Esen and Kielian, 2006), 
and for regulating microglial – induced neuronal toxicity (Dean et al., 2010). 
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Figure 4.1: Bid does not associate with TIR adapters MyD88 or TRIF, either 
at rest or upon LPS stimulation. (A) Co-immunoprecipitation of Bid and 
MyD88. (B) Co-immunoprecipitation of Bid and TRIF.  BV-2 cells were 
treated with LPS in serum – free media for 8 h or 24 h and cells were lysed in 
RIPA buffer and prepared for immunoprecipitation. 
 
As no evidence for an interaction between Bid and either MyD88 or TRIF 
was observed by co – immunoprecipitation, as demonstrated in Figure 4.1, 
the focus moved to the components of downstream signalling to NF-ҡB.  In-
depth pathway analysis was required for further elucidation of the role of Bid 
in TLR4 – NF-ҡB signalling. This was carried out by administering acute LPS 
stimulations ranging from 5 minutes to 1 h or 2 h to microglia, with 
subsequent analysis of the levels of several NF-ҡB pathway components in 
bid-/- microglia compared with wt microglia. 
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Firstly, the levels of phosphorylated IKKα and IKKβ subunits of the IKK 
complex were assessed. One of the events in the execution of NF-ҡB 
signalling and subsequent activation is the phosphorylation of IKKα and IKKβ 
(Karin, 1999). Phosphorylation of IKKα and IKKβ facilitates the 
phosphorylation, ubiquitination and subsequent degradation of the inhibitor of 
NF-ҡB, IҡBα, allowing the nuclear translocation of the NF-ҡB subunits p50 
and p65, and the induction of NF-ҡB – dependent transcription (See figure 
4.2). As IҡBα degradation is critical for canonical NF-ҡB signalling (Hay et al., 
1999, Scherer et al., 1995, Traenckner et al., 1994) the IKK complex has 
been described as the gatekeeper of NF-ҡB activation. Here levels of 
phosphorylated IKKα and IKKβ in bid-/- microglia compared with wt upon 
acute LPS stimulation were measured by Western Blot analysis and 
immunohistochemistry. Figure 4.2 highlights a schematic representing TLR4  
induced IKK activation and subsequent NF-ҡB activation.  
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Figure 4.2: Schematic representing the IKK – dependent degradation of IҡBα 
and subsequent translocation of NF-ҡB subunits to the nucleus. The 
schematic above outlines the sequence of events leading to the translocation 
of p65 and p50 NF-ҡB subunits to the nucleus. Upon TLR4 stimulation 
MyD88 activates the IRAK complex through IRAK4, leading to IRAK1 
phosphorylation and the recruitment of IKKγ/NEMO to the IKK complex. 
NEMO ubiquitination and subsequent phosphorylation of IKKα and IKKβ 
mediate the phosphorylation and subsequent K48 – linked ubiquitination of 
the NF-ҡB inhibitor IκBα, thus facilitating the NF-ҡB subunits p50 and p65 
translocation to the nucleus, resulting in NF-ҡB dependent gene transcription 
(Chen et al., 1995).  
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Figure 4.3: pIKKα/β levels are lower in bid-/- microglia following LPS 
stimulation compared with wt. (A) Representative images of CD11b+ 
pIKKα/β+ cells in unstimulated cells and 5 minutes post LPS stimulated wt 
and bid-/- microglia.  (B) Quantification of pIKKα/β levels in CD11b+ cells. A 
threshold was set for minimal pIKKα/β+ fluorescence on CD11b+ cells and 
all measurements were quantified above this threshold. (A + B, n = 7 – 8 
fields of view pooled from 2 separate platings, p = 0.06, three– way ANOVA, 
Tukey Multiple Comparison post hoc test). Primary wt and bid-/- microglia 
were stimulated with LPS for 5, 15, 30 minutes and 1 h in serum free media 
before being fixed in 3 % paraformaldehyde and stained with anti – pIKKα/β 
and anti - CD11b. Immunofluorescence  analysis measured anti - pIKKα/β  
mean fluorescence on CD11b positive cells.  (C) Representative Western 
Blot showing pIKKα/β levels in wt and bid-/- microglia upon acute LPS 
stimulation. (D) Quantification of pIKKα/β levels in wt and bid-/- LPS 
stimulated microglia as assessed by Optical Density and normalised to α-
Tubulin. Primary wt and bid-/- microglia were treated with LPS for 5, 15, 30 
minutes, 1 h and 2 h in serum free media before being lysed for Western Blot 
analysis  (n = 3 pooled from 3 separate experiments, 3 – way ANOVA Tukey 
Multiple Comparison post-hoc test).  
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A significant reduction in the phosphorylation of IKKα / β was apparent in bid 
– deficient microglia compared with wt, where phosphorylation is induced 
upon LPS stimulation (4.3D, 1.68 ± 1.3 vs. 0.71 ± 0.76 1 h post LPS 
stimulation), as demonstrated in Figure 4.3. 
 LPS – induced activation of the IKK complex leads to IҡBα degradation 
(Yang et al., 2003). This degradation of IҡBα in response to potent activators 
of canonical NF-ҡB activation is both phosphorylation – induced (DiDonato et 
al., 1997) and proteasome – dependent (Alkalay et al., 1995a, Brown et al., 
1995). IҡBα levels were assessed by Western Blotting in acute LPS – 
stimulated wt and bid – deficient microglia. 
 
 
Figure 4.4: IҡBα is degraded more rapidly in wt microglia compared with bid-/- 
microglia upon LPS stimulation. (A & B) IҡBα levels in wt and bid-/- microglia 
upon acute LPS stimulation (n = 3 cultures pooled from 3 separate platings).  
Primary wt and bid-/- microglia were stimulated with LPS for 5, 15, 30 minutes and 1 
h in serum free media, lysed in RIPA buffer and IҡBα levels were analysed by 
Western Blot. Quantification of protein levels were calculated from optical density 
measurements from Western Blot experiments and normalised to α – Tubulin.  
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IҡBα degradation was higher in wt microglia compared with that of bid - 
deficient cells (1.23 ± 0.33 fold increase in bid-/- microglia at 30 minutes post 
LPS stimulation, compared with wt at 30 minutes LPS stimulation) noted in 
bid - deficient microglia upon LPS stimulation in the time frame assessed 
(Figure 4.4).  
Next, the levels of the phosphorylated NF-ҡB subunit p65 were measured by 
Western Blot analysis. p65 is phosphorylated in an IKKβ - dependent manner 
(Yang et al., 2003) and its phosphorylation is crucial for NF-ҡB activation 
(Shinomiya et al., 1991).  
 
 
Figure 4.5: Phosphorylated p65 levels are lower in bid-/- microglia, compared 
with wt, upon LPS stimulation. (A) Representative Western Blot of 
phosphorylated p65 levels in wt and bid-/- microglia and (B) quantification of 
phosphorylated p65 (n = 4 cultures from 4 separate platings, LPS treatments 
30 minutes – 2 h p = 0.09, paired two - tailed t - test). wt and bid-/- microglia 
were stimulated with LPS in serum - free media for 5 minutes, 15 minutes, 30 
minutes, 1 h or 2 h before being lysed in RIPA buffer and prepared for 
Western Blot analysis.  
 
                                                                                                           Chapter IV: Results 
 
 
124 
 
The levels of phosphorylation of p65 was 0.52 ± 0.41 fold lower in bid – 
deficient microglia compared with wt during the LPS stimulations of 30 
minutes to 2 h (Figure 4.5). Following on from these findings NF-ҡB 
activation was assessed using two different methods; by the measurement of 
alkaline phosphatase which is induced and secreted in response to NF-ҡB 
activation of the transfected  SEAP – NF-ҡB reporter gene, and quantification 
of luciferase activity from the transfected pGL4.32[luc2P/NF-κB-RE/Hygro] 
reporter. NF-ҡB transcription is a key event in the induction of inflammatory 
genes and in immune response in microglia (Kaltschmidt et al., 1994a). 
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Figure 4.6: NF-ҡB activation is reduced upon LPS activation in bid-/- microglia 
and when Bid is inhibited in BV-2 cells. (A & B) NF-ҡB activation in wt and 
bid-/- microglia post stimulation with LPS for 1 h (A, n = 3 – 6 wells, p = 
0.1757) or 8 h (B, n = 6 wells, p = 0.662), as determined by secreted levels 
of alkaline phosphatase. Microglia were stimulated with LPS (100 ng / ml) in 
serum - free media which was collected post LPS treatment for SEAP assay 
analysis. (C) NF-ҡB activation in BI-6C9 -  treated BV-2 cells stimulated with 
LPS for 24 h. BV-2 cells were co-transfected with NF-κB-RE - luciferase and 
Renilla - luciferase plasmids for 24 h and treated with either 10 μΜ Bid 
Inhibitor (BI) or 100 μΜ BI 30 minutes prior to LPS stimulation. The cells 
were lysed 24 h post LPS treatment in 1 X passive lysis buffer for 20 minutes 
shaking at room temperature and NF-ҡB activation was quantified by 
measuring the expression of Firefly luciferase reporter by luminescence 
relative to Renilla luciferase (represented as relative ҡB - dependent firefly 
activity, n = 6 - 16 wells pooled from 2 separate experiments, p < 0.001, 2 
outliers removed, Grubbs followed by Kruskal Wallis and Dunn’s Multiple 
Comparison post hoc test). 
 
In Figure 4.6 lower levels of NF-ҡB activation were demonstrated in bid – 
deficient and Bid - inhibited microglia in response to acute LPS stimulation (1 
h, 4.6A 1.29 ± 0.48 fold increase vs. 0.69 ± 0.18 fold decrease), and 
prolonged LPS stimulation (8 h, 4.6B, 7.48 ± 8.3 fold increase vs. 6.09 ± 1.3 
fold increase; 24 h, 4.6C, 100 µM BI-6C9 plus LPS decreased 3.00 ± 1.858 
fold compared to DMSO plus LPS). Interestingly this suggests that the Bid – 
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dependent diminished NF-ҡB pro - inflammatory response is sustained upon 
more chronic stimulation with LPS.  
To assess whether the Bid – dependent modulation of NF-ҡB activation is 
mediated by full – length Bid analysis of Bid cleavage, by measurement of 
tBid levels, was carried out in LPS – stimulated microglia, and represented 
by Western Blot in Figure 4.7 below. 
 
 
Figure 4.7: LPS does not induce Bid levels or Bid cleavage in microglia. (A & 
B) Bid levels are not induced upon acute LPS stimulation in wt microglia as 
measured by Western Blotting (n = 3 cultures pooled from 3 separate 
experiments). (C & D) Bid is not cleaved upon LPS stimulation up to 4 h as 
assessed by Western Blotting up to 4 h post treatment. (n = 3 cultures 
pooled from 3 separate experiments). wt microglia were stimulated with LPS 
(100 ng / ml) in serum free media for the appropriate timepoint prior to lysis 
in RIPA buffer and preparation for Western Blot analysis. 
 
                                                                                                           Chapter IV: Results 
 
 
127 
 
4.2.2 Examination of the effects of bid – deficiency on the levels of 
targets of K63 – linked poly-ubiquitination in TLR4 - NF-ҡB signalling 
NEMO 
NEMO is critical for the regulation and activation of the IKK complex which is 
essential for canonical NF-ҡB signalling (Liu et al., 2012, Rothwarf et al., 
1998). Specific ablation of IKKβ and NEMO resulted in decreased CNS 
inflammation in an Experimental Autoimmune Encephalitis (EAE) model (van 
Loo et al., 2006). Both IKKα and IKKβ have a C – terminal NEMO binding 
domain (Liu et al., 2012, Israel, 2010, Hoffmann et al., 2006), and 
additionally, NEMO contains a binding site for IKKα and IKKβ (Marienfeld et 
al., 2006). NEMO also contains a UBAN (Ubiquitin – binding in ABIN and 
NEMO) domain (Rahighi et al., 2009), and an IҡBα binding domain (Chen et 
al., 1996).  The UBAN domain on NEMO facilitates the binding of both K63 – 
linked and Linear polyubiquitin chains accepted from TRAF6 and RIP1, 
respectively (Emmerich et al., 2013, Tokunaga et al., 2009), leading to a 
conformational change which induces the phosphorylation of IKKα and IKKβ 
and subsequent downstream phosphorylation and K48 – linked ubiquitination 
of IҡBα (Tokunaga et al., 2009, Wu et al., 2006, Karin and Ben-Neriah, 2000, 
Scherer et al., 1995). However, interestingly overexpression of NEMO had a 
significant inhibitory effect on NF-ҡB activation (Krappmann et al., 2000, Ye 
et al., 2000). Recently our laboratory has identified an interaction between 
NEMO and the Bcl - 2 family protein Bid in astrocytes (Konig et al., 2014). In 
Figure 4.8 NEMO levels in unstimulated motoneurons, astrocytes and 
microglia were assessed in wt and bid-/- conditions to investigate any Bid – 
dependent modulation in NEMO levels. 
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Figure 4.8: NEMO levels are unchanged in bid-/- microglia and motoneurons 
at rest compared with wt. (A & B) NEMO levels in unstimulated wt and bid-/- 
motoneurons (n = 3 cultures pooled from 2 separate platings).  (C & D)  
NEMO levels in unstimulated wt and bid-/- astrocytes (n = 3 cultures pooled 
from 3 separate platings, p = 0.4126). (E & F) NEMO levels in unstimulated 
wt and bid-/- microglia (n = 4 cultures pooled from 4 separate platings, p = 
0.6857). Mixed motoneurons were lysed in RIPA buffer at DIV7, and purified 
astrocytes and microglia were lysed in RIPA buffer 2 days post plating in 
order to allow time to become quiescent, and lysates were prepared for 
Western Blot analysis. (G) Molecular structure of NEMO domains, adapted 
from (Clark et al., 2013). NEMO is composed of multiple domains including 
two coiled – coil domains (CC1 and CC2), and Leu zipper (LZ) domain and a 
zinc - finger domain (ZNF). Binding sites for IKKα and IKKβ are located at 
the N – terminal spanning some of the CC1 domain. The CC2 and LZ 
domains make up the UBAN domain (Rahighi et al., 2009). NEMO interacts 
with IҡBα at the ZNF domain, and contains a TANK binding domain (TRAF 
family member associated NF-ҡB activator) between the CC domains (Hinz 
and Scheidereit, 2014, Clark et al., 2013). 
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Expression analysis of NEMO levels revealed no change in NEMO levels 
between wt and bid - deficient microglia at rest. NEMO deficiency or 
depletion is also reported to lead to immunodeficiency (Picard et al., 2011, 
Mooster et al., 2010). Moderately lower NEMO levels were noted in bid – 
deficient astrocytes (0.74 ± 0.27 fold decrease), which may indicate a cell 
specific function of Bid. NEMO levels were assessed post LPS stimulation in 
wt microglia compared with bid – deficient microglia, to further examine 
whether Bid mediates NF-ҡB activity through the regulation of NEMO levels.  
 
 
Figure 4.9: NEMO levels are unchanged in wt and bid-/- microglia upon acute 
LPS stimulation. (A) Representative Western blot and (B) quantification of 
NEMO levels in wt and bid-/- microglia upon acute LPS stimulation (n = 3 
cultures from 3 separate platings). Microglia were stimulated with LPS (100 
ng / ml) in serum free media for 30 minutes or 1 h and lysed for Western blot 
analysis. 
 
There were no changes observed in the levels of NEMO in wt or bid-/- 
microglia upon acute LPS stimulations, as shown in Figure 4.9. As NEMO 
protein levels are not induced in LPS – stimulated wt microglia it can be 
suggested that constitutive NEMO levels are sufficient for the regulation of 
the IKK complex, with basal levels reaching a threshold that is not 
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physiologically induced. It has been proposed that the protein levels of 
NEMO may provide a rate – limiting step in NF-ҡB activation (Huang et al., 
2002).  Of note, regulation of NF-ҡB activation by NEMO may not be 
identified by quantification of levels, but rather by the examination of NEMO 
activation. However this data suggests that NEMO levels are not regulated in 
a Bid – dependent manner either at rest or upon TLR4 – induced signalling in 
microglia.  
Previously our group and others have demonstrated an interaction between 
Bid and NEMO (Konig et al., 2014, Yeretssian et al., 2011).  To investigate if 
a similar interaction occurs in microglia co - immunoprecipitation analysis 
was carried out 
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Figure 4.10: Bid does not associate with NEMO in BV-2 cells at rest or upon 
LPS stimulation. (A) Co - immunoprecipitation of Bid and NEMO in BV-2 cells 
stimulated with LPS for 8 h or 24 h. Bid was immunoprecipitated from BV-2 
cells and the lysates were prepared for Western Blot analysis and probed for 
NEMO. (B) Co-immunoprecipitation of NEMO and Bid in BV-2 cells 
stimulated with LPS for 15 minutes, 1 h or 24 h. NEMO was 
immunoprecipitated from BV-2 cells and bid-/- astrocytes, lysates were 
prepared for Western blot analysis and the membrane was probed for Bid. 
(C) Western Blot showing Bid levels in the supernatant of co-
immunoprecipitation of samples in (B). Supernatant refers to the protein 
sample after incubation with the antibody – bound DynaBeads. The 
supernatant was concentrated in size exclusion columns, by centrifugation at 
300 x g for 45 minutes at 4° C. The flow through was denatured after loading 
buffer was added, and the samples were analysed by Western Blot. Protein 
levels in the supernatant represent the protein that did not bind to the 
antibody – bound beads. BV-2 cells were treated with LPS (1 µg / ml) in 
serum free media and lysed at the appropriate timepoint in RIPA buffer.  
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Microglial Bid and NEMO were not demonstrated to associate either at rest 
or upon LPS stimulation by co - immunoprecipitation analysis under these 
conditions (Figure 4.10). As the activation of IKKα and IKKβ were 
suppressed in a Bid – dependent manner, as indicated by lack of induced 
phosphorylation in LPS stimulated bid – deficient microglia, and with a lack of 
interaction of Bid and NEMO, upstream regulators of IKK were next 
examined with regard to Bid – dependent modification of NF-ҡB activation. 
 
Peli1 
Recent evidence has highlighted a critical role of the E3 Ubiquitin ligase 
Peli1 in TLR signalling (Moynagh, 2009, Jiang et al., 2003a), and in 
microglial – mediated CNS inflammation (Xiao et al., 2013). Peli1 - deficient 
mice are resistant to TLR4 induced septic shock (Chang et al., 2009). 
Previous data in this study indicates that protein abundance may be a critical 
determinant of NF-ҡB activation, and it was hypothesized that the absence of 
Bid modulates Peli1 – mediated TLR4 – NF-ҡB signalling. To investigate this, 
firstly Peli1 levels were examined at rest in unstimulated mixed motoneurons, 
astrocytes and microglia in wt and bid-/- cells. 
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Figure 4.11: Peli1 levels are lower in bid-/- microglia compared with wt but 
there is no change between wt and bid-/- astrocytes or mixed motoneurons at 
rest. (A & B) Peli1 levels in unstimulated wt and bid-/- motoneurons (n = 5 
cultures pooled from 2 separate platings).  (C & D)  Peli1 levels in 
unstimulated wt and bid-/- astrocytes (n = 5 wells pooled from 3 separate 
platings). (E & F) Peli1 levels in unstimulated wt and bid-/- microglia (n = 6 
wells from 3 separate platings, p = 0.1548). Mixed motoneurons were lysed 
in RIPA buffer at DIV7, and purified astrocytes and microglia were lysed in 
RIPA buffer 2 days post plating in order to allow time to become quiescent. 
Cells were prepared for Western Blot analysis. (G) Peli1 protein structure, 
adapted from (Moynagh, 2014). All Pellino family members contain a 
forkhead associated (FHA) domain, a wing domain, and a RING domain. 
Ubiquitination (Ub) sites are marked on the wing domain and the FHA 
domain, and a site for sumoylation (Su) is marked on the FHA domain, the 
effect of which is unknown. Phosphorylation sites specific for Peli1 are 
highlighted showing threonine or serine residues that facilitate Peli1 
phosphorylation by IRAK or TBK (TANK binding Kinase) (Moynagh, 2014, 
Smith et al., 2009, Lin et al., 2008).  
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The observation of lower levels of Peli1 in bid-/- microglial cells compared 
with wt (0.62 ± 0.51 fold decrease), as shown in Figure 4.11, led to the 
hypothesis that Bid may be regulating NF-ҡB activation by directly or 
indirectly altering the levels of Peli1. Next, the effects of bid – deficiency on 
Peli1 levels in LPS stimulated microglia were assessed (Figure 4.12).  
 
Figure 4.12: Peli1 levels are reduced when Bid is absent in microglia upon 
acute LPS stimulation. (A & B) Peli1 levels in wt and bid-/- microglia upon 
acute LPS stimulation (n = 3 cultures pooled from 3 separate platings, p < 
0.001, two - way ANOVA, Bonferroni’s post hoc test). Microglia were 
stimulated with LPS (100 ng / ml) in serum – free media for the relevant 
treatment timepoint, lysed in RIPA buffer and prepared for Western Blot 
analysis. 
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Peli1 levels were significantly reduced in bid-/- microglia on acute LPS 
stimulation compared with wt (1.49 ± 0.55 fold increase in wt microglia vs. 
0.59 ± 1.3 fold decrease in bid-/- microglia at 1 h post LPS treatment). As 
Peli1 – induced polyubiquitination of the IRAK complex is essential for IRAK 
mediated signal propagation to the IKK complex (Moynagh, 2014), co - 
immunoprecipitation experiments were carried out in an effort to elucidate 
whether Bid - dependent modulation of TLR4 – NF-ҡB signalling is facilitated 
by an interaction between Bid and Peli1 (Figure 4.13). 
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Figure 4.13: Bid does not associate with Peli1 in BV-2 cells at rest or when 
stimulated with LPS. (A) Co - immunoprecipitation of Peli1 and Bid in BV-2 
cells stimulated with LPS for 10 minutes, 30 minutes, or 4 h. Peli1 was 
immunoprecipitated and the immunoprecipitate was probed for Bid. (B) Co- 
immunoprecipitation of Peli1 and Bid in BV-2 cells stimulated with LPS for 8 
h or 24 h. Peli1 was immunoprecipitated and the immunoprecipitate was 
probed for Bid.  (C) Co - immunoprecipitation of Bid and Peli1 in BV-2 cells 
stimulated with LPS in serum - free media for 8 h or 24 h. Bid was 
immunoprecipitated from BV-2 cells and the immunoprecipitate was probed 
for Peli1. (D)  Co-immunoprecipitation of Bid and Peli1 in BV-2 cells and bid-/- 
astrocytes. Bid was immunoprecipitated from the BV-2 cells and the samples 
were probed for Peli1. bid-/- astrocytes were used as a negative control for 
Bid immunoprecipitation.  BV-2 cells were stimulated with LPS (1 µg / ml) in 
serum free media. Cells in A, B & C were lysed in Totex buffer, and cells in D 
were lysed in RIPA buffer. 
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TRAF6 
TRAF6 mediates NF-ҡB signalling (Cao et al., 1996b), and also the 
activation of MAPK and IRF3 (Wu and Arron, 2003). traf6-/- mice 
phenotypically present with systemic inflammation and impaired TLR 
signalling (King et al., 2006, Kobayashi et al., 2004, Yeiser et al., 2004). The 
domain structure of TRAF6 consists of an N - terminal RING domain which is 
essential for the K63 - linked ubiquitination of the IKK complex upstream of 
NF-ҡB activation (Funakoshi-Tago et al., 2009, Lamothe et al., 2007).  
TRAF6 contains several lysine residues and upon its K63 – linked 
autoubiquitination docking sites are provided for the further ubiquitination of 
target proteins which mediate NF-ҡB activation (Chen, 2005). There was no 
evidence from the above co – immunoprecipitation experiments of an 
interaction between Bid and Peli1 or Bid and NEMO. Next TRAF6 was 
examined as Peli1 is a mediator of TRAF6 downstream activation in TLR4 – 
induced NF-ҡB signalling (Jiang et al., 2003a). Firstly, the effect of bid – 
deficiency on TRAF6 levels in unstimulated mixed motoneurons, astrocytes 
and microglia was assessed, as shown in Figure 4.14 below. 
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Figure 4.14: Lower levels of TRAF6 were observed in bid-/- astrocytes and 
microglia compared with wt, but similar TRAF6 levels are noted in wt and  
bid-/- mixed motoneurons. (A & B) TRAF6 levels in unstimulated wt and bid-/- 
mixed motoneurons (n = 3 cultures).  (C & D)  TRAF6 levels in unstimulated 
wt and bid-/- astrocytes (n = 3 cultures from 3 separate platings, p = 0.1432). 
(E & F) TRAF6 levels in unstimulated wt and bid-/- microglia (n = 4 cultures 
from 4 separate platings, p =0.0725). Mixed motoneurons were lysed in RIPA 
buffer at DIV7, and purified astrocytes and microglia were lysed in RIPA 
buffer 2 days post plating in order to allow time to become quiescent, and 
lysates were prepared for Western Blot analysis. (G) TRAF6 protein 
structure. Adapted from (Walsh et al., 2008, Lamothe et al., 2007). TRAF6 
contains a RING domain and a Zinc Finger domain. The RING domain of 
TRAF6 interacts with the E2 ubiquitin ligase Ubc13-Uev1A and facilitates 
either autoubiquitination or the ubiquitination of a target protein (Lamothe et 
al., 2007). The first zinc finger of the zinc finger domain also contributes to 
ubiquitination (Yin et al., 2009).The TRAF domain, also known as MATH 
domain, interacts with the cytoplasmic components of TNF receptors (Wu 
and Arron, 2003).  
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Expression analysis of TRAF6 levels revealed lower levels of TRAF6 in bid-/- 
astrocytes (0.66 ± 0.59 fold decrease) and microglia (0.53 ± 0.30 fold 
decrease) compared with wt. This is similar to observations of bid – deficient 
microglial Peli1 levels. It was then proposed that an interaction between 
TRAF6 and Bid may occur and elicit attenuated downstream signalling to 
NF-ҡB. To investigate this, a number of co – immunoprecipitation and pull – 
down experiments were carried out using BV-2 cells and primary glia 
stimulated with LPS and / or overexpressing TRAF6 and Bid. 
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Figure 4.15: Bid associates with TRAF6, as shown by co-
immunoprecipitation and pull-down. (A) Co-immunoprecipitation of Bid and 
TRAF6 in BV-2 cells and bid-/- astrocytes. BV-2 cells were stimulated with 
LPS for 15 minutes or 1 h and Bid was immunoprecipitated from the lysates 
along with control unstimulated BV-2 cells and unstimulated bid-/- astrocytes, 
and samples were analysed for TRAF6 content after immunoprecipitation of 
Bid. (B) Co-immunoprecipitation of Bid and TRAF6 in wt primary microglia 
stimulated with LPS for 1 h and 4 h. wt microglia were lysed post LPS 
stimulation and Bid was immunoprecipitated from the lysates. The samples 
were analysed for TRAF6 content by Western Blot. (C) Pull - down of FLAG 
and detection of endogenous Bid in the immunoprecipitated of BV-2 cells 
overexpressing Bid - Cherry and TRAF6wtFLAG. BV-2 cells were transfected 
with Bid - Cherry and TRAF6wtFLAG (1.5 µg / 3 x 105 cells) using 
lipofectamine, and stimulated with LPS (1 µg / ml for BV-2 and 100 ng / ml 
for primary glia) in serum free media for 1 h. The coomasie stained gel is 
shown as a loading control and TRAF6 levels in FLAG immunoprecipitated 
samples were detected by Western Blot. Cells were lysed in RIPA buffer.  
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In Figure 4.15, co – immunoprecipitation and pull – down  experiments 
provided positive results for an interaction between Bid and TRAF6 in 
unstimulated and LPS – stimulated BV-2 cells and mixed glia. An interaction 
with FLAG and overexpressed Bid – Cherry was not detected on this blot 
perhaps due to an issue with epitope confirmation of the tag, however 
endogenous Bid immunoprecipitated with FLAG in BV-2 cells, suggesting an 
interaction between TRAF6-FLAG and endogenous Bid in these cells.  
To confirm this interaction an alternative technique to detect protein - protein 
interation in situ was exploited. The Proximity Ligation Assay (PLA) was 
carried out in BV-2 cells overexpressing TRAF6. Both unstimulated and LPS 
– stimulated TRAF6 – overexpressing BV-2 cells were fixed and stained with 
anti - TRAF6 and anti - Bid and imaged after the PLA was complete (Figure 
4.16). 
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Figure 4.16: Bid associates with TRAF6 at rest and upon LPS stimulation, 
demonstrated with PLA assay. (A) Quantification of PLA assay in BV-2 cells. 
BV-2 cells were transfected with TRAF6wtFLAG or empty FLAG vector and 
stimulated with LPS for 1 h (p < 0.001, significant increase of PLA dots in 
TRAF6 transfected vs. control transfected cells and Vehicle versus LPS 
treated cells, two-way ANOVA). The cells were fixed with 3 % 
paraformaldehyde, stained with anti - Bid and anti - TRAF6 and PLA 
interaction was quantified. Negative controls included immunostaining with 
anti - Bid plus anti - IRF2, and anti - TRAF6 plus anti - HA-tag.  (B) 
Representative Western Blot showing anti - Bid antibody specificity. A new 
anti – Bid antibody (Abcam) was used here due to the discontinuation of the 
anti – Bid (Enzo) antibody used in previous Western Blot experiments. (C) 
Representative image of PLA and phase contrast in TRAF6wtFLAG 
overexpressing BV-2 cells immunostained with anti - Bid and anti - TRAF6 (n 
= 2 wells, 4 fields of view per well). (D) Negative control representative image 
of PLA in TRAF6wtFLAG overexpressing BV-2 cells immunostained with anti 
- TRAF6 plus anti - HA-tag (n = 1, 6 fields of view – LPS, 1 field of view + 
LPS). (E) Negative control representative image of PLA in TRAF6wtFLAG 
overexpressing BV-2 cells immunostained with anti - Bid plus anti - IRF2 (n = 
1 well, 7 fields of view). Scale bar = 10 µm.  
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Both PLA and co - immunoprecipitation experiments (Figures 4.15 and 4.16) 
determined an interaction between Bid and TRAF6 that is present in 
unstimulated mixed glia and BV-2 cells, and increased upon LPS stimulation.   
 
4.2.3. Investigation of a Role of Bid in RIP1 - dependent activation of 
NF-ҡB 
Next, the possible TLR4 – induced downstream effects of Bid signalling were 
expanded, with a focus on Receptor – Interacting Protein 1 (RIP1). RIP1 is 
an adaptor kinase that mediates TNFR, TLR3 – and TLR4 – induced 
signalling to NF-ҡB (Ofengeim and Yuan, 2013).  Peli1 mediates the K63 – 
linked polyubiquitination of RIP1 in the TRIF- dependent TLR3 – stimulated 
pathway only (Chang et al., 2009, Adhikari et al., 2007). Induced kinase 
activity of RIP1 in response to LPS has been reported, confirming RIP1 
involvement in TRIF – dependent TLR4 signalling (Cusson-Hermance et al., 
2005). RIP1 is composed of a kinase domain, a death domain and an 
interdomain which contains specific docking sites for NEMO and TAK1 
ubiquitination, making RIP1 a positive regulator of TLR4 signalling through its 
interaction with NEMO and TAK1 (Ofengeim and Yuan, 2013). Additionally 
RIP1 is polyubiquitinated by K63 - linked and M1 – linked linear ubiquitin 
chains (Gerlach et al., 2011, Wu et al., 2006). Figure 4.17 shows an 
overview of RIP1 mediated TLR4 - induced signalling via the TRIF – 
dependent pathway. 
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Figure 4.17: Schematic of MyD88 – independent TLR4 signalling. Adapted 
from (Ofengeim and Yuan, 2013, Wertz and Dixit, 2010). The MyD88 – 
independent / TRIF - dependent pathway (described in section 1.3.1), is 
mediated through the interaction of TIR adaptor TRIF with RIP1 and TRAF6, 
resulting in the activation of NF-ҡB, mitogen activated protein kinases 
(MAPK). Additionally the TRIF – dependent pathway results in IFNγ 
transcription through the activation of Interferon Regulatory Factor 3 (IRF3) 
(Cusson-Hermance et al., 2005, Kawai et al., 2001). 
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In order to examine whether the Bid – dependent modulation of the TLR4 - 
NF-ҡB pathway is mediated through RIP1, firstly the expression profile of 
RIP1 protein levels in unstimulated wt and bid-/- motoneurons, astrocytes and 
microglia was assessed. 
 
 
Figure 4.18: RIP1 levels are similar between wt and bid-/- motoneurons, 
astrocytes and microglia. (A & B) RIP1 levels in unstimulated wt and bid-/- 
motoneurons (n = 4 cultures from 2 separate platings). (C & D)  RIP1 levels 
in unstimulated wt and bid-/- astrocytes (n = 5 cultures from 3 separate 
platings). (E & F) RIP1 levels in unstimulated wt and bid-/- microglia (n = 4 
cultures from 3 separate platings, p = 0.4188). Mixed motoneurons were 
lysed in RIPA buffer at DIV7, and purified astrocytes and microglia were 
lysed in RIPA buffer 2 days post plating in order to allow time to become 
quiescent, and lysates were prepared for Western Blot analysis. 
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Figure 4.18 reveals no significant difference in RIP1 levels noted between wt 
and bid – deficient mixed motoneurons (0.8 ± 0.32 fold decrease), astrocytes 
(0.93 ± 0.51 fold decrease) and microglia (0.86 ± 0.56).  Further examination 
of a Bid – dependent role in RIP1 – mediated TLR4 signalling looked at RIP1 
levels upon LPS stimulation wt and bid-/- microglia. Microglia were treated 
with LPS acutely from 5 minutes to 1 h, and for prolonged stimulations of 4 h 
and 24 h and RIP1 levels were subsequently assessed by Western Blotting.  
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Figure 4.19: RIP1 levels are similar in wt and bid-/- microglia upon acute and 
prolonged LPS stimulation. (A & B) RIP1 levels in wt and bid-/- microglia after 
acute LPS stimulations (n = 3 cultures from 3 separate platings, p = 0.3050). 
Microglia were stimulated with LPS in serum – free media for 5 minutes, 15 
minutes, 30 minutes and 1 h, and lysed for Western Blot analysis. (B)  RIP1 
levels in wt and bid-/- microglia stimulated with LPS for 4 h and 24 h (n = 3 
cultures from 3 separate platings). Microglia were stimulated with LPS (100 
ng / ml) in serum – free media and lysed in RIPA buffer for Western Blot 
analysis. 
 
As seen in Figure 4.19, there was no significant difference detected in the 
induction of RIP1 levels at rest or upon LPS stimulation between wt and bid-/- 
microglia, suggesting that Bid does not have a regulatory effect on RIP1 – 
mediated TLR4 signalling. However, it is to be noted that protein levels are 
not indicative of the K63 – linked activation of RIP1, however formation of 
K63 – linked ubiquitin chains on RIP1 is proposed to prevent its K48 – 
mediated degradation (Wertz et al., 2004). In this light the above data 
                                                                                                           Chapter IV: Results 
 
 
148 
 
suggests a non differential ubiquitin – dependent activation of RIP1 between 
wt and bid – deficient microglia. Next, co – immunoprecipitation experiments 
were carried out in order to assess whether Bid interacts with RIP1 either at 
rest or upon LPS activation. 
 
 
 
 
Figure 4.20: Bid and RIP1 do not associate at rest or when BV-2 cells are 
stimulated with LPS.   (A) Co - immunoprecipitation of Bid with RIP1 in BV-2 
cells stimulated with LPS for 5 minutes, 15 minutes and 30 minutes. BV-2 
cell were lysed in Totex buffer. Bid was immunoprecipitated and the samples 
were probed for RIP1. BV-2 cells were stimulated with LPS (1 µg / ml) in 
serum free media and lysed in RIPA buffer.  
 
 
As suggested by the lack of Bid – dependent LPS – induced RIP1 signalling, 
there was no interaction between Bid and RIP1 identified by co – 
immunoprecipitation experiments in BV-2 cells (Figure 4.20), suggesting a 
redundant effect of Bid on RIP1 – mediated activation of NF-ҡB. 
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4.3 Discussion 
In this chapter reduced NF-ҡB activation was identified in bid – deficient and 
Bid – inhibited microglia and BV-2 cells, respectively. Critical examination of 
the effects of microglial bid - deficiency on components of TLR4 – induced 
NF-ҡB signalling pathway in response to LPS stimulation was carried out. 
Finally, an interaction between Bid and the E3 ubiquitin ligase TRAF6 was 
identified, and it is proposed that this is a mechanism by which Bid 
modulates TLR4 - NF-ҡB signalling. 
4.3.1 Reduced NF-ҡB activation in bid – deficient microglia 
Microglial NF-ҡB activation has been shown to contribute to 
neuroinflammation and neurodegeneration (Bales et al., 2000, Kaltschmidt et 
al., 1994a). In Chapter III mutant SOD1G93A - induced microglial activation 
was demonstrated via activation of TLR2 / TLR4 - NF-ҡB signalling (Figure 
3.6). Here the effects of the absence of Bid on TLR4 – induced NF-ҡB 
activation in microglia were examined, with a reduction in NF-ҡB activation 
observed in bid – deficient microglia following acute LPS stimulation. 
Additionally, NF-ҡB activation was lower in Bid – inhibited BV-2 cells, 
compared with non - inhibited cells following 24 h of LPS stimulation. The 
lack of induced phosphorylation of p65 is evident in bid – deficient microglia 
and taken together these results affirm that the absence or depletion of Bid 
attenuates microglial activation via NF-ҡB. Interestingly, a delayed activation 
of TLR4 in the absence of Bid, as demonstrated by the hampered 
degradation of NF-ҡB inhibitor IҡBα is indicated in bid-/- microglia. These data 
imply that TLR4 signalling is not ablated upon deficiency of Bid, however it is 
attenuated.  
                                                                                                           Chapter IV: Results 
 
 
150 
 
4.3.2 Bid and the IKK complex 
Our laboratory has previously identified decreased levels of phosphorylated 
IKKα and IKKβ in bid - deficient astrocytes in response to 24 h exposure to 
LPS (Konig et al., 2014), indicating decreased astrocytic TLR4 – mediated 
NF-ҡB activation in the absence of Bid. Here, the effect of Bid on IKK 
activation in microglia was assessed. Phosphorylation of IKKα and IKKβ 
subunits was not induced in bid – deficient microglia, compared with wt 
which displayed higher levels of phosphorylated IKKα and IKKβ upon acute 
LPS stimulations, as determined by immunofluorescence analysis and 
Western Blot analysis. Our laboratory has also previously demonstrated that 
Bid associates with NEMO in astrocytes upon LPS stimulation (Konig et al., 
2014). Here the examination of a microglial Bid association with NEMO in a 
TLR4 dependent manner revealed no evidence for an interaction between 
Bid and NEMO in microglia nether in unstimulated cells nor in LPS 
stimulated microglia, following both acute and 24 h stimulations. It is 
proposed that Bid may have a cell specific role in promoting TLR4 - NF-ҡB 
activation, and that NEMO and Bid do not associate in microglia at rest or in 
response to LPS. 
 
4.3.3 Microglial bid – deficiency and E3 ubiquitin ligases 
As there was no observation of a Bid – NEMO interaction in our system, and 
as NEMO polyubiquitination prior to its activation is a key event in NF-ҡB 
activation (Wu et al., 2006), the effects of bid – deficiency on the levels of 
TRAF6 and Peli1 in microglia, which are upstream of NEMO ubiquitination, 
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were examined. The data demonstrates that there are lower levels of TRAF6 
and Peli1 in bid - deficient microglia, which is not observed in motoneurons, 
and as microglia are primarily immunoregulatory in function this further 
highlights a role of Bid in mediating the inflammatory response. Although 
expression of TLRs have been reported on neuronal cells (Lafon et al., 
2006), signalling of neuronal TLRs to NF-ҡB has not been reported (Tang et 
al., 2007), which is in line with the presented data showing little difference 
between TRAF6 and Peli1 levels in wt and bid – deficient motoneurons   
Reduced levels of Peli1 are observed in the absence of Bid upon acute LPS 
stimulation. Peli1 is phosphorylated by IRAK1 leading to Peli1 – mediated 
K63 linked polyubiquitination of IRAK1, which subsequently initiates 
autoubiquitination in a K63 - linked manner (Smith et al., 2009, Butler et al., 
2007). Peli1 is a positive modulator of TLR4 – signalling and facilitates the 
polyubiquitination of not only IRAK1 but also TAK1 and TBK1 (Murphy et al., 
2015). The mechanism by which Peli1 is degraded is not clear to date, 
however from this data we propose that the reduced levels of Peli1 in bid – 
deficient microglia may result from a lack of recruitment of Peli1 to the TLR4 
- NF-ҡB signalling pathway which may result in the lack of Peli1 resynthesis. 
Of note, Peli1 transcription is regulated by TRIF- dependent signalling in 
response to LPS (Weighardt et al., 2004). This is examined further in 
Chapter V.  
Here an interaction between TRAF6 and Bid was identified in unstimulated 
and in LPS stimulated microglia. Taken together these data suggest that the 
absence of microglial Bid diminishes TRAF6 recruitment to, or downstream 
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activation of the TLR4 - NF-ҡB pathway, resulting in an attenuation of signal 
transduction. 
4.3.4. Bid does not modulate MyD88 - independent TLR4 signalling to 
NF-ҡB through RIP1 
TRAF6 is reported to be critical for the MyD88 - dependent pathway, 
however it is dispensable in the MyD88 - independent pathway (Gohda et al., 
2004). Here it is demonstrated that microglial bid – deficiency has no effect 
on RIP1 levels in unstimulated glia, and RIP1 induction is not affected by the 
absence of Bid in response to LPS. As RIP1 is a mediator of the TRIF – 
dependent TLR signalling (Cusson-Hermance et al., 2005), it is suggested 
that Bid does not modulate TRIF – dependent signalling to NF-ҡB by 
mediating RIP1 activation. Bid is proposed to modulate TLR4 – induced NF-
ҡB activation by interacting with TRAF6 and attenuating MyD88 – dependent 
signalling. However, as TRAF6 binds with both TRIF (Sato et al., 2003) and 
TRAM (Verstak et al., 2014), a Bid – dependent modulation of the TLR4 – 
induced TRIF signalling pathway to NF-ҡB may occur through the interaction 
between Bid and TRAF6.  
 
4.3.4 Conclusions 
In this chapter it has been demonstrated that bid - deficiency attenuates 
TLR4 – induced microglial NF-ҡB activation. An interaction between Bid and 
the E3 – ubiquitin ligase TRAF6 was identified and this is proposed to be a 
mechanism by which Bid positively regulates the TLR4 - NF-ҡB signalling 
pathway. 
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Chapter V 
Bid and TRAF6 – mediated Ubiquitination in the 
TLR4 pathway 
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5.1 Introduction 
Ubiquitin is a 76 amino acid cellular protein which can covalently attach to a 
target molecule and form ubiquitin chains, executing the multifunctional post 
translational modification termed ubiquitination,  which leads to alterations in 
the turn - over or function of a target protein (Wertz and Dixit, 2010, Chen 
and Sun, 2009, Ikeda and Dikic, 2008). Ubiquitination is a three step process 
requiring E1, E2 and E3 ubiquitin proteins which facilitate activation, 
conjugation and ligation stages, respectively (Liu and Chen, 2011, Hershko, 
1983). Human genome studies have reported 2 E1 enzymes, 38 E2 
enzymes and over 600 E3 ubiquitin ligases (Zinngrebe et al., 2014, Li et al., 
2008).  Ubiquitin linkage to the target protein is a highly precise process, with 
the specificity of the substrate ensured by the E3 ubiquitin ligases (Deshaies 
and Joazeiro, 2009). Ubiquitin has seven lysine residues, termed K6, K11, 
K27, K29, K33, K48 and K63, each of which can form different linkage types 
leading to different functional outcomes (Zinngrebe et al., 2014). An eighth 
type of ubiquitin linkage can be formed at the methionine residue and leads 
to the formation of M1 or linear ubiquitination (Kirisako et al., 2006). 
Ubiquitination plays a critical role in the orchestration of the innate immune 
response (Zinngrebe et al., 2014). The TLR4 – NF-ҡB signalling pathway is 
tightly regulated by a number of E3 ubiquitin ligases that facilitate the 
polyubiquitination of several critical components mediating TLR4 - induced 
pro-inflammatory signalling (Wertz and Dixit, 2010, Lamothe et al., 2007, 
Schauvliege et al., 2006). E3 ubiquitin ligases are divided into three 
subgroups based on their structure; the really interesting new gene (RING) 
domain family, the  homology to E6 - AP C -  terminus (HECT) domain family 
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and the RING - between - RING (RBR) family (Berndsen and Wolberger, 
2014). Additionally ubiquitination is modulated by a number of de - ubiquitin 
enzymes (DUBs), which negatively regulate the TLR4 – NF-ҡB response 
(Zinngrebe et al., 2014).  DUBs ensure the removal of polyubiquitin chains 
from target proteins and thus terminate signalling, and approximately 80 
DUBs are encoded by the human genome, including A20, CYCLD and 
OTUB1 which cleave K63 –, K63 – plus M1 – , and K48 – linked polyubiquitin 
chains respectively (Edelmann et al., 2009, Komander et al., 2009, Wertz et 
al., 2004).  Importantly, IRAK1, Peli1, TRAF6 and NEMO are all targets for 
K63 – linked polyubiquitination (Conze et al., 2008), with linear ubiquitin 
chains forming on NEMO and RIP1 (Tokunaga and Iwai, 2012, Niu et al., 
2011).  
TRAF6 facilitates TLR4 signalling to NF-ҡB by the formation of K63 - linked 
polyubiquitin chains mediating interactions with IRAK1, Peli1, and NEMO 
(Song and Qian, 2013, Wu et al., 2006). Additionally, TRAF6 interacts with 
TAK1 in a K63 – linked ubiquitin - dependent manner via TAK1 - binding 
protein 2 (TAB2) which forms a complex together with TAK1-binding protein 
1 (TAB1) (Wang et al., 2001, Takaesu et al., 2000). Furthermore, TAB2 
facilitates TRAF6 polyubiquitination of the IKK complex (Kishida et al., 2005).  
Peli1 forms K63 – linked ubiquitin chains on IRAK1, and IRAK1 can 
modulate Peli1 ubiquitin ligase activity through phosphorylation via multiple 
phosphorylation sites identified on Peli1 (Ordureau et al., 2008, Schauvliege 
et al., 2006). 
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The formation of linear ubiquitin linkages is catalysed by the Linear Ubiquitin 
Chain Assembly Complex (LUBAC), which consists of two RBR (RING – 
between – RING) proteins HOIP and HOIL-1 (Iwai and Tokunaga, 2009).   
Different complexes of M1 ubiquitin chains with different protein complexes 
have been identified, such as HOIP and HOIL-1, HOIP and SHARPIN, and a 
tripartite complex HOIP, HOIL-1 and SHARPIN (Gerlach et al., 2011). 
LUBAC activates NF-ҡB signalling and HOIP and HOIL-1 have specific 
domains for NEMO binding (Tokunaga et al., 2009). 
Here the Bid – dependent effects on the E3 ligases Peli1 and TRAF6 in 
facilitating the TLR4 - NF-ҡB signalling cascade are examined. The below 
schematic shows the TRAF6 – and Peli1 – mediated polyubiquitination in 
TLR4 - NF-ҡB signalling (Figure 5.1). 
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Figure 5.1: Schematic of Ubiquitination in MyD88 - dependent and MyD88 - 
independent TLR4 - NF-ҡB is signalling. TLR4 signalling to NF-ҡB is tightly 
regulated by a number of E3 ubiquitin ligase. Peli1 and TRAF6 are essential 
for the polyubiquitination and activation of several components in this 
pathway and ensure downstream signalling to the IKK complex and the 
induction of the pro-inflammatory response, by mediating K63 - linked 
polyubiquitination, as shown above. IҡBα is ubiquitinated, in a K48 – ubiquitin 
dependent manner, upon activation of the IKK complex and it is degraded 
allowing NF-ҡB to translocate to the nucleus (Moynagh, 2014, Liu and Chen, 
2011). RIP1 and NEMO also form linear polyubiquitin chains at a methionine 
residue, also known as M1 ubiquitination (Tokunaga and Iwai, 2012, Gerlach 
et al., 2011).  
 
 
Additionally, impairment of the ubiquitin proteasome system is implicated in 
neurodegenerative disease, with misfolded proteins forming insoluble 
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inclusions together with ubiquitin proteasome subunits (Zheng et al., 2014, 
Ross and Poirier, 2004). In ALS the accumulation of intracellular SOD1G93A 
aggregates leads to modifications in proteasomal function in an attempt to be 
cleared and degraded by the ubiquitin proteasome mediated pathway 
(Tydlacka et al., 2008, Bence et al., 2001). Initial induction of the 
immunoproteasome is suggested to be a protective mechanism however it is 
ineffective in the clearance of intracellular SOD1 aggregates and is believed 
to exacerbate pathogenesis (Puttaparthi and Elliott, 2005). In mutant SOD1 – 
associated ALS, M1 microglia have an increased immunoproteasome and 
increased pro-inflammatory activation, resulting from both intracellular and 
extracellular mutant SOD1 stimulation. As described above, extracellular 
SOD1G93A is a ligand for TLR2 and TLR4 (Zhao et al., 2010), and intracellular 
SOD1G93A aggregates induce the formation of the immunoproteasome, and 
both intracellular and extracellular mutant SOD1 – induced stimulation result 
in an increased pro-inflammatory response and further polarization of 
microglia to the M1 activation state (Henkel et al., 2009). 
In Chapter IV an interaction between Bid and TRAF6 in microglia was 
identified. Here further elucidation of the role of Bid in regulating TRAF6 
polyubiquitination and TRAF6 – mediated signalling to NF-ҡB in response to 
TLR4 stimulation is carried out. Firstly, the autoubiquitination of TRAF6 in the 
presence and absence of Bid is assessed. Secondly, Bid – dependent K63 – 
linked ubiquitination in microglia is explored in the context of LPS stimulation 
and SOD1G93A overexpression in microglia. Finally, it is investigated whether 
Bid – dependent regulation of microglial NF-ҡB activation is mediated 
through the activation of the IRAK complex. 
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5.2 Results 
5.2.1 Bid promotes the polyubiquitination of TRAF6 
TRAF6 polyubiquitination is critical for the activation of the IKK complex 
(Deng et al., 2000). As TRAF6 was identified to associate with Bid the next 
experiments focus on the Bid – dependent modulation of TRAF6 ubiquitin 
ligase activity. Investigation of the effects of Bid on TRAF6 polyubiquitination 
was carried out by overexpressing Bid - dsRed and Ubiquitin - HA in wt and 
bid - deficient mixed glial cells, and subsequent immunoprecipitation of 
TRAF6.  
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Figure 5.2: Bid promotes TRAF6 polyubiquitination. (A) TRAF6 was 
immunoprecipitated and TRAF6 polyubiquitination was assessed in wt mixed 
glia overexpressing Bid – dsRed and Ubiquitin – HA (HA-Ub), wt glia 
overexpressing Ubiquitin – HA plus dsRed, and wt glia overexpressing Bid – 
dsRed plus dsRed. bid-/- glia were transfected with Ubiquitin – HA and 
dsRed. A non-transfected bid-/- mixed glia control was also assessed. 
Immunoprecipitation of IgG was used as an immunoprecipitation control. (B) 
The immunoprecipitation supernatant was concentrated in a 10 K size 
exclusion column by centrifugation for 40 minutes at 4 ° C, and prepared for 
Western Blot analysis. The supernatant samples were probed for TRAF6 in 
order to determine the immunoprecipitation of TRAF6 from the supernatant. 
(C) Repeat of TRAF6 immunoprecipitation in mixed glial cells showing wt glia 
overexpressing Bid – dsRed plus Ubiquitin – HA, and bid - deficient mixed 
glia overexpressing dsRed empty vector plus Ubiquitin – HA. Mixed glia were 
transfected for 24 h before being lysed in RIPA buffer and prepared for 
immunoprecipitation. Single plasmid transfections were carried out with 
equal concentration of dsRed empty vector as an additional control. The cells 
were transfected with a total plasmid concentration of 1.5 µg / 3 x 105 cells 
using lipofectamine, at a ratio of 1:1 of each plasmid.  
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Figure 5.2 demonstrates that overexpression of Bid plus Ubiquitin - HA 
induced more TRAF6 autoubiquitination than either wt or bid - deficient glia 
overexpressing Ubiquitin – HA alone. Additionally, figure 5.2A shows that wt 
glia had more TRAF6 autoubiquitination than bid - deficient glia. These 
results provide evidence for a positive role of Bid in promoting TRAF6 
polyubiquitination. 
Next, the type of TRAF6 polyubiquitination that Bid is promoting was 
examined. K63 - linked polyubiquitin chains were first reported from the 
examination of TRAF6 mediated activation of the IKK complex (Deng et al., 
2000), and are not targets of the proteasome (Chen et al., 2006b, Laine and 
Ronai, 2005). Deng and co – workers identified that inhibition of polyubiquitin 
chain synthesis, and not proteasomal inhibition, attenuated IKK activation 
facilitated by TRAF6, highlighting a non - degradative role of these 
polyubiquitin chains (Deng et al., 2000). Additionally, TRAF6 K63 – linked 
autoubiquitination is reported to be critical for the formation of downstream 
TRAF6 – mediated polyubiquitination and IKK activation (Lamothe et al., 
2007). Here, using mixed glial cells as above, Bid - dsRed and Ubiquitin – 
HA were overexpressed and glia were subsequently stimulated with LPS for 
1 h. TRAF6 was immunoprecipitated from the samples and subsequent 
detection of K63 – linked ubiquitination was assessed using a anti - K63 
ubiquitin chain specific antibody.  
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Figure 5.3: Bid promotes K63 – linked polyubiquitination of TRAF6. wt mixed 
glia were transfected with Bid – dsRed plus dsRed or Bid - dsRed plus 
Ubiquitin – HA, and bid - deficient mixed glia were transfected with dsRed 
plus Ubiquitin – HA. One of each genotype overexpressing Ubiquitin – HA 
plus Bid - dsRed were stimulated with LPS (100 ng / ml)  for 1 h in serum 
free media, with unstimulated cells also exposed to serum free media. The 
cells were lysed in RIPA buffer 16 h post transfection and prepared for 
immunoprecipitation. The cells were transfected with a total plasmid 
concentration of 1.5 µg / 3 x 105 cells using lipofectamine, at a ratio of 1:1 of 
each plasmid. The empty dsRed vector was used as a transfection control 
for the dsRed tag on Bid. Experiment repeated once with similar results.  
 
 
As shown in Figure 5.3, overexpression of Bid promotes K63 – linked 
autoubiquitination of TRAF6. As linear ubiquitin chains have been shown to 
regulate immune signalling, and specifically the regulation of NF-ҡB 
activation (Tokunaga and Iwai, 2012), subsequent analysis was carried out 
examining  whether TRAF6 autoubiquitination is mediated by M1 – linked 
chains, and if so, whether Bid promotes this process.   
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Figure 5.4: Bid does not affect TRAF6 Linear Ubiquitination in microglia. wt 
and bid-/- deficient mixed glia were transfected with Bid – dsRed and 
Ubiquitin – HA for 16 h prior to stimulation with LPS  (100 ng / ml) for 1 h in 
serum free media. Last lane on the right cut off in transfer stage due to 
technical error. The cells were lysed in RIPA buffer and prepared for 
immunoprecipitation of TRAF6. The samples were analysed by Western Blot 
which was exposed to anti - LUB9 Linear antibody that detects M1- linked 
polyubiquitin chains specifically. The cells were transfected with a total 
plasmid concentration of 1.5 µg / 3 x 105 cells using lipofectamine, at a ratio 
of 1:1 of each plasmid. Experiment repeated once with similar results. 
 
Although the formation of M1 – linked chains on NEMO and RIP1 are critical 
for NF-ҡB activation, our results in Figure 5.4 are in line with previous studies 
which show that TRAF6 does not form linear ubiquitin chains (Gerlach et al., 
2011).  
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As full – length Bid is cleaved to form tBid, which leads to the initiation of 
apoptosis (Li et al., 1998), investigation of whether overexpression of Bid is 
inducing apoptosis in our model was carried out. 
 
 
 
Figure 5.5: Overexpression of Bid does not induce Bid cleavage. (A & B) Bid 
levels were assessed in Bid - dsRed overexpressing BV-2 cells (n = 3 
cultures from 2 separate platings). (A & C) tBid levels were measured in BV-
2 cells overexpressing Bid (n = 3 cultures from 3 separate platings).  BV-2 
cells were transfected with a range of concentrations of Bid – dsRed from 
0.25 µg to 1 µg / 3 X 105 cells using lipofectamine. The cells were lysed after 
16 h in RIPA buffer and prepared for Western Blot analysis. 
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In Chapter III (Figure 4.7) it was demonstrated that Bid cleavage is not 
induced by LPS stimulation in microglia. Here (Figure 5.5) it is demonstrated 
that tBid levels are not increased upon increasing Bid expression levels, and 
therefore Bid is not cleaved in BV-2 cells by the overexpression of Bid at any 
of the concentrations assessed.  
As previous experiments in this Chapter confirmed Bid as a positive regulator 
of TRAF6 K63 - linked autoubiquitination, a process which is critical for 
subsequent TRAF6 – mediated NF-ҡB activation (Deng et al., 2000), 
assessment of the effect of the absence of Bid on total K63 – linked 
microglial ubiquitination was carried out. Primary wt and bid - deficient 
microglia were stimulated with LPS and subsequently examined by Western 
Blotting for the total levels of K63 – linked polyubiquitin chains or Linear 
polyubiquitin chains.  
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Figure 5.6: K63 - linked and Linear ubiquitination levels in wt and bid – 
deficient microglia upon LPS stimulation. (A) K63 – linked ubiquitin chains in 
wt and bid-/- microglia at rest and upon 30 minute and 1 h LPS stimulations 
(repeated once with similar results). (B) Linear ubiquitin chains in wt and bid-/- 
microglia at rest and upon 30 minute and 1 h LPS stimulation (repeated once 
with similar results). Primary microglia were stimulated with LPS (100 ng / 
ml) in serum free media and lysed in RIPA buffer at the appropriate 
timepoint. The de-ubiquitin enzyme inhibitor PR-619 (50 µM) was added to 
the RIPA buffer in order to retain the integrity of the polyubiquitin chains upon 
lysis.   
 
 
In Figure 5.6 above, reduced levels of K63 – linked polyubiquitin chains are 
observed in LPS - stimulated bid - deficient microglia compared with wt. This 
may suggest reduced positive feedback of the TLR4 signalling pathway in 
bid - deficient microglia, thus leading to reduced K63 – linked 
polyubiquitination. Interestingly, there was no effect of bid – deficiency on 
microglial linear ubiquitin chain formation upon LPS stimulation, consistent 
with the role of Bid in promoting TRAF6 K63 - linked polyubiquitination. 
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In addition to LPS stimulation, further examination of the effect of bid – 
deficiency on the formation of K63 – linked polyubiquitin chains in SOD1G93A 
overexpressing microglia was performed.    
 
 
Figure 5.7: Lower levels of K63 – linked polyubiquitin chains in SOD1G93A 
overexpressing bid-/- microglia compared with wt.  (A & B) Western Blot 
analysis of K63 – linked ubiquitination levels in wt and bid-/- microglia 
overexpressing SOD1G93A (n = 2 cultures from 2 separate platings). wt and 
bid – deficient microglia were transfected with CFP or SOD1G93A (1.5 µg DNA 
/ 3 x 105 cells) for 24 h before being lysed in RIPA buffer and prepared for 
western Blot analysis. 
 
Lower levels of K63 – linked polyubiquitin chains were observed in bid – 
deficient SOD1G93A overexpressing microglia, compared with wt, as 
demonstrated in Figure 5.7 above.  Focusing on SOD1G93A as a TLR4 ligand, 
the evidence suggests that Bid promotes K63 – linked ubiquitination in 
SOD1G93A overexpressing microglia. Of interest, SOD1G93A aggregates are 
associated with K63 – linked polyubiquitin chains (Tan et al., 2008), which is 
investigated further in this chapter.  
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5.2.2 Does Bid – dependent TRAF6 polyubiquitination modulate IRAK 
activation?  
TRAF6 interacts with and promotes K63 – linked polyubiquitin chains on 
IRAK1 at the C - terminal domain, inducing subsequent activation of the IKK 
complex (Conze et al., 2008, Cooke et al., 2001). In addition, TRAF6 
interacts with IRAK and Peli1 to form a complex that becomes dissociated 
from MyD88 and the TLR4 receptor, translocating to the cytoplasm where 
further downstream signalling occurs (Tseng et al., 2010, Jiang et al., 
2003a).  TRAF6 subsequently interacts with TAK1 and IKK directly forming 
K63 - linked polyubiquitin chains with each kinase complex (Adhikari et al., 
2007, Chen et al., 2006a). This section focuses on the involvement of Bid in 
the activation of IRAK and also the TRAF6 – Peli1 – IRAK complex, as a 
mechanism for attenuation of TLR4 – mediated pro-inflammatory signalling.  
IRAK – induced phosphorylation of Peli1 increases Peli1 ubiquitin ligase 
activity, including its autoubiquitination, and K63 – linked polyubiquitination of 
IRAK1 (Smith et al., 2009, Ordureau et al., 2008). Additionally Peli1 is critical 
for mediating TRAF6 downstream signalling to MAPK activation (Xiao et al., 
2013). To investigate the specific Bid – dependent modulation of Peli1, 
experiments were carried out in wt and bid – deficient microglia employing an 
siRNA targeting Peli1. 
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Figure 5.8: TLR4 activation, as assessed by IҡBα degradation, in wt and bid - 
deficient microglia transfected with an siRNA targeting Peli1. (A & B) IҡBα 
levels in wt and bid – deficient microglia transfected with siPeli1 (n = 3 
cultures pooled from 2 separate platings). wt and bid-/- microglia were 
transfected with siPeli1 (100 µM / 3 X 105 cells) for 24 h prior to treatment 
with LPS for 1 h (100 ng / ml) in serum free media. (C) Peli1 mRNA levels 
following transfection with two siRNAs targeting Peli1. siPeli1 ‘A’ was used 
for these experiments, and transfection took place 24 h before stimulation 
with LPS for optimal Peli1 knockdown (n = 3 - 4 cultures pooled from 2 
separate experiments).  
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Figure 5.8 demonstrated that IҡBα degradation was not attenuated from 
silencing Peli1 in wt or bid – deficient microglia upon LPS stimulation. This 
may be explained by a potential compensatory activity when Peli1 is 
deficient, possibly from other members of the Pellino family as they share a 
strong structural sequence homology (Moynagh, 2009, Schauvliege et al., 
2007). Additionally a study demonstrated that Peli1 is dispensable for MyD88 
– dependent TLR4 – induced NF-ҡB activation (Chang et al., 2009), however 
Peli1 is indispensable for TLR4 induced TAK1 and MAPK activation (Xiao et 
al., 2013). These data suggest that the reduced TLR4 – induced 
inflammation observed in bid – deficient microglia may also attributed to the 
reduced activation of TAK1 and  MAPK, rather than targeting NF-ҡB 
activation alone. However, it can also be proposed that the Peli1 knockdown 
is not optimal to perturb the functioning of Peli1 in this pathway. 
As an expendable role of Peli1 is proposed for MyD88 – dependent NF- ҡB 
activation the previous data using siPeli1 does not clarify whether bid – 
deficiency modulates Peli1 ubiquitin ligase activity.  From here the role of Bid 
in regulating Peli1 – induced IRAK1 activation in response to LPS was 
assessed. A schematic representing the possible role of Bid in the TRAF6 – 
IRAK1 – Peli1 complex is outlined in Figure 5.9 below. 
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Figure 5.9: Schematic representing the structure of IRAK1 and the proposed 
association of Bid with the TRAF6 – Peli1 – IRAK complex. (A) Domain 
structure of IRAK1. IRAK1 contains a Death Domain (DD), a ProST domain, 
a kinase domain, and a C – terminal domain for interactions with TRAF6. 
The IRAK1 DD facilitates the IRAK1 – MyD88 interaction, and IRAK1 is 
phosphorylated by IRAK4 upon TLR4 activation at the kinase domain. (B) 
Schematic showing the proposed association of Bid with the TRAF6 – Peli1 
– IRAK1 complex. The role of Bid in positively regulating the TLR4 – induced 
pro-inflammatory signalling to NF-ҡB may occur via association with the 
TRAF6 – IRAK – Peli1 complex, mediated through the Bid – dependent 
modulation of TRAF6 K63 – linked polyubiquitination. 
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Previous data in Chapter VI (Figure 4.13) demonstrates that bid – deficiency 
results in reduced levels of microglial Peli1 in response to LPS, suggesting 
that the Bid – dependent modulation of TLR4 – induced signalling may be 
due to reduced Peli1 – mediated activation of the IRAK complex. To further 
examine this proposal the effects of bid – deficiency on the Peli1 – mediated 
activation of IRAK1 were assessed. Firstly, microglial Peli1 turnover was 
investigated. 
 
 
Figure 5.10: Peli1 is rapidly turned over in microglia. (A & B) Peli1 levels in 
BV-2 cells treated with Bortezomib (100 µM), which inhibits proteasomal 
degradation, for 1 h, 2 h or 6 h (n = 4 wells from 2 separate experiments). (C 
& D) Peli1 levels in BV-2 cells treated with Cycloheximide (CHX, 1 µg / ml) 
which blocks protein translation, for 1 h, 2 h or 6 h ( n = 3 wells from 2 
separate experiments). BV-2 cells were treated with Bortezomib or CHX in 
full serum media before being lysed in RIPA buffer for Western Blot analysis. 
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The data in Figure 5.10 demonstrates that microglial Peli1 is rapidly 
degraded, via the proteasome, and rapidly resynthesized in microglia, as 
represented by the accumulation of Peli1 upon proteasome inhibition (1 h 
post Bortezomib treatment 2.8 ± 1.3 fold increase), and reduced Peli1 
translation upon 1 h treatment with Cycloheximide. This suggests that 
microglial Peli1 has a high turnover, which may in part explain the 
degradation of Peli1 observed upon acute LPS stimulation in bid – deficient 
microglia (Figure 4.13), alluding to a Bid – dependent effect on the 
stabilisation of Peli1 levels in response to TLR4 activation.  
Activation of Peli1 by IRAK – induced phosphorylation leads to the Peli1 – 
mediated K63 – linked polyubiquitination of IRAK1 (Smith et al., 2009). 
Additionally, IRAK1 levels are reduced in response to LPS stimulation 
(Ordureau et al., 2008, Hu et al., 2002). Here firstly, IRAK1 levels were 
assessed at 1 hour post LPS stimulation in wt and bid – deficient microglia.  
Although it has been shown that IRAK1 is degraded via the proteasome in 
response to IL-1β – induced activation (Yamin and Miller, 1997), more recent 
studies demonstrated that inhibition of the proteasome did not affect the 
reduction in IRAK1 levels upon MyD88 signalling (Windheim et al., 2008, 
Ordureau et al., 2008).  To investigate the effects of bid – deficiency on Peli1 
– mediated regulation of IRAK1 levels, wt and bid-/- microglia were treated 
with the proteasome inhibitor Bortezomib, and subsequently stimulated with 
LPS. This experiment attempted to elucidate the effects of Bid on the Peli1 – 
mediated activation of IRAK1 in response to LPS. 
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Figure 5.11: IRAK levels are similarly reduced in wt and bid – deficient 
microglia upon LPS stimulation, even when the proteasome is inhibited. (A & 
B) IRAK1 levels in wt and bid – deficient microglia 1 h post LPS stimulation. 
(n = 4 wells from 2 separate experiments). (C & D) wt and bid-/- microglia 
were treated with Bortezomib (100 µM) for 2 h prior to stimulation with LPS 
(100 ng / ml) in serum free media. (n = 4 wells from 2 separate 
experiments).The cells were lysed in RIPA buffer and prepared for Western 
Blot analysis.  
 
There was no Bid – dependent effect on IRAK1 levels observed upon LPS 
stimulation, with or without proteasomal inhibition, as shown in Figure 5.11. 
As previously shown Peli1 highly accumulates at 2 h post proteasomal 
inhibition suggesting that the increased levels of Peli1 did not modulate 
IRAK1 levels in a Bid – dependent manner (figure 5.10). However, 
interestingly Windheim and co-workers report that proteasomal inhibition has 
a redundant effect on the polyubiquitination of IRAK (Windheim et al., 2008). 
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It can be proposed that elevated Peli1 levels do not affect the reduction of 
IRAK1 levels upon LPS stimulation in bid-/- microglia. These data suggest 
that the activation of IRAK1 is unchanged when Bid is absent and is 
unaffected by Peli1 levels. Interestingly, it may be proposed that IRAK1 is 
degraded by an alternative mechanism than the proteasome upon TLR4 
activation; however reduced IRAK1 levels may reflect the formation of K63 – 
linked polyubiquitinated IRAK1, a modification which may not be detected by 
this antibody. 
 
5.2.3. Bid – dependent regulation of Peli1  
As demonstrated above Peli1 is rapidly degraded and resynthesized in 
microglia. Lack of induction of Peli1 and TLR4 – induced depletion of Peli1 
levels upon acute LPS stimulation in bid – deficient microglia suggest a Bid – 
dependent regulation of Peli1 degradation or transcription.   
Peli1 is phosphorylated, ubiquitinated and sumoylated (Moynagh, 2014, 
Butler et al., 2007), and although Peli1 is degraded via the proteasome it is 
unclear to date what targets Peli1 for degradation. Peli1 transcription is 
induced by IRF3 activation (Smith et al., 2011). IRF3 is activated by TLR4 – 
induced TRIF – dependent pathway signalling (Yamamoto et al., 2003a). 
TRIF recruits TRAF3 and activates the TBK1 (TANK binding kinase 1) – IKKε 
(IҡB kinase ε) complex which subsequently activates IRF3 (Hacker and 
Karin, 2006, Fitzgerald et al., 2003a). IRF3 activation induces the 
transcription of  type 1 Interferons and also the transcription of Peli1 (Smith 
et al., 2011).   
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Although TRIF – dependent NF-ҡB and MAPK activation is induced via RIP1 
and TRAF6, RIP1 is not implicated in the activation of IRF3 (Ofengeim and 
Yuan, 2013, Cusson-Hermance et al., 2005). Studies show that TRAF6 does 
not directly activate IRF3 (Jiang et al., 2004). However, TAK1 – mediated 
JNK activation is proposed to induce IRF3 activation by phosphorylation, 
thus suggesting that crosstalk between the MyD88 – independent and  
dependent pathways with respect to IRF3 activation is mediated via MAPK 
activation (Zhang et al., 2009). This may provide a potential role for TRAF6 
in modulating IRF3 activation via the MyD88 – dependent pathway, as 
TRAF6 induces TAK1 and MAPK activation. Figure 5.12 shows an overview 
of the potential role of Bid in the regulation of Peli1 transcription by IRF3 
activation in the MyD88 – independent pathway. 
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Figure 5.12: Potential role of Bid in the regulation of Peli1 transcription by 
IRF3 activation in the MyD88 – independent pathway.Peli1 transcription is 
mediated by IRF3 activation, which is regulated via the TRIF dependent 
pathway. TLR4 activation induces TRIF - dependent activation of IRF3 via 
interactions with TRAF3 and the TBK1/IKKε complex (Smith et al., 2011, 
Hacker and Karin, 2006). Reduced IRF3 activation in the absence of Bid may 
lead to the reduction in Peli1 transcription. TRAF6 facilitates TAK1 activation, 
and TAK1 and JNK are shown to activate IRF3 (Zhang et al., 2009), thus 
providing a potential role of Bid in attenuating IRF3 activation and therefore 
modulating Peli1 transcription (shown by grey line). 
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To investigate the Bid – dependent effects on Peli1 levels upon prolonged 
stimulation with LPS, wt and bid – deficient microglia were exposed to LPS 
or LPS plus IFNγ for 4 h and Peli1 levels were subsequently assessed. 
 
 
 
Figure 5.13: Peli1 levels are reduced upon LPS stimulation but induced upon 
dual stimulation of LPS plus IFNγ.  (A & B) Peli1 levels in wt and bid – 
deficient microglia stimulated with LPS (100 ng / ml) or LPS plus IFNγ (500 U 
/ ml) in serum free media (n = 3 cultures from 3 separate platings). Cells 
were lysed in RIPA buffer and prepared for Western Blot analysis. 
 
Figure 5.13 demonstrates that Peli1 levels are downregulated in LPS 
stimulated bid – deficient microglia. However this effect is rescued by the 
dual stimulation of LPS plus IFNγ. IFNγ signals through the Jak / Stat 
pathway (Sakatsume et al., 1995), and this may suggest a TLR4 - pathway 
specificity of Bid – mediated attenuation of the pro-inflammatory response. 
Additionally, increased levels of Peli1 in IFNγ plus LPS co – treated bid-/- 
microglia point to IRF3 activation pathways that are independent of Bid. This 
may be accounted for by the cross - talk between the Jak / Stat and TLR4 – 
induced signalling pathways. It has been long established that IFNγ 
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synergizes the effects of TLR ligands to create a more robust inflammatory 
response (Adams and Hamilton, 1984). Additionally, IFNγ is reported to 
inhibit negative feedback to TLR signalling loops (Hu et al., 2008). This 
suggests that the dual stimulation with LPS and IFNγ may result in an 
orchestrated insult that signals to IRF3 without the regulation of Bid.  
 
5.2.4 Does Bid – mediated TRAF6 polyubiquitination contribute to 
cytosolic mutant  SOD1G93A  aggregates? 
 
The Ubiquitin Proteasome System (UPS) is a regulatory machinery for 
protein turnover in the cell (Pickart, 2001), and a strict regulation of the 
balance between protein synthesis and degradation is essential for cellular 
homeostasis (Gaczynska et al., 2001). The UPS is composed of the 
ubiquitination system, which labels proteins for degradation, and the 
proteasome, which carries out protein degradation (Jansen et al., 2014).  
Components of the UPS co - localize with misfolded proteins in 
neurodegenerative disease, and impairment of the UPS leads to increased 
levels of neuronal misfolded protein aggregates (Jansen et al., 2014, Cheroni 
et al., 2005, Mori et al., 1987). Interestingly, examination of the UPS in 
neurons and glia overexpressing misfolded proteins identified lower UPS 
activity in neurons compared with glia, which is proposed to account for the 
higher levels of protein aggregates in neurons (Jansen et al., 2014, Tydlacka 
et al., 2008). The increased glial reactivity seen in neuroinflammation, termed 
reactive gliosis, induces the formation of the immunoproteasome (Jansen et 
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al., 2014). In addition, a decrease in the constitutive proteasome and 
increase in the immunoproteasome correlates with the inflammatory 
response mediated by glial cells in neurodegenerative disease (Mendonca et 
al., 2006, Cheroni et al., 2005).  Intracellular aggregation of mutant SOD1 in 
microglia has been shown to contribute to ALS disease progression (Henkel 
et al., 2009, Puttaparthi and Elliott, 2005). Both K48 – linked and K63 – 
linked ubiquitin chains are associated with SOD1G93A aggregates (Tan et al., 
2008). 
In ALS ubiquitin co - localizes with mutant SOD1 aggregates (Stieber et al., 
2000), and reduced proteasomal activity contributes to the lack of clearance 
of SOD1G93A (Hoffman et al., 1996). Here co – immunoprecipitation 
experiments determined the association of K63 – linked ubiquitin chains on 
mutant SOD1 aggregates in presymptomatic (day 50) and symptomatic (day 
90) SOD1G93A transgenic mouse cortices.  
Interestingly, TRAF6 has been found to co-localize with α-synuclein 
aggregates in Parkinson’s disease and to regulate inclusion formation by an 
atypical form of ubiquitination (Zucchelli et al., 2010).  In order to determine 
whether TRAF6 associates with mutant SOD1 aggregates in microglia, co - 
immunoprecipitation of SOD1G93A and TRAF6 was carried out. It was also 
investigated whether Bid interacts with SOD1G93A aggregates, in an attempt 
to elucidate whether the Bid – TRAF6 interaction and Bid – dependent 
modulation of TRAF6 – mediated K63 – linked polyubiquitination would 
impact on mutant SOD1 protein aggregation. 
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Figure 5.14: K63 – linked ubiquitination of SOD1G93A is evident in SOD1G93A 
mouse cortices, and neither Bid nor TRAF6 associate with SOD1G93A.  (A) 
K63 – linked ubiquitination of SOD1G93A was detected by co – 
immunoprecipitation of hSOD1 in mouse cortices and exposure to anti - K63 
specific antibody. The cortices were harvested at days 50 and 90, which 
represent the presymptomatic and symptomatic stages in this ALS mouse 
model. (B) Primary wt and bid - deficient glia overexpressing SOD1G93A were 
immunoprecipitated with anti - GFP, as SOD1G93A fusion protein contains 
CFP which is detected by anti – GFP. The samples were analysed by 
Western Blot and probed for Bid. (C) wt and bid - deficient glia 
overexpressing SOD1G93A were co-immunoprecipitated with anti – GFP, and 
the samples were analysed by Western Blot for TRAF6.  The glial cells were 
transfected for 24 h before being lysed in RIPA buffer.  
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The data in Figure 5.14 shows that K63 – linked ubiquitination of SOD1G93A 
occurs in the cortex of the SOD1G93A mouse model. Additionally, more K63 – 
linked ubiquitination occurs in the presymptomatic cortex compared with the 
symptomatic, which may be explained by the elevated ubiquitin activity early 
in disease progression as a protective mechanism (Puttaparthi and Elliott, 
2005). However, this data does not indicate that either TRAF6 or Bid 
associate with SOD1G93A aggregates in SOD1G93A overexpressing microglia. 
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5.3 Discussion 
Here it is demonstrated that Bid promotes the K63 – linked polyubiquitination 
of TRAF6.  Additionally lower levels of total K63 – linked ubiquitin chains are 
observed in bid - deficient microglia, compared with wt, in response to acute 
TLR4 activation. However, Peli1 – mediated activation of IRAK1 is 
unaffected by the absence of Bid. Finally, neither Bid nor TRAF6 co -
immunoprecipitated with SOD1G93A in microglia, suggesting that the Bid – 
TRAF6 interaction may not be relevant with regard to aggregated protein 
dysregulation of the UPS. 
 
5.3.1 Bid promotes K63 – polyubiquitination of TRAF6 
Our experiments show that Bid promotes TRAF6 K63 – linked 
polyubiquitination. The requirement of TRAF6 autoubiquitination in order for 
its downstream - mediated activation has been debated, however studies 
have demonstrated that TRAF6 autoubiquitination is essential for TRAF6 – 
mediated ubiquitination of NEMO (Lamothe et al., 2008). Conversely, a study 
by Wash and colleagues identified TRAF6 – mediated activation of NF-ҡB 
that was TRAF6 autoubiquitination – independent (Walsh et al., 2008). 
However, the presented data demonstrates Bid – dependent 
autoubiquitination of TRAF6 in microglia. Immunoprecipitation experiments 
exploited mixed cultures of astrocytes and microglia as a large number of 
cells were required for protein precipitation, which proved difficult and 
cumbersome to obtain from microglial cultures alone. However the mixed 
population is taken into account, and although we have examined the Bid 
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and TRAF6 interaction in microglia, it is possible that a similar association is 
seen in astrocytes.  
Total levels of K63 – linked polyubiquitination are reduced in bid – deficient 
microglia compared with wt upon acute LPS stimulation, which may be 
attributed to the attenuation of TRAF6 – mediated ubiquitination of 
downstream targets when Bid is absent. NEMO, RIP1, RIP2 and IRAK1 have 
been identified as substrates for linear ubiquitination (Emmerich et al., 2013, 
Fiil et al., 2013, Gerlach et al., 2011). However, TRAF6 is not shown to 
generate or accept linear ubiquitin chains (Gerlach et al., 2011), and the 
similar levels of linear ubiquitin chains in wt and bid – deficient microglia 
stimulated with LPS is in line with our proposal of the Bid – mediated effects 
on TRAF6 K63 – linked polyubiquitination. 
Importantly Bid cleavage was not detected in Bid overexpressing microglia; 
implying apoptosis is not induced in our model, which negates Bid 
involvement in apoptotic pathways in response to LPS in our model.  
 
5.3.2 LPS – induced IRAK1 activation is not affected in a Bid – 
dependent manner  
Inhibition of the formation of the TRAF6 – Peli1 – IRAK complex was shown 
to prevent the degradation of IҡBα, thus inhibiting NF-ҡB activation (Choi et 
al., 2006). Here it was demonstrated that the Bid – dependent modulation of 
TRAF6 ubiquitin ligase activity does not regulate the Peli1 – mediated 
activation of IRAK1 in response to LPS. IRAK bridges the TIR domain to 
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downstream signalling and NF-ҡB activation, relaying signals between 
MyD88 and TRAF6 (Suzuki et al., 2002). Complete activation of Peli1 is 
associated with IRAK1 – induced autoubiquitination of Peli1 (Smith et al., 
2009), and Peli1 drives the K63 – linked polyubiquitination of IRAK1 (Murphy 
et al., 2015).  
IRAK1 is degraded following its activation within minutes following LPS 
stimulation, and TLR – mediated IRAK1 degradation is not facilitated by the 
proteasome (Windheim et al., 2008). Activation of the IRAK complex was 
shown to be dependent on both MyD88 and TRAF6 (Kawai et al., 2001). 
Examination of the Bid – dependent modulation of LPS – induced IRAK1 
activation was carried out by assessing IRAK1 levels and there was no 
difference in IRAK1 degradation between wt and bid – deficient microglia 
upon LPS stimulation observed, suggesting that Bid – mediated TRAF6 
polyubiquitination does not mediate Peli1 – induced IRAK1 polyubiquitination 
and activation in response to LPS stimulation.  
Peli1 K63 – linked polyubiquitination of cellular Inhibitor of Apoptosis (cIAP2) 
induces the degradation of TRAF3 via cIAP2 – mediated K48 ubiquitination 
of TRAF3 (Xiao et al., 2013). The cIAP2 – induced degradation of TRAF3 is 
critical for the disassociation of the TRAF6 - Peli1 - IRAK complex from the 
MyD88 membrane complex and subsequent translocation to the cytosol 
(Tseng et al., 2010). The absence of Bid may exert its reduced pro-  
inflammatory effects by preventing cIAP2 – mediated TRAF3 degradation 
and the subsequent dissociation of TRAF6 – Peli1 – IRAK complex from the 
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membrane, resulting in an attenuation of downstream signalling to IKK and 
MAPK via TAK1 (Tseng et al., 2010).  
Furthermore, Bid may modulate Peli1 transcription via the TRAF6 mediated 
activation of TAK1 and JNK which have been shown to activate IRF3 (Zhang 
et al., 2009), leading to Peli1 transcription. Additionally Peli1 – mediated K63 
linked polyubquitination of TBK1 is induced upon LPS stimulation (Murphy et 
al., 2015),  and the TBK1/IKKε can phosphorylate Peli1 (Smith et al., 2011). 
The reduced levels of Peli1 in bid – deficient microglia upon LPS stimulation 
may lead to a reduced abundance of Peli1 available to mediate TRAF6 – 
induced polyubiquitination and subsequent TRAF3 degradation, inducing 
TRAF6 – Peli1 - IRAK complex cytosolic translocation, and this may be one 
way in which bid – deficient microglia attenuate TLR4 – induced pro-
inflammatory signalling to NF-ҡB.  
 
5.3.3 Bid – TRAF6 interaction does not associate with SOD1G93A 
aggregates 
The formation of K63 – linked polyubiquitin chains co – localize with 
misfolded protein aggregates in neurodegenerative disease. Here it is shown 
that SOD1G93A aggregates associate with K63 - linked ubiquitin in 
presymptomatic and symptomatic SOD1G93A mouse cortices. Although 
TRAF6 is shown to associate with intracellular aggregated proteins we show 
no evidence for this with regard to microglial SOD1G93A overexpression in 
vitro. Additionally there was no association between Bid and SOD1G93A in 
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microglia. However, it is important to note that at the timepoint of 24 h mutant 
SOD1 aggregates may not have formed. 
 
5.2.4 Conclusions 
We conclude that Bid promotes the K63 – linked polyubiquitination of 
TRAF6, and that depletion in TRAF6 ubiquitination may account for the 
reduced downstream signalling to NF-ҡB in bid – deficient microglia. 
However, it was demonstrated that the Bid – dependent regulation of TRAF6 
does not affect IRAK1 activation in LPS – stimulated microglia. Finally Bid 
may also function in the stabilization of Peli1 transcription thus regulating NF-
ҡB activation, via TRAF6 interaction with TAK1 and JNK, which are shown to 
activate IRF3.  
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6. Discussion  
In this study Bid is identified to be a positive regulator of microglial TLR4 – 
NF-ҡB activation. bid – deficiency leads to an attenuation of the SOD1G93A – 
mediated microglial activation and specifically TLR2 and TLR4 - induced NF-
ҡB activation. Bid is demonstrated to associate with TRAF6 in unstimulated 
and LPS – stimulated microglia. Furthermore, Bid promotes the K63 – linked 
polyubiquitination of TRAF6 in microglia, activation of which is critical in LPS 
– induced MyD88 – dependent NF-ҡB activation. Bid is a novel potential 
therapeutic target for neuroinflammatory pathogenic conditions including ALS 
and other neurodegenerative diseases. The following schematic represent 
the proposed role of Bid in SOD1G93A – induced microglial M1 activation via 
TLR4 – NF-ҡB activation (Figure 6.1). 
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Figure 6.1: Schematic representing extracellular and intracellular toxicity of 
SOD1G93A aggregates in microglia, and the role of Bid in SOD1G93A – induced 
toxicity. Microglia are polarized towards an M1 pro-inflammatory activation 
state in response to both extracellular stimulation of TLR2 and TLR4 with 
SOD1G93A aggregates or intracellular SOD1G93A accumulation. Intracellular 
SOD1G93A accumulation leads to increased ubiquitination and a conversion 
of the constitutive proteasome to the immunoproteasome, contributing to 
ALS disease progression (reviewed in (Henkel et al., 2009)). Extracellular 
mutant SOD1 binds to TLR2 and TLR4 and activation pro- inflammatory 
signalling and NF-ҡB activation. This study identified Bid as a positive 
regulator of TLR4 – induced NF-ҡB activation by promoting TRAF6 K63 - 
linked polyubiquitination in microglia. 
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6.1 TLR2 and TLR4 facilitate SOD1G93A – induced microglial activation 
Microglial activation occurs early in the development of inflammatory 
disorders of the CNS (Heneka et al., 2014, Hall et al., 1998), and is mediated 
by TLR signalling (Olson and Miller, 2004, Nguyen et al., 2002). Microglial – 
mediated neurotoxicity is progressive, which can account for the persistent 
and relentless nature of neurodegenerative disease pathology (Huh et al., 
2003, McGeer et al., 2003). Importantly microglial – mediated inflammation 
not only perturbs neuronal integrity (Trapp et al., 1998, Gentleman et al., 
1993, Chao et al., 1992), but can also lead to detrimental feedback by 
restricting neurotrophic factors to glia (Nagatsu and Sawada, 2005, Boillee et 
al., 2006b). A plethora of evidence exists linking the overexpression of 
mutant SOD1 in glial cells and motoneuron degeneration in the pathogenesis 
of ALS (Dirren et al., 2015, Zhao et al., 2010, Gruzman et al., 2007, Beers et 
al., 2006, Turner et al., 2004).  
There is a substantial argument for mutant SOD1 - induced upregulation of 
TLR receptor expression in ALS (Hovden et al., 2013, Casula et al., 2011, 
Trudler et al., 2010, Zhao et al., 2010). Microglia overexpressing SOD1G93A 
have an increased sensitivity to LPS and are more neurotoxic than wt 
microglia in vitro (Xiao et al., 2007, Hensley et al., 2006). Moreover, 
SOD1G93A binds to TLR2 and TLR4, inducing motoneuron death (Zhao et al., 
2010). Here it is demonstrated that SOD1G93A mediates microglial NF-ҡB 
activation via TLR2 and TLR4, and it is proposed that this contributes to 
neurotoxicity (Zhao et al., 2010). Interestingly, the presented data suggests 
an autocrine and paracrine toxicity of SOD1G93A, implying a self – 
propagating toxicity that activates TLR2 and TLR4 extracellularly similar to 
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paracrine stimulation. Additionally SOD1G93A aggregates can mediate toxicity 
intracellularly by increasing proteasomal functionality, thereby facilitating the 
formation of the immunoproteasome which shifts microglia towards an M1 
activation state (Puttaparthi and Elliott, 2005) (Figure 6.1).  
Moreover, MyD88 – deficiency in the APP/PS1 Alzheimer’s transgenic 
mouse model leads to a reduced expression of il-1β (Michaud et al., 2011), 
however ALS mice deficient in microglial MyD88 were reported to have an 
early disease onset and decreased survival, highlighting the critical role of 
innate immunity in neuroprotection (Kang and Rivest, 2007).  While the initial 
microglial MyD88 – dependent signalling is neuroprotective, chronic 
inflammation which is mediated by TLR2 and TLR4 contributes to rapid 
disease progression (Lewis et al., 2012, Liao et al., 2012, Hume et al., 2001, 
Gebicke-Haerter et al., 1996). These studies highlight the importance of an 
immunoregulatory balance between neuroprotection and neurotoxicity in the 
development of neurotherapeutics.  
 
6.2 Bid is a positive regulator of SOD1G93A – and LPS – induced NF-
ҡB activation 
Bid modulates the immunological profile in microglia and macrophages 
(Mayo et al., 2011). Our laboratory has previously shown that Bid protein 
levels are upregulated in the spinal cord of SOD1G93A mice concurrent with 
disease progression (Konig et al., 2014), and here microglial Bid is identified 
to be highly expressed. This study demonstrates the role of Bid as a positive 
modulator of the microglial – mediated innate immune response and 
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highlights the action of Bid in promoting TLR4 – induced activation of NF-ҡB. 
It is important to note that the absence of Bid has no developmental effects 
in the CNS (Yin et al., 1999, Krajewska et al., 2002), and that bid-/- microglia 
can undergo apoptosis through the extrinsic pathway which does not require 
Bid [reviewed in (Putcha et al., 2002)].  
Multiple sophisticated cascades of protein complex formation and activation 
in TLR4 - induced signalling occurs via the MyD88 – dependent and TRIF – 
dependent pathways (Covert et al., 2005). The LPS induced MyD88 – 
dependent pathway initiates a rapid and transient activation of NF-ҡB, 
whereas TRIF – dependent NF-ҡB activation is more delayed and persistent 
(Roy et al., 2014, Palsson-McDermott and O'Neill, 2004, Jiang et al., 2003b). 
Delayed kinetics of TRIF – dependent signalling have been proposed to be 
due to CD14 – mediated internalization of TLR4 following MyD88 activation, 
with signalling from TRIF occurring at the endosomal compartment (Roy et 
al., 2014, Husebye et al., 2006), however microglial TLR4 receptor 
internalization needs to be further explored. Regardless, in this study the 
absence of Bid facilitates the attenuation of both the acute (30 minutes – 1 h) 
and prolonged (4 h) LPS inflammatory response, indicating that Bid may 
regulate both the MyD88 – dependent and TRIF – dependent pathways. 
Modulation of TLR4 signalling in the absence of Bid may result in a reduced 
activation of the TRIF – dependent pathway upon inhibition or attenuation of 
MyD88 signalling. However, LPS – induced NF-ҡB activation occurs in the 
absence of MyD88 (Yamamoto et al., 2003a), although the MyD88 pathway 
has a dominant role in mediating acute toxicity (Buchholz et al., 2010). 
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Therefore it is proposed that Bid may impact on both TLR4 – induced 
signalling pathways to NF-ҡB, but not via RIP1.   
The TLR4 agonist LPS and the cytokine IFNγ are well defined inducers of 
the M1 phenotype, and markers of M1 activation include pro-inflammatory 
cytokines such as IL-1β, IL-6, TNFα, and the enzyme COX-II (Chhor et al., 
2013). NF-ҡB activation leads to the transcription of pro – IL-1β which is 
further processed to IL-1β by the NOD - like receptor family pyrin domain 
containing 3 (NLRP3) inflammasome (Hanamsagar et al., 2011), and here it 
is proposed that the reduced LPS – induced IL-1β levels in bid – deficient 
microglia is due to the absence of the positive role of Bid in the regulation of 
NF-ҡB – induced transcription of pro – IL-1β. 
SOD1G93A overexpression in BV-2 cells induced a significant increase in NF-
ҡB activation (Liu et al., 2009). Here, microglial activation is reduced in 
SOD1G93A stimulated bid – deficient cells, with lower levels of COX-II 
observed in Bid – depleted BV-2 cells compared with control, indicating 
decreased activation levels of NF-ҡB.  It is also demonstrated that SOD1G93A 
exerts its toxicity by activating microglial NF-ҡB via TLR2 and TLR4. In this 
study experiments focus on LPS – induced NF-ҡB activation, and of note 
TLR2 can also facilitate LPS stimulated activation of NF-ҡB, although it is not 
a critical mediator (Heine et al., 1999, Yang et al., 1999). Both TLR2 and 
TLR4 activation are of importance when considering SOD1G93A – mediated 
toxicity, and both TLR4 and TLR2 signal via the MyD88 pathway (Akira and 
Hoshino, 2003, O'Neill, 2003). 
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6.3 Bid promotes TLR4 signalling by mediating TRAF6 K63 – linked 
polyubquitination 
 
In this study an association between Bid and TRAF6 is identified in microglia. 
TRAF6 is an essential effector of the MyD88 – dependent activation of NF-
ҡB (Naito et al., 1999, Medzhitov et al., 1998) , and TRAF6 polyubiquitination 
is critical for activation of the IKK complex (Deng et al., 2000). Additionally, 
TRAF6 mediates the TRIF - dependent ‘late phase’ response to NF-ҡB 
activation (Sato et al., 2003), although TRIF- dependent activation of NF-ҡB 
can also be facilitated by RIP1 (Kawai et al., 2001). 
As TRAF6 facilitates the activation of both TLR and NOD receptor pathways 
(Abbott et al., 2007, Lomaga et al., 1999), previous findings in our laboratory 
and that of Yeretssian and co – workers,  with regard to the association 
between Bid and IKK subunits, may show that Bid can also interact with 
TRAF6 in a complex containing NEMO in immune cells, modulating both 
NOD and TLR4 pathway (Konig et al., 2014, Yeretssian et al., 2011). This 
may also be suggested by the fact that Bid associates with TRAF6 in 
unstimulated conditions which may implicate the Bid – dependent modulation 
of TRAF6 to have a role in basal activation as well as LPS – induced 
microglial TLR4 signalling. However it may also suggest the existence of a 
cell type specificity of Bid in regulating the inflammatory response. 
One current caveat in this research is the possibility of an interaction 
between Bid and the E2 ligase complex Ubiquitin - conjugating enzyme 13 / 
Ubiquitin – conjugating enzyme variant 1A (Ubc13 / Uev1A), resulting in a 
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gain of function of TRAF6 ubiquitin ligase activity. Ubc13 / Uev1A is required 
for the formation of K63 – linked polyubiquitin chains (Deng et al., 2000, 
Hofmann and Pickart, 1999), and specifically TRAF6 K63 – linked 
polyubquitination (Wang et al., 2001), with Ubc13 – deficient mice displaying 
blunted LPS – induced NF-ҡB activation mediated by TRAF6 (Fukushima et 
al., 2007). It is possible that the Bid – dependent promotion of TRAF6 
polyubiquitination is due to an interaction between Bid and the Ubc13 / 
Uev1A complex, thus promoting the conjugating activity of Ubc13 / Uev1A 
and subsequently promoting TRAF6 K63 – linked polyubiquitination, however 
further experiments will be needed to further explore this. 
 
6.4 Bid regulates TLR4 signalling by promoting TRAF6 – mediated 
polyubquitination of downstream targets in TLR4 – NF-ҡB signalling 
 
Peli1 is a positive regulator of both TRIF – dependent and MyD88 – 
dependent TLR4 signalling, mediating the polyubiquitination of IRAK1, TAK1 
and TBK1 (Murphy et al., 2015, Smith et al., 2011, Jiang et al., 2003a). In 
addition, Peli1 promotes the assembly of signalling complexes in a K63 – 
ubiquitin  dependent manner, and is identified as a key player in both the 
MyD88 - IRAK1 - TAK1 - TRAF6 and TRIF - TBK1 axes (Murphy et al., 
2015).   
Although the mechanism of Peli1 degradation is unknown it may be induced 
by the IRAK – mediated autoubiquitination of Peli1 (Butler et al., 2007). Here 
it is shown that Peli1 is quickly degraded via the proteasome and rapidly 
                                                                                                       Chapter VI: Discussion 
 
 
197 
 
resynthesized. Peli1 is a target gene of IRF3 (Smith et al., 2011), and its 
reduced expression upon LPS stimulation in bid – deficient cells may be 
accounted for by the reduced signalling of the TRIF – dependent pathway. 
While NF-ҡB activation can occur in the absence of MyD88 (Fitzgerald et al., 
2003b), optimal TLR4 – induced signalling requires MyD88 signalling to 
initiate the TRIF – dependent pathway. This is evident in studies 
demonstrating that the polyubiquitination of NEMO precedes TBK1 activation 
(Wang et al., 2012, Zhao et al., 2007). From the results provided in this study 
it is hypothesized that reduced Peli1 levels result from reduced IRF3 
signalling in the absence of Bid, leading to the diminished abundance of 
Peli1 available to participate in further LPS – induced signalling in bid – 
deficient cells. The attenuation of IRF3 signalling and subsequent reduction 
in Peli1 transcription may be caused by depleted MyD88 – dependent 
signalling. Critical pathway analysis pointed to a few possible explanations 
for this. 
Firstly, the investigation of the role of Bid in the Peli1 – mediated activation of 
IRAK1 demonstrated that LPS – induced IRAK1activation is not modulated in 
a Bid – dependent manner. 
Secondly, MyD88 – dependent signal transduction to TAK1 requires the 
dissociation of the TRAF6 – Peli1 – IRAK complex from the receptor complex 
(Tseng et al., 2010).  It is proposed that the cytoplasmic translocation of this 
complex, regulated by TRAF3 degradation and essential for MAPK activation 
(Xiao et al., 2013, Tseng et al., 2010), may be delayed or reduced in the 
absence of Bid. 
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Thirdly, reduced TRAF6 – mediated polyubiquitination may result in reduced 
polyubiquitination of NEMO, and the reduced activation of TAK1. This has 
two implications for IRF3 signalling; NEMO ubiquitination precedes TBK1 
activation (Wang et al., 2012), and the recent evaluation of TAK1 -  and JNK 
- mediated TBK1 activation (Zhang et al., 2009). 
TLR4 signalling leads to the IRAK4 – mediated induction of IRAK1 kinase 
activation, which in turn results in the phosphorylation of Peli1 and 
subsequent Peli1 – mediated activation of IRAK1, leading to reduced IRAK1 
levels. Of note, IRAK1 deficiency does not abolish TLR4 - induced cytokine 
expression, suggesting a compensatory role of IRAK4 (Thomas et al., 1999), 
with Peli1 capable of polyubiquitinating the both IRAK1 and IRAK4 (Smith et 
al., 2009). TRAF6 may not be required for the bi - directional communication 
between IRAK1 and Peli1, and activation of the IRAK complex may occur 
upstream of the Bid – dependent TRAF6 – mediated polyubiquitination in 
microglia. 
Accumulation of TRAF3 in Peli1 – deficient mice was demonstrated to 
contribute to inflammatory pathogenesis in Experiments Autoimmune 
Encephalitis (EAE) (Chang et al., 2009). The cIAP2 – induced degradation of 
TRAF3 is critical for the dissociation of the TRAF6 – Peli1 – IRAK complex 
from the MyD88 membrane complex and subsequent translocation to the 
cytosol (Tseng et al., 2010). TRAF6 does not directly bind to cIAP2 
(Werneburg et al., 2001). cIAP2, a member of the Inhibitor of Apoptosis 
family and an E3 ubiquitin ligase protein, is redundant in the TRIF – 
dependent pathway, but is indispensable for MyD88 – dependent signalling 
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from TLR4 (Tseng et al., 2010). Peli1 mediates TRAF6 K63 – linked 
polyubiquitination of cIAP2 which induces the degradation of TRAF3 via the 
K48 – linked ubiquitination of TRAF3 (Xiao et al., 2013). Figure 6.2 below 
demonstrates a potential role of Bid in regulating TRAF6 – induced 
degradation of TRAF3 and subsequent dissociation of the receptor complex. 
 
 
Figure 6.2: Schematic representing the potential role of Bid in the TRAF6 
mediated ubiquitination of Peli1 which is critical for the dissociation of the 
TRAF6 – Peli1 – IRAK complex from the membrane.  Peli1 facilitates the 
TRAF6 – mediated polyubiquitination of cIAP2 which leads to the K48 – 
linked ubiquitination of TRAF3. TRAF3 degradation is essential for the 
disassociation of the TRAF6 – Peli1 – IRAK complex from the receptor 
complex which mediates downstream signalling to TAK1 (Xiao et al., 2013, 
Tseng et al., 2010).  
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Importantly, TRAF3 has a differential role in the regulation in the MyD88 and 
TRIF – dependent pathway dictated by the alternative ubiquitination of 
TRAF3 (Tseng et al., 2010). TRAF3 negatively regulates MyD88 signalling, 
with the induction of pro-inflammatory genes restored in Peli1 – deficient 
mice by the depletion of TRAF3 (Xiao et al., 2013).  TRAF3 positively 
regulates the TRIF – dependent pathway to IRF3, by exhibiting K63 – linked 
autoubiquitination on interaction with TRIF, which does not require cIAP1 or 
cIAP2 (Tseng et al., 2010). Interestingly, the K63 – linked polyubquitination 
of TRAF3 is not solely mediated by the E2 ligase Ubc13 (Tseng et al., 2010, 
Yamamoto et al., 2006), as is the case with TRAF6.  It is proposed that the 
absence of Bid may lead to reduced or delayed TRAF3 degradation in bid – 
deficient microglia resulting in the depletion of TRAF6 – mediated signalling 
to TAK1 and reduced MAPK signalling. 
TRAF6 was recently shown to promote the TAK1 - and JNK - mediated 
activation of TBK1 and subsequently IRF3 (Zhang et al., 2009), although an 
earlier study proposed that LPS – induced IRF3 activation is not impaired in 
TRAF6 deficient mice (Kawai et al., 2001).  Additionally, there is a reduction 
in the phosphorylation of JNK upon inhibition of TRAF6 K63 – linked 
polyubiquitination (Fukushima et al., 2007), which may support the proposed 
lack of TBK1 activation and reduced Peli1 transcription in the absence of Bid. 
It has also been suggested that TRAF6 can mediate TRIF – induced TBK1 
activation in the absence of TRAF3 (Hacker et al., 2006).  Peli1 mediates 
TRAF6 and TAK1 K63 – linked polyubquitination in macrophages (Murphy et 
al., 2015, Jiang et al., 2003a). Furthermore, Peli1 has been demonstrated to 
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promote the phosphorylation of TBK1 resulting in the enhanced activation of 
Peli1 (Murphy et al., 2015, Smith et al., 2011).  
Finally, the Bid – dependent regulation of Peli1 levels upon LPS stimulation 
may affect the interaction of Peli1 with the TBK1 / IKKε complex, thus adding 
to the complexity to the role of Bid in TLR4 – induced signalling. 
Figure 6.3 shows an overview of the possible roles of Bid in TLR4 pro-
inflammatory signalling, including NF-ҡB, IRF3 and MAPK activation. 
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Figure 6.3: Schematic of the potential Bid - dependent positive regulation of 
the TLR4 signalling pathway. 1. Bid promotes TRAF6 polyubiquitination, 
which does not affect IRAK complex activation, however there may be a 
reduced TRAF6 – mediated Peli1 ubiquitination of cIAP2, reduced TRAF3 
degradation and reduced translocation of TRAF6 – Peli1 - IRAK complex to 
the cytosol, and subsequently reduced TRAF6 signalling to TAK1 in the 
absence of Bid.  2. Bid – dependent TRAF6 – mediated polyubiquitination of 
NEMO may also be reduced in the absence of Bid, which is represented by 
reduced IKKα / β phosphorylation. 3. Bid – dependent polyubiquitination of 
TRAF6 may promote TAK1 / JNK mediated activation of TBK1, and reduced 
TBK1 activation in the absence of Bid may result in the reduction of Peli1 
transcription. 4. Bid may associate with TRAF6 in the context of TRIF – 
dependent TRAF6 – mediated NF-ҡB activation, although this is not 
specifically identified in this study.  
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IFNγ signalling is facilitated by the Janus Kinase / Signal Transducers and 
Activators of Transcription 1 (Jak / STAT1) pathway, however IFNγ is shown 
to increase LPS responsiveness by a process called ‘priming’ (Roy et al., 
2011, Bosisio et al., 2002, Hayes et al., 1995).  Increased Peli1 levels upon 
the dual treatment of LPS plus IFNγ may be explained by either an overall 
increase in TLR4 signalling due to the more robust nature of the stimulus, or 
by Jak / STAT1 and TLR4 pathway crosstalk. The latter is potentially 
mediated by STAT1, which has been shown to increase LPS sensitivity of 
cells via upregulation of MD2 (Roy et al., 2011), and also by interacting with 
TRAF6 (Luu et al., 2014). STAT1 association with TRAF6 may prevent the 
TRAF6 – mediated reduction in TBK1 binding to TRIF, which could explain 
the increased Peli1 levels upon IFNγ in bid – deficient microglia. Another 
explanation for the increased Peli1 levels could be from an interaction 
between TRAF3 and STAT1, with STAT1 promoting TRAF3 - mediated 
TBK1 / IKKε activation, thus increasing IRF3 activation and Peli1 
transcription, although there is no evidence for this currently.  
 
6.5 Context of Bid – dependent dysregulation of TLR4 signalling in 
ALS therapeutics  
Microglia are a promising therapeutic target in inflammatory pathogenic 
states as they elicit the primary immune response, their activation precedes 
macrophage infiltration from the peripheral nervous system (PNS) (Schilling 
et al., 2003), and microglia display a more heightened sensitivity than 
macrophages to TLR4 agonism (Regen et al., 2011). Microglia may be 
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primed early in disease by extracellular misfolded proteins leading to an 
exaggerated inflammatory response (Perry and Holmes, 2014). As misfolded 
SOD1 has also been shown to aggregate in the spinal cord of sALS patients 
(Gruzman et al., 2007), targeting microglial toxicity caused by mutant SOD1 
may span more than solely fALS pathogenesis. Additionally the findings in 
this study of the Bid – dependent regulation of TRAF6 is of relevance in both 
neurodegenerative disease and CNS inflammation as TRAF6 bridges innate 
and adaptive immune responses (Wu and Arron, 2003). 
Recently a critical evaluation of the activation phenotype of SOD1G93A 
microglia indicated that end stage SOD1G93A spinal cord microglia may be 
functionally impaired, demonstrated by blunted responses to LPS 
stimulation, and may display a unique phenotype to that of M1 or M2 
microglia (Chiu et al., 2013). Importantly, it is to be noted that cortical 
microglia did not revert to this differential activation state seen in the spinal 
cord of ALS mice (Nikodemova et al., 2014). This proposal needs to be 
further elucidated and if a regional microglial phenotypic heterogeneity were 
to be confirmed this should be highly considered when developing 
therapeutic mechanisms targeting microglial TLRs in SOD1G93A – induced 
neuroinflammation.  
Targeting the immune system by developing neurotherapeutics for the 
amelioration of neurodegeneration has been a central focus in recent years, 
however it has proven difficult to reach satisfactory outcomes. Anti-
inflammatory compounds, such as minocycline (Gordon et al., 2007), 
celecoxib (Cudkowicz et al., 2006), and glatiramer acetate (Meininger et al., 
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2009) have previously been tested in clinical trials for ALS therapeutics 
however they have all failed to ameliorate disease progression with some 
reported to even exacerbate symptoms (Gordon et al., 2007, Meininger et 
al., 2006). The proposed reason for the failures of these therapeutics points 
to the inhibition of the protective effects associated with the pro-inflammatory 
response, strongly indicating that the dual roles of the immune response in 
ALS need to be considered for further design of immunotherapies (Murdock 
et al., 2015).  
NF-ҡB has proven to be a difficult therapeutic target as inhibition of NF-ҡB  
activation eliminates the anti - apoptotic effects which would otherwise be 
neuroprotective (Lawrence, 2009). Additionally, inhibition of IKKβ results in 
increased IL-1β secretion (Greten et al., 2007). The anti – inflammatory 
compound BAY11-7802 is an NF-ҡB inhibitor effective across the blood – 
brain barrier (Koedel et al., 2000), and has been demonstrated to have 
multiple targets including tyrosine phosphatases such as CD45 (Krishnan et 
al., 2013), and IRF3 (Lee et al., 2012a). However, BAY11-7802 is 
demonstrated to induce apoptosis (Chen et al., 2014), thus adding to the 
aforementioned therapeutic complication. An attenuation, rather than 
inhibition, of the NF-ҡB response may prove to have a more beneficial 
outcome, and importantly the administration of therapeutics during a precise 
therapeutic window prior to neuronal death is vital (Liao et al., 2012). Bid – 
dependent modulation of TLR4 – induced NF-ҡB activation offers a potential 
avenue for the attenuation of inflammation in neurodegenerative disease. 
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Importantly, as bid – deficiency leads to reduced and not abolished activation 
of NF-ҡB, this may alleviate the previous negative effects of NF-ҡB inhibition.  
Regulation of NEMO activation may prove to be the most beneficial 
therapeutic target of the IKK subunits in regulating inflammatory responses, 
as a compensatory role of IKKβ and enhanced inflammatory response was 
seen when IKKα was inactivated in mice (Adli et al., 2010, Lawrence et al., 
2005). Bid – dependent TRAF6 K63 – linked polyubiquitination may 
positively regulate NEMO polyubiquitination. Previously our laboratory has 
demonstrated that the inhibition of Bid with a small molecule inhibitor shows 
reduced NF-ҡB activation in response to pro – inflammatory cytokines in 
astrocytes (Konig et al., 2014). Optineurin (Optn) contains a ubiquitin binding 
domain (UBD) similar to that of NEMO, and Optn mutations are associated 
with fALS aetiology (Clark et al., 2013). Optn negatively regulates NF-ҡB 
activation and ALS – linked mutations in Optn interfere with the inhibitory 
effect towards NEMO, exaggerating NF-ҡB activation (Munitic et al., 2013, 
Maruyama et al., 2010, Zhu et al., 2007). Targeting NEMO may have a dual 
effect in alleviating the chronic inflammation in mutant Optn – mediated and 
SOD1 – mediated ALS pathogenesis.  
Intracellular aggregates of misfolded proteins induce a chronic self – 
propagating microglial inflammatory response (Orre et al., 2013). Although 
this study did not identify the co – localization of TRAF6 and SOD1G93A 
intracellularly, TRAF6 has been shown previously to co – localize with 
aggregated misfolded proteins, and targeting the immunoproteasome by 
alleviating the downregulated neuronal proteasome (Cheroni et al., 2005, 
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Puttaparthi and Elliott, 2005), and upregulated the glial cell proteasome 
(Tydlacka et al., 2008) may ameliorate the polarization of microglia to the M1 
state. Additionally, mutations in Ubiquilin 2 (Ubqln2) are found in to be linked 
to ALS pathogenesis (Deng et al., 2011), and are proposed to inhibit the 
targeting of ubiquitinated proteins to the proteasome (Chang and Monteiro, 
2015), enhancing aggregate accumulation. Specific inhibitors of the induced 
immunoproteasome subunits has been proposed as an effective therapy 
targeting glial cell activation in neurodegeneration (Miller et al., 2013). 
Interestingly, Ubqln2 was recently shown to co – localize with Optn (Osaka et 
al., 2015). Further studies are necessary to identify whether TRAF6 
promotes the K63 – linked ubiquitination on aggregated misfolded SOD1 in 
order to define if the effects of the Bid – mediated promotion of TRAF6 
polyubiquitination may have a role in this aspect of ALS therapeutics.  
Interestingly, TBK1 has recently been identified to be an ALS – linked gene 
(Cirulli et al., 2015). As described above TBK1 is involved in IRF3 activation 
and the transcription of Peli1 (Smith et al., 2011). Further studies are 
required to determine the effects of Bid on TBK1 activation in microglia; 
however a Bid – dependent regulation of TRAF6 ubiquitin ligase activity may 
play a role. 
Pharmacological inhibitors of Bid have been developed (Becattini et al., 
2004), using small molecules (BI-6C9), and as demonstrated in this study, 
prove to be successful in attenuating NF-ҡB activation in microglia.  
Interestingly, the NF-ҡB inhibitor, BAY 11-7802, has recently been shown to 
interact with E2 ubiquitin ligases upon TLR4 activation, thus preventing K63 - 
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linked ubiquitin chain formation (Strickson et al., 2013). As BAY 11-7802 has 
multiple targets (Lee et al., 2012a), a more specific inhibitor of E2 – 
conjugating enzyme activation may prove beneficial as an anti- inflammatory 
therapeutic. 
Overall the evidence in this study provides a strong argument for the 
therapeutic potential for the inhibition of Bid in attenuating the microglial 
TLR4 - induced pro – inflammatory response.  
 
6.6 Conclusions and Future Directions 
Bid positively regulates microglial TLR4 mediated signalling by promoting 
TRAF6 K63 – linked polyubiquitination. Absence of microglial Bid leads to 
the attenuation of a series of complex multi - protein signalling pathways in 
response to TLR4 activation, which may not be restricted to NF-ҡB 
activation, but also MAPK and IRF3 activation. Further studies will elucidate 
the full potential of the positive role of Bid in MAPK and IRF3 pathways, thus 
potentially providing a novel therapeutic targeting all three pro - inflammatory 
signalling pathways induced by TLR4 activation. 
Moreover, targeting microglial Bid by exploiting the genetic targeting 
technique CRISPR-Cas9 (Pelletier et al., 2015, Barrangou et al., 2007) may 
provide a novel and advantageous therapeutic against TLR4 – induced 
microglial – mediated inflammation, as no exogenous DNA is required for 
therapeutic delivery which may elicit pro-inflammatory responses. However, 
further studies of uptake across the blood – brain barrier would need to be 
addressed. 
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